Modified guide RNA for gene editing
Truncated and modified gRNAs for NmeCas9 enhance gene editing efficiency and stability by improving synthesis yield and reducing degradation, addressing the challenges of long gRNA lengths and high degradation rates in the CRISPR/Cas9 system.
Patent Information
- Application Number
- JP2024525211
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-06-14
- Filing Date
- 2022-11-02
- Publication Date
- 2024-11-13
AI Technical Summary
The CRISPR/Cas9 system using Neisseria meningitidis Cas9 (NmeCas9) faces challenges due to long gRNA lengths complicating in vitro synthesis and high degradation rates, which affect gene editing efficiency and stability.
Development of truncated guide RNAs (gRNAs) with modified regions to enhance synthesis yield, uniformity, and stability, using NmeCas9, by shortening the gRNA length and incorporating modifications such as 2'-O-methyl, 2'-O-(2-methoxyethyl), and phosphorothioate linkages.
The modified gRNAs improve gene editing efficiency and stability, increasing crude yield and purity, and reducing degradation, making them suitable for therapeutic applications.
Smart Images

Figure 2024541962000001_ABST
Abstract
Description
[Technical Field]
[0001] This application claims priority to U.S. Provisional Application No. 63 / 275,426, filed November 3, 2021, and U.S. Provisional Application No. 63 / 352,161, filed June 14, 2022, the contents of both applications being incorporated by reference in their entirety.
[0002] This application contains a Sequence Listing that has been submitted electronically in ASCII format and is incorporated herein by reference in its entirety. This ASCII copy, created on November 1, 2022, has the name 01155-0048-00PCT_ST26 and is 1,429,694 bytes in size.
[0003] The present disclosure relates to the field of gene editing using the CRISPR / Cas9 system, which is part of the immune system of prokaryotes that recognizes and cleaves foreign genetic elements. [Background technology]
[0004] The CRISPR / Cas9 system relies on a single nuclease called CRISPR-associated protein 9 (Cas9), which induces site-specific cleavage of DNA. Cas9 is guided to a specific DNA sequence by a small RNA molecule called a guide RNA (gRNA). A complete guide RNA consists of a tracrRNA (trRNA) and a crisprRNA (crRNA). The crRNA containing the guide region is also called a gRNA, with the understanding that it must be covalently or noncovalently bound to the trRNA to form a complete gRNA. The trRNA and crRNA may be contained within a single guide RNA (sgRNA) or two separate RNA molecules, known as a dual guide RNA (dgRNA). Cas9 combined with the gRNA is called a Cas9 ribonucleoprotein complex (RNP).
[0005] CRISPR / Cas9 systems exist in various bacterial species and can have a variety of characteristics, such as the length of the gRNA and the degree of sequence specificity in cleavage. Neisseria meningitidis Cas9 (NmeCas9) has the advantage of a low off-target cleavage rate, but it uses a relatively long gRNA, which complicates in vitro gRNA synthesis.
[0006] Oligonucleotides, particularly RNA, can be degraded in cells and serum by non-enzymatic, endonucleolytic, or exonucleolytic cleavage. Oligonucleotides can be synthesized with modifications at various positions to reduce or prevent such degradation. Given the cyclical nature and incomplete yields of oligonucleotide synthesis, it would be desirable to shorten gRNAs while maintaining or improving gRNA activity. This could result, for example, in higher gRNA yields, greater uniformity in compositions containing gRNAs, or fewer defective or erroneous products. Furthermore, improved methods and compositions for preventing such degradation, improving gRNA stability, and increasing the efficiency of gene editing, particularly for therapeutic applications, are desirable. The present disclosure aims to meet one or more of these needs, provide other advantages, or at least provide the public with a useful option. Summary of the Invention
[0007] This disclosure relates to gene editing using the Neisseria meningitidis CRISPR / Cas9 system. NmeCas9 is smaller than Streptococcus pyogenes Cas9 (SpyCas9), making it suitable for messenger RNA (mRNA)-based delivery methods. However, NmeCas9 forms RNPs with gRNAs that are longer than the SpyCas9 guide RNAs. Conventional NmeCas9 gRNAs are 145 nucleotides or longer (Ibraheim et al. Genome Biology (2018) 19:137). Therefore, shortening the gRNA while maintaining or improving its activity is desirable to prevent gRNA degradation, improve stability, and increase gene editing efficiency.
[0008] In some embodiments, genome editing tools are provided that include guide RNAs (gRNAs) with one or more truncated regions, as described herein. The truncated regions described herein may facilitate synthesis of gRNAs with higher yield or uniformity, improve the stability of the gRNA and gRNA / Cas9 complex, or improve the activity of Cas9 to cleave target DNA.
[0009] In some embodiments, crisprRNA (crRNA) or tracrRNA (trRNA) are provided with one or more truncated regions or substitutions described herein. In some embodiments, a dual guide RNA (dgRNA) comprises a modified crRNA or modified trRNA. In some embodiments, a single guide RNA (sgRNA) comprises a modified crRNA or modified trRNA. The truncated regions or substitutions described herein may facilitate synthesis of gRNAs with higher yield or uniformity, improve the stability of the gRNA and gRNA / Cas9 complex, or improve the activity of NmeCas9 to cleave target DNA. Compared to the NmeCas9 145-mer sgRNA, synthesis of the currently disclosed gRNAs may increase the crude yield of gRNA. Similarly, the purity of gRNA samples, as measured by the proportion of full-length products, e.g., crude purity, may also be improved. Higher yields of guide RNA may be obtained, or compositions containing gRNAs may be more uniform, with fewer incomplete or erroneous products. Guide RNA purity can be assessed using ion-pair reversed-phase high-performance liquid chromatography (IP-RP-HPLC) or ion-exchange HPLC, as described in Kanavarioti et al., Sci Rep 9, 1019 (2019) (doi:10.1038 / s41598-018-37642-z). Using UV spectroscopy at 260 nm, crude and final purity can be determined by the ratio of the absorbance of the main peak in the chromatogram to the cumulative absorbance of all peaks. Synthesis yield is determined as the ratio of the absorbance at 260 nm of the final sample to the theoretical absorbance of the input material.
[0010] The following embodiments are included:
[0011] In some embodiments, a guide RNA (gRNA) is provided, wherein the guide RNA comprises a guide region and a conserved region, wherein the conserved region comprises one or more of the following: (a) a truncated repeat / anti-repeat region, wherein the truncated repeat / anti-repeat region lacks 2 to 24 nucleotides, wherein: (i) relative to SEQ ID NO: 500, one or more of nucleotides 37-48 and 53-64 are deleted, and optionally one or more of nucleotides 37-64 are substituted; and (ii) nucleotide 36 is connected to nucleotide 65 by at least two nucleotides; or (b) a truncated hairpin 1 region, wherein truncated hairpin 1 lacks 2 to 10 nucleotides, optionally 2 to 8 nucleotides, and wherein: (i) relative to SEQ ID NO: 500, one or more of nucleotides 82-86 and 91-95 are deleted, and optionally one or more of positions 82-96 are substituted; and (ii) nucleotide 81 is connected to nucleotide 96 by at least four nucleotides; or (c) a truncated hairpin 2 region, wherein the truncated hairpin 2 lacks 2 to 18 nucleotides, optionally 2 to 16 nucleotides, wherein: (i) relative to SEQ ID NO: 500, one or more of nucleotides 113-121 and 126-134 are deleted, and optionally one or more of nucleotides 113-134 are substituted; and (ii) nucleotide 112 is connected to nucleotide 135 by at least four nucleotides; wherein, relative to SEQ ID NO: 500, one or both of nucleotides 144-145 are optionally deleted; wherein at least 10 nucleotides are modified nucleotides.
[0012] In some embodiments, a guide RNA (gRNA) is provided, wherein the guide RNA comprises a guide region and a conserved region, wherein the conserved region comprises one or more of the following: (a) a truncated repeat / anti-repeat region, wherein the truncated repeat / anti-repeat region lacks 18 to 22 nucleotides relative to SEQ ID NO: 500, wherein: (i) nucleotides 37-48 and 53-64 are deleted, and (ii) nucleotide 36 is connected to nucleotide 65 by 6 to 10 nucleotides; or (b) a truncated hairpin 1 region, wherein the truncated hairpin 1 lacks two nucleotides, with nucleotides 86 and 91 deleted or nucleotides 85 and 92 deleted relative to SEQ ID NO:500; or (c) a truncated hairpin 2 region, wherein the truncated hairpin 2 lacks 18 nucleotides, and nucleotides 113-121 and 126-134 are deleted relative to SEQ ID NO: 500; and wherein nucleotides 144-145 are deleted relative to SEQ ID NO: 500, wherein at least 10 nucleotides are modified nucleotides.
[0013] 10. The guide RNA (gRNA) of the preceding embodiment, comprising a guide region and a conserved region, wherein the conserved region comprises: (a) a truncated repeat / anti-repeat region, wherein the truncated repeat / anti-repeat region lacks 18 to 22 nucleotides, wherein: (i) nucleotides 37-48 and 53-64 are deleted relative to SEQ ID NO: 500; and (ii) nucleotide 36 is connected to nucleotide 65 by 6 to 10 nucleotides; (b) a truncated hairpin 1 region, wherein the truncated hairpin 1 lacks two nucleotides relative to SEQ ID NO: 500, wherein nucleotides 86 and 91 are deleted, or nucleotides 85 and 92 are deleted; (c) a truncated hairpin 2 region, wherein the truncated hairpin 2 lacks 18 nucleotides, and nucleotides 113-121 and 126-134 are deleted relative to SEQ ID NO: 500; and (d) wherein nucleotides 144-145 are deleted relative to SEQ ID NO: 500; wherein at least 10 nucleotides are modified nucleotides.
[0014] In a further embodiment, in the truncated repeat / anti-repeat region, the truncated repeat / anti-repeat region lacks 22 nucleotides relative to SEQ ID NO: 500. In a further embodiment, nucleotide 36 is linked to nucleotide 65 by a sequence comprising the nucleotide sequence UGAAAC. In a further embodiment, nucleotide 36 is linked to nucleotide 65 by 10 nucleotides. In a further embodiment, nucleotide 36 is linked to nucleotide 65 by a sequence comprising the nucleotide sequence UUCGAAAGAC (SEQ ID NO: 950).
[0015] In some embodiments, the gRNA comprises a 5'-end modification. In some embodiments, the gRNA comprises a 3'-end modification. In some embodiments, the gRNA comprises a 5'-end modification and a 3'-end modification. In some embodiments, the gRNA comprises a modification in the upper stem region of the repeat / anti-repeat region. In some embodiments, the gRNA comprises a modification in the hairpin 1 region. In some embodiments, the gRNA comprises a modification in the hairpin 2 region.
[0016] In some embodiments, any of the foregoing modifications is a modified nucleotide selected from 2'-O-methyl (2'-OMe) modified nucleotides, 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotides, 2'-fluoro (2'-F) modified nucleotides, phosphorothioate internucleotide (PS) linkages, or inverted abasic modified nucleotides; and optionally, the gRNA comprises at least two modifications independently selected from 2'-O-methyl (2'-OMe) modified nucleotides, 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotides, 2'-fluoro (2'-F) modified nucleotides, phosphorothioate internucleotide (PS) linkages, and inverted abasic modified nucleotides.
[0017] In some embodiments, the 5' end modification comprises modified nucleotides selected from (i) 2'-O-methyl (2'-OMe) modified nucleotides, (ii) 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotides, (iii) 2'-fluoro (2'-F) modified nucleotides, (iv) internucleotide phosphorothioate (PS) linkages, or (v) inverted abasic modified nucleotides, and optionally, the gRNA comprises at least two 5' end modifications independently selected from (i)-(v).
[0018] In some embodiments, the 3' end modification comprises modified nucleotides selected from (i) 2'-O-methyl (2'-OMe) modified nucleotides, (ii) 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotides, (iii) 2'-fluoro (2'-F) modified nucleotides, (iv) internucleotide phosphorothioate (PS) linkages, or (v) inverted abasic modified nucleotides, and optionally, the gRNA comprises at least two 3' end modifications independently selected from (i)-(v).
[0019] In some embodiments, the 5' end modification is i. one or more modifications of the first 1 to 4 nucleotides, wherein the modification is a PS linkage, an inverted abasic nucleotide, 2'-OMe, 2'-O-moe, or 2'-F; ii. 2'-OMe, 2'-O-moe, or 2'-F modification to the first nucleotide and any one or two PS linkages to the next nucleotide or the first nucleotide of the 3' tail; iii. modification of the first or second nucleotide with 2'-OMe, 2'-O-moe, or 2'-F, and optionally one or more PS linkages; iv. modification of the first, second, or third nucleotide with 2'-OMe, 2'-O-moe, or 2'-F, and optionally one or more PS linkages; or v. Modification of the first, second, third, or fourth nucleotide with 2'-OMe, 2'-O-moe, or 2'-F, and optionally one or more PS linkages; Optionally, the gRNA comprises at least two 5' end modifications independently selected from (i) to (v).
[0020] 10. The gRNA of any one of the preceding claims, wherein the 3' end modification is i. one or more modifications of the last 1 to 4 nucleotides, wherein the modification is a PS linkage, an inverted abasic nucleotide, 2'-OMe, 2'-O-moe, or 2'-F; ii. 2'-OMe, 2'-O-moe, or 2'-F modification to the last nucleotide and any one or two PS linkages to the next nucleotide or the first nucleotide of the 3' tail; iii. modification of the last or penultimate nucleotide with 2'-OMe, 2'-O-moe, or 2'-F, and optionally one or more PS linkages; iv. modification of the last, penultimate, or penultimate nucleotide with 2'-OMe, 2'-O-moe, or 2'-F, and optionally one or more PS linkages; or v. Modification of the last, second to last, third to last or fourth to last nucleotide with 2'-OMe, 2'-O-moe or 2'-F, and optionally one or more PS linkages; Optionally, the gRNA comprises at least two 3' end modifications independently selected from (i) to (v).
[0021] In some embodiments, the modifications in the repeat / anti-repeat region, hairpin 1 region, or hairpin 2 region comprise modified nucleotides selected from (i) 2'-O-methyl (2'-OMe) modified nucleotides, (ii) 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotides, (iii) 2'-fluoro (2'-F) modified nucleotides, or (iv) internucleotide phosphorothioate (PS) linkages, and optionally, the modifications in the repeat / anti-repeat region, hairpin 1 region, or hairpin 2 region comprise at least two modifications independently selected from (i)-(iv).
[0022] In some embodiments, the modifications in the repeat / anti-repeat region, hairpin 1 region, or hairpin 2 region comprise modified nucleotides selected from (i) 2'-O-methyl (2'-OMe) modified nucleotides, (ii) 2'-fluoro (2'-F) modified nucleotides, or (iii) phosphorothioate (PS) internucleotide linkages, and optionally, the repeat / anti-repeat region, hairpin 1 region, or hairpin 2 region comprises at least two modifications independently selected from (i)-(iii).
[0023] In some embodiments, the modifications in the repeat / anti-repeat region, hairpin 1 region, or hairpin 2 region comprise modified nucleotides selected from (i) 2'-O-methyl (2'-OMe) modified nucleotides, or (ii) phosphorothioate (PS) internucleotide linkages, and optionally, the repeat / anti-repeat region, hairpin 1 region, or hairpin 2 region comprises at least two modifications independently selected from (i) and (ii).
[0024] In some embodiments, a composition is provided comprising a gRNA associated with a lipid nanoparticle (LNP) disclosed herein. In some embodiments, a LNP composition is provided comprising a gRNA disclosed herein. In some embodiments, the composition further comprises a nuclease or an mRNA encoding a nuclease.
[0025] The following additional embodiments are provided herein:
[0026] Embodiment 1 is a guide RNA (gRNA) comprising a guide region and a conserved region, wherein the conserved region comprises one or more of the following: (a) a truncated repeat / anti-repeat region, wherein the truncated repeat / anti-repeat region lacks 2 to 24 nucleotides, wherein: (i) relative to SEQ ID NO: 500, one or more of nucleotides 37-48 and 53-64 are deleted, and optionally one or more of nucleotides 37-64 are substituted; and (ii) nucleotide 36 is connected to nucleotide 65 by at least two nucleotides; or (b) a truncated hairpin 1 region, wherein truncated hairpin 1 lacks 2 to 10 nucleotides, optionally 2 to 8 nucleotides, and wherein: (i) relative to SEQ ID NO: 500, one or more of nucleotides 82-86 and 91-95 are deleted, and optionally one or more of positions 82-96 are substituted; and (ii) nucleotide 81 is connected to nucleotide 96 by at least four nucleotides; or (c) a truncated hairpin 2 region, wherein the truncated hairpin 2 lacks 2 to 18 nucleotides, optionally 2 to 16 nucleotides, wherein: (i) relative to SEQ ID NO: 500, one or more of nucleotides 113-121 and 126-134 are deleted, and optionally one or more of nucleotides 113-134 are substituted; and (ii) nucleotide 112 is connected to nucleotide 135 by at least four nucleotides; wherein, relative to SEQ ID NO: 500, one or both of nucleotides 144-145 are optionally deleted; wherein at least 10 nucleotides are modified nucleotides.
[0027] Embodiment 2 is the gRNA of embodiment 1, wherein the gRNA is a single guide RNA (sgRNA), and the gRNA comprises (a) a truncated repeat / anti-repeat region, wherein the truncated repeat / anti-repeat region lacks 2 to 24 nucleotides; (i) relative to SEQ ID NO: 500, one or more of nucleotides 37-48 and 53-64 are deleted, and optionally one or more of nucleotides 37-64 are substituted; and (ii) nucleotide 36 is linked to nucleotide 65 by at least two nucleotides;
[0028] Embodiment 3 is the gRNA of embodiment 1 or 2, wherein the guide region (i) has a 1 nucleotide insertion or 1-4 nucleotide deletion within positions 1-24 relative to SEQ ID NO: 500, or (ii) is 24 nucleotides in length.
[0029] Embodiment 4 is the gRNA of embodiment 3, wherein the guide region is 25, 24, 23, 22, 21, or 20 nucleotides in length, and optionally, the guide region is 25, 24, 23, or 22 nucleotides in length.
[0030] Embodiment 5 is the gRNA of Embodiment 4, wherein the length of the guide region is 23 to 24 nucleotides.
[0031] Embodiment 6 is the gRNA of any one of Embodiments 1 to 5, wherein the gRNA further comprises a 3' tail.
[0032] Embodiment 7 is the gRNA of embodiment 6, wherein the 3' tail comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides.
[0033] Embodiment 8 is the gRNA of embodiment 7, wherein the 3' tail comprises 1, 2, 3, 4, or 5 nucleotides.
[0034] Embodiment 9 is the gRNA of any one of embodiments 6 to 8, wherein the 3' tail terminates with a nucleotide comprising uracil or modified uracil.
[0035] Embodiment 10 is the gRNA of any one of Embodiments 6 to 9, wherein the 3' tail is 1 nucleotide in length.
[0036] Embodiment 11 is the gRNA of any one of Embodiments 6 to 10, wherein the 3' tail consists of nucleotides containing uracil or modified uracil.
[0037] Embodiment 12 is the gRNA of any one of embodiments 6 to 11, wherein the 3' tail comprises a modification to any one or more of the nucleotides present in the 3' tail.
[0038] Embodiment 13 is the gRNA of any one of embodiments 6 to 12, wherein the modification of the 3' tail is one or more of 2'-O-methyl (2'-OMe) modified nucleotides and internucleotide phosphorothioate (PS) linkages.
[0039] Embodiment 14 is the gRNA of any one of embodiments 6 to 13, wherein the 3' tail is fully modified.
[0040] Embodiment 15 is the gRNA of any one of Embodiments 1 to 14, wherein the 3' nucleotide of the gRNA is a nucleotide containing uracil or modified uracil.
[0041] Embodiment 16 is the gRNA of any one of Embodiments 1 to 5, wherein one or more of nucleotides 144 and 145 are deleted relative to SEQ ID NO:500.
[0042] Embodiment 17 is the gRNA of any one of Embodiments 1 to 5, wherein nucleotides 144 and 145 are both deleted relative to SEQ ID NO:500.
[0043] Embodiment 18 is the gRNA of any one of embodiments 1 to 5, wherein the gRNA does not comprise a 3' tail.
[0044] Embodiment 19 is the gRNA of any one of embodiments 1 to 18, wherein the truncated repeat / anti-repeat region lacks 2 to 24 nucleotides.
[0045] Embodiment 20 is the gRNA of any one of embodiments 1 to 19, wherein the length of the shortened repeat / anti-repeat region is 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides.
[0046] Embodiment 21 is the gRNA of any one of embodiments 1 to 20, wherein the truncated repeat / anti-repeat region lacks 12 to 24 nucleotides, optionally 18 to 24 nucleotides, optionally 20 to 22 nucleotides.
[0047] Embodiment 22 is the gRNA of any one of embodiments 1 to 21, wherein the length of the shortened repeat / anti-repeat region is 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides.
[0048] Embodiment 23 is the gRNA of any one of embodiments 1 to 22, wherein the length of the shortened repeat / anti-repeat region is 28, 29, 30, 31, 32, 33, or 34 nucleotides, or 30, 31, or 32 nucleotides.
[0049] Embodiment 24 is the gRNA of any one of embodiments 1 to 23, wherein nucleotides 37 to 64 of SEQ ID NO: 500 form the upper stem, and one or more base pairs of the upper stem of the truncated repeat / anti-repeat region are deleted.
[0050] Embodiment 25 is the gRNA of any one of embodiments 1 to 24, wherein the upper stem of the truncated repeat / anti-repeat region comprises 1, 2, 3, or 4 or fewer base pairs.
[0051] Embodiment 26 is the gRNA of any one of embodiments 1 to 25, wherein all of positions 39 to 48 and all of positions 53 to 62 of the upper stem of the truncated repeat / anti-repeat region are deleted, and optionally nucleotide 38 or 63 is substituted.
[0052] Embodiment 27 is the gRNA of any one of embodiments 1 to 26, wherein all of positions 38-48 and all of positions 53-63 of the upper stem of the truncated repeat / anti-repeat region are deleted, and optionally nucleotide 37 or 64 is substituted.
[0053] Embodiment 28 is the gRNA of any one of embodiments 1 to 27, wherein nucleotides 37 to 48 and 53 to 64 of the upper stem of the truncated repeat / anti-repeat region are all deleted, and optionally nucleotide 36 or 65 is substituted.
[0054] Embodiment 29 is the gRNA of any one of embodiments 1 to 28, wherein the truncated repeat / anti-repeat region has a duplex portion 11 base pair nucleotides in length.
[0055] Embodiment 30 is the gRNA of any one of embodiments 1 to 29, wherein the truncated repeat / anti-repeat region has a single duplex portion.
[0056] Embodiment 31 is the gRNA of any one of Embodiments 1 to 29, wherein the truncated repeat / anti-repeat region has a first duplex portion and a second duplex portion.
[0057] Embodiment 32 is the gRNA of embodiment 31, wherein the length of the second double-stranded portion is 2 to 3 base pair nucleotides.
[0058] Embodiment 33 is the gRNA of embodiment 31, wherein the length of the first duplex portion is 11 base pair nucleotides and the length of the second duplex portion is 3 base pair nucleotides.
[0059] Embodiment 34 is the gRNA of any one of embodiments 1 to 33, wherein the upper stem of the truncated repeat / anti-repeat region comprises one or more substitutions relative to SEQ ID NO:500.
[0060] Embodiment 35 is the gRNA of any one of Embodiments 1 to 34, wherein one or more of nucleotides 49 to 52 are substituted relative to SEQ ID NO:500.
[0061] Embodiment 36 is the gRNA of any one of embodiments 1 to 33, wherein the truncated repeat / anti-repeat region is not replaced.
[0062] Embodiment 37 is the gRNA of any one of embodiments 1 to 36, wherein the truncated repeat / anti-repeat region has 12 to 22 modified nucleotides.
[0063] Embodiment 38 is the gRNA of embodiment 37, wherein the truncated repeat / anti-repeat region does not comprise a modification at nucleotide 76.
[0064] Embodiment 39 is the gRNA of embodiment 37, wherein the truncated repeat / anti-repeat region does not comprise a phosphorothioate (PS) modification at nucleotide 76.
[0065] Embodiment 40 is the gRNA of any one of embodiments 1 to 39, wherein the shortened hairpin 1 region lacks 2 to 10 nucleotides, optionally 2 to 8 or 2 to 4 nucleotides.
[0066] Embodiment 41 is the gRNA of any one of embodiments 1 to 40, wherein the length of the shortened hairpin 1 region is 13, 14, 15, 16, 17, 18, 19, 20, or 21 nucleotides.
[0067] Embodiment 42 is the gRNA of any one of embodiments 1 to 41, wherein the shortened hairpin 1 region has a duplex portion of 4 to 8, optionally 7 to 8 base pair nucleotides in length.
[0068] Embodiment 43 is the gRNA of any one of embodiments 1 to 41, wherein the shortened Hairpin 1 region has a single double-stranded portion.
[0069] Embodiment 44 is the gRNA of any one of embodiments 1 to 43, wherein one or two base pairs of the shortened hairpin 1 region are deleted.
[0070] Embodiment 45 is the gRNA of any one of embodiments 1 to 44, wherein the stem of the shortened Hairpin 1 region is 7 or 8 base pair nucleotides in length.
[0071] Embodiment 46 is the gRNA of any one of embodiments 1 to 45, wherein one or more of positions 85-86 and one or more of nucleotides 91-92 of the truncated hairpin 1 region are deleted.
[0072] Embodiment 47 is the gRNA of any one of embodiments 1 to 46, wherein nucleotides 86 and 91 or nucleotides 85 and 92 of the shortened hairpin 1 region are deleted.
[0073] Embodiment 48 is the gRNA of any one of embodiments 1 to 47, wherein one or more of nucleotides 82 to 95 of the truncated hairpin 1 region are substituted relative to SEQ ID NO:500.
[0074] Embodiment 49 is the gRNA of any one of Embodiments 1 to 48, wherein one or more of nucleotides 87 to 90 are substituted relative to SEQ ID NO:500.
[0075] Embodiment 50 is the gRNA of any one of embodiments 1 to 48, wherein the shortened hairpin 1 region is not replaced.
[0076] Embodiment 51 is the gRNA of any one of embodiments 1 to 49, wherein the shortened hairpin 1 region has between 6 and 15 modified nucleotides.
[0077] Embodiment 52 is the gRNA of any one of embodiments 1 to 50, wherein the shortened hairpin 2 region lacks 2 to 18, optionally 2 to 16, nucleotides.
[0078] Embodiment 53 is the gRNA of any one of embodiments 1 to 51, wherein the length of the shortened hairpin 2 region is 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides.
[0079] Embodiment 54 is the gRNA of any one of embodiments 1 to 52, wherein the length of the shortened hairpin 2 region is 28, 29, 30, 31, 32, 33, or 34 nucleotides.
[0080] Embodiment 55 is the gRNA of any one of embodiments 1 to 53, wherein one or more of nucleotides 113 to 121 and one or more of nucleotides 126 to 134 of the truncated hairpin 2 region are deleted.
[0081] Embodiment 56 is the gRNA of any one of embodiments 1 to 54, wherein the shortened hairpin 2 region comprises an unpaired region.
[0082] Embodiment 57 is the gRNA of any one of embodiments 1 to 55, wherein the shortened hairpin 2 region has two double-stranded portions.
[0083] Embodiment 58 is the gRNA of any one of embodiments 1 to 56, wherein the shortened hairpin 2 region has a duplex portion 4 base pair nucleotides in length.
[0084] Embodiment 59 is the gRNA of any one of embodiments 57-58, wherein the shortened hairpin 2 region has a duplex portion between 4 and 8 base pair nucleotides in length.
[0085] Embodiment 60 is the gRNA of any one of embodiments 57 to 59, wherein the shortened hairpin 2 region has a duplex portion 4 to 6 base pair nucleotides in length.
[0086] Embodiment 61 is the gRNA of any one of embodiments 1 to 60, wherein nucleotides 109 to 138 of SEQ ID NO: 500 form the upper stem, and the upper stem of the shortened hairpin 2 region comprises 1, 2, 3, or 4 base pairs.
[0087] Embodiment 62 is the gRNA of any one of embodiments 1 to 61, wherein at least one pair of nucleotides 113 and 134, nucleotides 114 and 133, nucleotides 115 and 132, nucleotides 116 and 131, nucleotides 117 and 130, nucleotides 118 and 129, nucleotides 119 and 128, nucleotides 120 and 127, and nucleotides 121 and 126 are deleted.
[0088] Embodiment 63 is the gRNA of any one of embodiments 1 to 62, wherein all of positions 113-121 and 126-134 of the truncated hairpin 2 region are deleted.
[0089] Embodiment 64 is the gRNA of any one of embodiments 1 to 63, wherein one or more of nucleotides 113 to 134 of the truncated hairpin 2 region are substituted relative to SEQ ID NO:500.
[0090] Embodiment 65 is the gRNA of any one of embodiments 1 to 64, wherein one or more of nucleotides 122 to 125 are substituted relative to SEQ ID NO:500.
[0091] Embodiment 66 is the gRNA of any one of embodiments 1 to 64, wherein the shortened hairpin 2 region is not replaced.
[0092] Embodiment 67 is the gRNA of any one of embodiments 1 to 66, wherein the shortened hairpin 2 region has between 6 and 15 modified nucleotides.
[0093] Embodiment 68 is the gRNA of any one of embodiments 1 to 67, wherein the guide region of the gRNA comprises at least two modified nucleotides, optionally at least four modified nucleotides.
[0094] Embodiment 69 is the gRNA of any one of embodiments 1 to 68, wherein the guide region of the gRNA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 modified nucleotides, optionally 1, 2, or 3 modified nucleotides.
[0095] Embodiment 70 is the gRNA of any one of embodiments 1 to 69, wherein the guide region of the gRNA comprises 4, 5, 6, 7, 8, 9, 10, 11, or 12 modified nucleotides.
[0096] Embodiment 71 is the gRNA of any one of embodiments 1 to 70, wherein the guide region of the gRNA comprises 6, 7, 8, 9, 10, 11, or 12 modified nucleotides.
[0097] Embodiment 72 is the gRNA of any one of embodiments 1 to 71, wherein the guide region does not comprise 3' modified nucleotides in the first three nucleotides of the guide region.
[0098] Embodiment 73 is the gRNA of any one of embodiments 1 to 66, wherein the guide region does not comprise modified nucleotides.
[0099] Embodiment 74 is the gRNA of any one of embodiments 1 to 72, wherein the gRNA comprises a 5' end modification.
[0100] Embodiment 75 is the gRNA of any one of embodiments 1 to 74, wherein the gRNA comprises a 3' end modification.
[0101] Embodiment 76 is the gRNA of any one of embodiments 1 to 75, wherein the gRNA comprises a 5' end modification and a 3' end modification.
[0102] Embodiment 77 is the gRNA of any one of embodiments 1 to 76, comprising a modification in the upper stem region of the repeat / anti-repeat region.
[0103] Embodiment 78 is the gRNA of any one of embodiments 1 to 77, comprising a modification in the hairpin 1 region.
[0104] Embodiment 79 is the gRNA of any one of embodiments 1 to 78, comprising a modification in the hairpin 2 region.
[0105] Embodiment 80 is the gRNA of embodiment 79, wherein the modification in the hairpin 2 region comprises modifications to 1, 2, 3, or 4 nucleotides from nucleotides 106 to 109.
[0106] Embodiment 81 is the gRNA of embodiment 80, wherein the modifications in the hairpin 2 region comprise modifications at each of nucleotides 106 to 109.
[0107] Embodiment 82 is the gRNA of any one of embodiments 80 or 81, wherein the modification comprises a 2'-O-methyl (2'-O-Me) modification.
[0108] Embodiment 83 is the gRNA of any one of embodiments 1 to 82, comprising a 3' end modification and a modification in the upper stem region of the repeat / anti-repeat region.
[0109] Embodiment 84 is the gRNA of any one of embodiments 1 to 83, comprising a 3' end modification and a modification in the hairpin 1 region.
[0110] Embodiment 85 is the gRNA of any one of embodiments 1 to 83, comprising a 3' end modification and a modification in the hairpin 2 region.
[0111] Embodiment 86 is the gRNA of any one of embodiments 1 to 85, comprising a 5' end modification and a modification in the upper stem region of the repeat / anti-repeat region.
[0112] Embodiment 87 is the gRNA of any one of embodiments 1 to 86, comprising a 5' end modification and a modification in the hairpin 1 region.
[0113] Embodiment 88 is the gRNA of any one of embodiments 1 to 87, comprising a 5' end modification and a modification in the hairpin 2 region.
[0114] Embodiment 89 is the gRNA of any one of embodiments 1 to 88, comprising a 5'-end modification, a modification in the upper stem region of the repeat / anti-repeat region, and a 3'-end modification.
[0115] Embodiment 90 is the gRNA of any one of embodiments 1 to 89, comprising a 5'-end modification, a modification in the hairpin 1 region, and a 3'-end modification.
[0116] Embodiment 91 is the gRNA of any one of Embodiments 1 to 90, comprising a 5'-end modification, a modification in the hairpin 1 region, a modification in the hairpin 2 region, and a 3'-end modification.
[0117] Embodiment 92 is the gRNA of any one of Embodiments 1 to 91, comprising a 5'-end modification, a modification in the repeat / anti-repeat region, a modification in the hairpin 1 region, a modification in the hairpin 2 region, and a 3'-end modification.
[0118] Embodiment 93 is the gRNA of any one of embodiments 1 to 92, wherein the modifications in the repeat / anti-repeat region do not include a phosphorothioate (PS) modification at nucleotide 76.
[0119] Embodiment 94 is the gRNA of any one of embodiments 1 to 93, wherein the modifications in the repeat / anti-repeat region do not include a modification at nucleotide 76.
[0120] Embodiment 95 is the gRNA of any one of embodiments 74 to 94, wherein the 5'-end modification comprises a modified nucleotide selected from a 2'-O-methyl (2'-OMe) modified nucleotide, a 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotide, a 2'-fluoro (2'-F) modified nucleotide, an internucleotide phosphorothioate (PS) linkage, or an inverted abasic modified nucleotide.
[0121] Embodiment 96 is the gRNA of any one of embodiments 74 to 95, wherein the 3'-end modification comprises a modified nucleotide selected from a 2'-O-methyl (2'-OMe) modified nucleotide, a 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotide, a 2'-fluoro (2'-F) modified nucleotide, an internucleotide phosphorothioate (PS) linkage, or an inverted abasic modified nucleotide.
[0122] Embodiment 97 is the gRNA of any one of embodiments 74 to 96, wherein the 5' end modification is: i. modification of one or more of the first 1, 2, 3, or 4 nucleotides; ii. one modified nucleotide; iii. two modified nucleotides; iv. three modified nucleotides; and v. Containing any of the four modified nucleotides.
[0123] Embodiment 98 is the gRNA of any one of embodiments 74 to 97, wherein the 5' end modification is: i. Phosphorothioate (PS) linkages between nucleotides; ii. 2'-OMe modified nucleotides; iii. 2'-O-moe modified nucleotides; iv. 2'-F modified nucleotides; and v. Containing one or more inverted abasic modified nucleotides.
[0124] Embodiment 99 is the gRNA of any one of embodiments 74 to 98, wherein the 3' end modification is: i. modification of one or more of the last 4, 3, 2, or 1 nucleotides; ii. one modified nucleotide; iii. two modified nucleotides; iv. three modified nucleotides; and v. Containing any of the four modified nucleotides.
[0125] Embodiment 100 is the gRNA of any one of embodiments 74 to 99, wherein the 3' end modification is: i. Phosphorothioate (PS) linkages between nucleotides; ii. 2'-OMe modified nucleotides; iii. 2'-O-moe modified nucleotides; iv. 2'-F modified nucleotides; and v. Containing one or more inverted abasic modified nucleotides.
[0126] Embodiment 101 is the gRNA of any one of embodiments 74 to 100, wherein the 5' end modification comprises at least one PS linkage and includes one or more of the following: i. There is one PS linkage, and the linkage is between the first and second nucleotides; ii. There are two PS linkages between the first three nucleotides; iii. There is a PS linkage between one or more of the first four nucleotides; and iv. There is a PS bond between one or more of the first five nucleotides.
[0127] Embodiment 102 is the gRNA of embodiment 101, wherein the 5' end modification further comprises at least one 2'-OMe, 2'-O-moe, inverted abasic, or 2'-F modified nucleotide.
[0128] Embodiment 103 is the gRNA of any one of embodiments 1 to 102, wherein the 5' end modification is i. one or more modifications of the first 1 to 4 nucleotides, wherein the modification is a PS linkage, an inverted abasic nucleotide, 2'-OMe, 2'-O-moe, or 2'-F; ii. A modification to the first nucleotide with 2'-Ome, 2'-O-moe, or 2'-F and any one or two PS linkages to the next nucleotide or the first nucleotide of the 3' tail; iii. modification of the first or second nucleotide with 2'-Ome, 2'-O-moe, or 2'-F, and optionally one or more PS linkages; iv. modification of the first, second, or third nucleotide with 2'-Ome, 2'-O-moe, or 2'-F, and optionally one or more PS linkages; or v. Modification of the first, second, third, or fourth nucleotide with 2'-Ome, 2'-O-moe, or 2'-F, and optionally one or more PS linkages.
[0129] Embodiment 104 is the gRNA of any one of embodiments 1 to 103, wherein the 3' end modification comprises at least one PS linkage and includes one or more of the following: i. There is one PS linkage, and the linkage is between the last and penultimate nucleotides; ii. There are two PS linkages between the last three nucleotides; and iii. There is a PS linkage between one or more of the last four nucleotides.
[0130] Embodiment 105 is the gRNA of embodiment 104, wherein the 3' end modification further comprises at least one 2'-Ome, 2'-O-moe, inverted abasic, or 2'-F modified nucleotide.
[0131] Embodiment 106 is the gRNA of any one of embodiments 1 to 105, wherein the 3' end modification is: i. one or more modifications of the last 1 to 4 nucleotides, wherein the modification is a PS linkage, an inverted abasic nucleotide, 2'-OMe, 2'-O-moe, or 2'-F; ii. 2'-OMe, 2'-O-moe, or 2'-F modification to the last nucleotide and any one or two PS linkages to the next nucleotide or the first nucleotide of the 3' tail; iii. modification of the last or penultimate nucleotide with 2'-OMe, 2'-O-moe, or 2'-F, and optionally one or more PS linkages; iv. modification of the last, penultimate, or penultimate nucleotide with 2'-OMe, 2'-O-moe, or 2'-F, and optionally one or more PS linkages; or v. Modification of the last, second to last, third to last, or fourth to last nucleotide with 2'-OMe, 2'-O-moe, or 2'-F, and optionally one or more PS linkages.
[0132] Embodiment 107 is the gRNA of any one of embodiments 1 to 106, wherein the modification in the repeat / anti-repeat region, hairpin 1 region, or hairpin 2 region comprises modified nucleotides selected from 2'-O-methyl (2'-OMe) modified nucleotides, 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotides, 2'-fluoro (2'-F) modified nucleotides, or internucleotide phosphorothioate (PS) linkages.
[0133] Embodiment 108 is the gRNA of any one of embodiments 1 to 106, wherein the modification in the repeat / anti-repeat region, hairpin 1 region, or hairpin 2 region comprises modified nucleotides selected from 2'-O-methyl (2'-OMe) modified nucleotides, 2'-fluoro (2'-F) modified nucleotides, or internucleotide phosphorothioate (PS) linkages.
[0134] Embodiment 109 is the gRNA of any one of embodiments 1 to 106, wherein the modification in the repeat / anti-repeat region, hairpin 1 region, or hairpin 2 region comprises modified nucleotides selected from 2'-O-methyl (2'-OMe) modified nucleotides, or internucleotide phosphorothioate (PS) linkages.
[0135] Embodiment 110 is the gRNA of any one of embodiments 1 to 109, wherein the modifications in the repeat / anti-repeat region do not include a phosphorothioate modification at nucleotide 76.
[0136] Embodiment 111 is the gRNA of any one of embodiments 1 to 110, wherein the modifications in the repeat / anti-repeat region do not include a modification at nucleotide 76.
[0137] Embodiment 112 is the gRNA of any one of embodiments 1 to 111, wherein at least 20%, 30%, 40%, or 50% of the nucleotides are modified nucleotides.
[0138] Embodiment 113 is the gRNA of embodiment 112, wherein the gRNA comprises modified nucleotides selected from 2'-O-methyl (2'-OMe) modified nucleotides, 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotides, 2'-fluoro (2'-F) modified nucleotides, phosphorothioate (PS) internucleotide linkages, or combinations thereof.
[0139] Embodiment 114 is the gRNA of any one of embodiments 1 to 113, wherein the modification comprises modifications to one, two, three, or four nucleotides of nucleotides 106 to 109.
[0140] Embodiment 115 is the gRNA of embodiment 113 or 114, wherein the modification comprises a modification in each of nucleotides 106 to 109.
[0141] Embodiment 116 is the gRNA of any one of embodiments 114-115, wherein the modification comprises a 2'-O-methyl modification.
[0142] Embodiment 117 is the gRNA of any one of embodiments 112 to 116, wherein the gRNA comprises modified nucleotides selected from 2'-O-methyl (2'-Ome) modified nucleotides, 2'-fluoro (2'-F) modified nucleotides, internucleotide phosphorothioate (PS) linkages, or combinations thereof.
[0143] Embodiment 118 is the gRNA of any one of Embodiments 1 to 117, wherein nucleotides 1 to 3 of the guide region are modified, and nucleotides other than nucleotides 1 to 3 in the guide region are unmodified.
[0144] Embodiment 119 is the gRNA of any one of embodiments 1 to 118, wherein a 3' tail of nucleotide 144 is present in the gRNA, wherein nucleotides 141 to 144 comprise 2'-O-Me modified nucleotides, and wherein nucleotides 141 to 142 and 142 to 143 each comprise two PS linkages.
[0145] Embodiment 120 is the gRNA of any one of embodiments 1 to 120, wherein one or more of positions 49-52, 87-90, or 122-125 are substituted.
[0146] Embodiment 121 is a single guide RNA (sgRNA) comprising any one of SEQ ID NOs: 1 to 19 and 21 to 42.
[0147] Embodiment 122 is the gRNA of any one of embodiments 1 to 121, comprising a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 85%, 80%, 75%, or 70% identity to the nucleotide sequence of any one of SEQ ID NOs: 1 to 19 and 21 to 42.
[0148] Embodiment 123 is the gRNA of any one of embodiments 1 to 121, comprising a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 85%, 80%, 75%, or 70% identity to the nucleotide sequence of any one of SEQ ID NOs: 1 to 19 and 21 to 42, wherein the modifications at each nucleotide of the gRNA corresponding to the nucleotides of the reference sequence identifiers in Table 1 are the same as or equivalent to the modifications set forth in the reference sequence identifiers in Table 2.
[0149] Embodiment 124 is the gRNA of any one of embodiments 1 to 122, comprising a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, or 90% identity to the sequence from X to the 3' end of any one of the nucleotide sequences set forth in SEQ ID NOs: 1-5, 7, 8, 11, 12, 13, 15, 16, 18, 19, 21, 23, 24, 26, 27, 28, 30, 31, 33, 34, 35, 37, 39, 41, 101-291, 301-494, 931-946, 951, and 952, wherein X is the first nucleotide of the conserved region.
[0150] Embodiment 125 is the gRNA of any one of embodiments 121 to 124, further comprising a 3' tail comprising 2'-O-Me modified nucleotides.
[0151] Embodiment 126 is the gRNA of any one of embodiments 1 to 125, wherein the gRNA guides the nuclease to a target sequence for binding.
[0152] Embodiment 127 is the gRNA of any one of embodiments 1 to 126, wherein the gRNA guides a nuclease to a target sequence to induce a double-stranded break within the target sequence.
[0153] Embodiment 128 is the gRNA of any one of embodiments 1 to 127, wherein the gRNA guides a nuclease to a target sequence to induce a single-strand break within the target sequence.
[0154] Embodiment 129 is the gRNA of any one of embodiments 126 to 129, wherein the nuclease is Nme Cas9.
[0155] Embodiment 130 is the gRNA of any one of embodiments 1 to 129, wherein the gRNA comprises a conservative substitution, and optionally, the conservative substitution maintains at least one base pair.
[0156] Embodiment 131 is a composition comprising the gRNA of any one of embodiments 1 to 130 associated with a lipid nanoparticle (LNP).
[0157] Embodiment 132. An LNP composition comprising the gRNA of any one of embodiments 1 to 130.
[0158] Embodiment 133 is a composition comprising the gRNA of any one of embodiments 1 to 130 or the composition of any one of embodiments 131 to 132, further comprising a nuclease or an mRNA encoding a nuclease.
[0159] Embodiment 134 is the composition of embodiment 133, wherein the nuclease is a Cas protein.
[0160] Embodiment 135 is the composition of embodiment 134, wherein the Cas protein is NmeCas9.
[0161] Embodiment 136 is the composition of embodiment 135, wherein the Nme Cas9 is Nme1 Cas9, Nme2 Cas9, or Nme3 Cas9.
[0162] Embodiment 137 is the composition of any one of embodiments 133 to 136, wherein the nuclease has double-strand cleavage activity.
[0163] Embodiment 138 is the composition of any one of embodiments 133 to 137, wherein the nuclease has nickase activity.
[0164] Embodiment 139 is the composition of any one of embodiments 133 to 138, wherein the nuclease has a dCas DNA binding domain.
[0165] Embodiment 140 is the composition of any one of embodiments 133 to 139, wherein the nuclease is modified.
[0166] Embodiment 141 is the composition of embodiment 140, wherein the modified nuclease comprises a heterologous functional domain.
[0167] Embodiment 142 is the composition of embodiment 141, wherein the heterologous functional domain is a deaminase.
[0168] Embodiment 143 is the composition of embodiment 142, further comprising UGI or mRNA encoding UGI.
[0169] Embodiment 144 is the composition of any one of embodiments 142-143, wherein the heterologous functional domain is a cytidine deaminase.
[0170] Embodiment 145 is the composition of any one of embodiments 140 to 144, wherein the modified nuclease comprises a nuclear localization signal (NLS).
[0171] Embodiment 146 is the composition of any one of embodiments 133 to 145, comprising an mRNA encoding a nuclease.
[0172] Embodiment 147 is the composition of embodiment 146, wherein the mRNA comprises the sequence of any one of SEQ ID NOs: 636-638.
[0173] Embodiment 148 is a pharmaceutical formulation comprising the gRNA of any one of embodiments 1 to 130 or the composition of any one of embodiments 131 to 147 and a pharmaceutically acceptable carrier.
[0174] Embodiment 149 relates to a Cas protein or a nucleic acid encoding a Cas protein, as well as one of the following: i. The gRNA of any one of embodiments 1 to 130; ii. The composition of any one of embodiments 131 to 147, and iii. A method for modifying target DNA, comprising delivering one or more of the pharmaceutical formulations of embodiment 148 to a cell.
[0175] Embodiment 150 is the method of embodiment 149, wherein the method results in the insertion or deletion of a gene.
[0176] Embodiment 151 is the method of embodiment 149 or 150, wherein the method results in at least one base edit.
[0177] Embodiment 152 is the method of any one of embodiments 149 to 151, further comprising delivering a template to the cell, wherein at least a portion of the template is incorporated into the target DNA at or near the site of the double-stranded break induced by the Cas protein.
[0178] Embodiment 153 is the gRNA of any one of embodiments 1 to 130, the composition of embodiments 131 to 147, or the pharmaceutical formulation of embodiment 148 for use in the preparation of a medicament for treating a disease or disorder.
[0179] Embodiment 154 is the use of a gRNA of any one of embodiments 1 to 130, a composition of embodiments 131 to 147, or a pharmaceutical formulation of embodiment 148 in the manufacture of a medicament for treating a disease or disorder. [Brief explanation of the drawings]
[0180] [Figure 1] FIG. 1 shows the average editing results and standard deviation in HEK-Blue™ cells using truncated gRNAs. [Figure 2] FIG. 1 shows the average editing rate results of dual guide RNA (dgRNA) targeting VEGFA in HEK-Nme2 cells. [Figure 3] FIG. 1 shows the average editing rate results of chemically modified sgRNAs in HEK-Nme2 cells targeting the VEGFA gene at the T47 site. [Figure 4] FIG. 1 shows the average editing rate results of modified sgRNAs in HEK-293 cells targeting the VEGFA gene at the T47 site. [Figure 5] FIG. 1 shows the average editing rate at the TTR locus in PMH with increasing doses of Nme2Cas9 mRNA and chemically modified sgRNA. [Figure 6] FIG. 1 shows the average editing rate at the PCSK9 locus in PMH with modified sgRNAs. [Figure 7] FIG. 1 shows the average editing rates in PMH of several Nme2Cas9 mRNAs with modified sgRNAs. [Figure 8A] FIG. 1 shows the average editing rate at the TTR locus in PMH using various ratios of sgRNA to Nme2Cas9 mRNA. [Figure 8B] FIG. 1 shows the average editing rate at the TTR locus in PMH using various ratios of pgRNA to Nme2Cas9 mRNA. [Figure 9] FIG. 1 shows the average editing rate at the TTR locus in PMH of pgRNA carrying Nme2Cas9 mRNA. [Figure 10A] FIG. 1 shows the average editing rates at the VEGFA TS-25 locus in HEK-Nme2 cells for combinations of modified crRNA and trRNA with Nme2Cas9 mRNA. [Figure 10B] FIG. 1 shows the average editing rates at the VEGFA TS-47 locus in HEK-Nme2 cells for combinations of modified crRNA and trRNA with Nme2Cas9 mRNA. [Figure 11] FIG. 1 shows the average editing rates at the VEGFA TS-47 locus of HEK-Nme2 cell dgRNAs consisting of different crRNA and tracrRNA combinations for modified crRNA and trRNA combinations with Nme2Cas9 mRNA. [Figure 12A] FIG. 1 shows the average editing rate in TTR exon 1 in PMH of pgRNAs with 2'-OMe modifications in the guide sequence. [Figure 12B] FIG. 1 shows the average editing rate in TTR exon 3 in PMH of pgRNAs with 2'-OMe modifications in the guide sequence. [Figure 12C]FIG. 1 shows the average editing rate in TTR exon 1 in PMH of pgRNAs with mild 2'-OMe modifications in the guide sequence. [Figure 12D] FIG. 1 shows the average editing rate in TTR exon 3 in PMH of pgRNAs with mild 2'-OMe modifications in the guide sequence. [Figure 13] FIG. 1 shows the average editing rate at the PCSK9 locus in PMH. [Figure 14A] FIG. 1 shows the average editing results at the VEGFA locus in HEK cells treated with mRNA C (SEQ ID NO: 622). [Figure 14B] FIG. 1 shows the average editing results at the VEGFA locus in HEK cells treated with mRNA I (SEQ ID NO: 627). [Figure 14C] FIG. 1 shows the average editing results at the VEGFA locus in HEK cells treated with mRNA J (SEQ ID NO: 628). [Figure 14D] FIG. 1 shows the average editing results at the VEGFA locus in PHH cells treated with mRNA C (SEQ ID NO: 622). [Figure 14E] FIG. 1 shows the average editing results at the VEGFA locus in PHH cells treated with mRNA I (SEQ ID NO: 627). [Figure 14F] FIG. 1 shows the average editing results at the VEGFA locus in PHH cells treated with mRNA J (SEQ ID NO: 628). [Figure 15] FIG. 1 shows the average editing rate at the mouse TTR locus in PMH cells treated with NmeCas9 constructs designed with one or two nuclear localization sequences. [Figure 16] FIG. 1 shows the average editing rates at the mouse TTR locus in PMH cells treated with pgRNA and various Nme2Cas9 mRNAs. [Figure 17] FIG. 1 shows the fold change in Nme2Cas9 protein expression compared to SpyCas9 protein expression in PMH, PRH, PCH, and PHH cells. [Figure 18A]FIG. 1 shows the fold change in Nme2Cas9 protein expression compared to SpyCas9 protein expression in T cells from donor 1 examined 24 hours after treatment. [Figure 18B] FIG. 1 shows the fold change in Nme2Cas9 protein expression compared to SpyCas9 protein expression in T cells from donor 2 examined 24 hours post-treatment. [Figure 18C] FIG. 1 shows the fold change in Nme2Cas9 protein expression compared to SpyCas9 protein expression in T cells from donor 1 examined 48 hours after treatment. [Figure 18D] FIG. 1 shows the fold change in Nme2Cas9 protein expression compared to SpyCas9 protein expression in T cells from donor 2 examined 48 hours post-treatment. [Figure 18E] FIG. 1 shows the fold change in Nme2Cas9 protein expression compared to SpyCas9 protein expression in T cells from donor 1 examined 72 hours after treatment. [Figure 18F] FIG. 1 shows the fold change in Nme2Cas9 protein expression compared to SpyCas9 protein expression in T cells from donor 2 examined 72 hours after treatment. [Figure 19] FIG. 1 shows the average editing rate at the TTR locus in mouse livers treated with sgRNA and Nme2Cas9. [Figure 20A] FIG. 1 shows the average editing rate at the TTR locus in mouse liver after treatment with pgRNA and Nme2Cas9. [Figure 20B] FIG. 1 shows mean serum TTR protein after treatment with pgRNA and Nme2Cas9. [Figure 20C] FIG. 1 shows the average percentage of TTR knockdown after treatment with pgRNA and Nme2Cas9. [Figure 20D] FIG. 1 shows the average editing rate at the TTR locus in mouse liver after treatment with pgRNA and various Nme2Cas9s. [Figure 20E]FIG. 1 shows serum TTR protein knockdown after treatment with pgRNA and various Nme2Cas9s. [Figure 21] FIG. 1 shows the average editing rate in mouse liver after treatment with various Nme2Cas9 constructs. [Figure 22] FIG. 1 shows the average editing rates in mouse liver after treatment with pgRNA and various Nme2Cas9s. [Figure 23] FIG. 1 shows the average editing rate in mouse liver after treatment with various base editors. [Figure 24] 1 is an exemplary schematic diagram of an Nme2 sgRNA in possible secondary structures, including the repeat / anti-repeat region and the hairpin region, including the hairpin 1 and hairpin 2 regions, and further showing the guide region (or target region) (shown in gray fill with a dashed outline), bases that are not suitable for single or pairwise deletions (shown in gray fill with a solid outline), and bases that are suitable for single or pairwise deletions (open circle). [Figure 25]
[0023] Figure 1 shows an exemplary sgRNA (G021536; SEQ ID NO: 490) in possible secondary structures. Methylations are indicated in bold, and phosphorothioate linkages are indicated with "*". Watson-Crick base pairs are indicated with "-" between nucleotides in the duplex portion. Non-Watson-Crick base pairs are indicated with "·" between nucleotides in the duplex portion. [Figure 26] FIG. 1 shows the editing rate at the TTR locus in primary mouse hepatocytes. [Figure 27] FIG. 1 shows serum TTR levels in mice. [Figure 28] FIG. 1 shows the editing rate at the TTR locus in mouse liver samples. [Figure 29] FIG. 1 shows the results of serum TTR measurements after treatment in mice. [Figure 30] FIG. 1 shows the editing rate at the TTR locus in mouse liver samples. [Figure 31] FIG. 1 shows the average percentage of CD3-negative T cells after TRAC editing with Nme1Cas9. [Figure 32] FIG. 1 shows the average percentage of CD3-negative T cells after TRAC editing with Nme3Cas9. [Figure 33] FIG. 1 shows expression of Nme-HiBiT constructs in T cells at 24 hours. [Figure 34] FIG. 1 shows the CD3-negative cell population as a function of NmeCas9 mRNA dosage. [Figure 35] FIG. 1 shows dose-response curves of selected gRNAs in PCH. [Figure 36] FIG. 1 shows dose-response curves of LNP dilution series in PCH. [Figure 37]
[0023] Figure 1 shows an exemplary sgRNA (guide ID G032572, SEQ ID NO: 951) in possible secondary structures. Unmodified nucleotides are shown in bold, methylations are shown in light type, and phosphorothioate linkages are indicated by "*". Watson-Crick base pairs are indicated by a "-" between nucleotides in the duplex portion. Non-Watson-Crick base pairs are indicated by a "·" between nucleotides in the duplex portion. [Figure 38]
[0023] Figure 1 shows an exemplary sgRNA (guide ID G031771, SEQ ID NO:952) in possible secondary structures. Unmodified nucleotides are shown in bold, methylations are shown in light type, and phosphorothioate linkages are indicated by "*". Watson-Crick base pairs are indicated by a "-" between nucleotides in the duplex portion. Non-Watson-Crick base pairs are indicated by a "·" between nucleotides in the duplex portion. [Figure 39] FIG. 1 shows serum TTR levels in mice. [Figure 40] FIG. 1 shows the editing rate at the TTR locus in mouse liver samples. [Figure 41] FIG. 1 shows dose-response curves of selected gRNAs in PMH. [Figure 42] FIG. 1 shows dose-response curves of selected gRNAs in PMH. DETAILED DESCRIPTION OF THE INVENTION
[0181] Provided herein are truncated gRNAs for use in gene editing methods. Examples of engineered and tested gRNA sequences are shown in Tables 1-2.
[0182] Certain gRNAs provided herein are single guide RNAs (sgRNAs) used in gene editing methods.
[0183] Certain gRNAs provided herein are dual guide RNAs (dgRNAs) for use in gene editing methods.
[0184] The disclosure further provides exemplary uses of these gRNAs to modify the genome of a target nucleic acid in vitro (e.g., in cells cultured in vitro for use in ex vivo therapy or other applications of the gene-edited cells) or in the cells of a subject, such as a human (e.g., for use in in vivo therapy). [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] [Table 2-5]
Table 2-6
Table 2-7
Table 2-8
Table 2-9
Table 2-10
Table 2-11
Table 2-12
Table 2-13
Table 2-14
Table 2-15
Table 2-16
Table 2-17
Table 2-18
Table 2-19
Table 2-20
Table 2-21
Table 2-22
[0185] N represents a nucleotide with any base, such as A, C, G, or U. (mN*)3 represents three consecutive nucleotides, each with any base, a 2'-OMe, and a 3'PS linkage to the next nucleotide. (N) 20-25 represents 20 to 25, i.e., 20, 21, 22, 23, 24, or 25 consecutive Ns. A, C, G, and U represent nucleotides with adenine, cytosine, guanine, and uracil bases, respectively.
[0186] Nucleotide modifications are indicated in Tables 1-2 as follows: m: 2'-OMe; *: PS linkage; f: 2'-fluoro; (invd): inverted abasic; moe: 2'-moe; e: ENA; d: deoxyribonucleotide (note also that T is always a deoxyribonucleotide); x: UNA. In the sgRNA modified sequence, in certain embodiments, A, C, G, U, and N are each independently a ribose sugar (2'-OH). In certain embodiments, A, C, G, U, and N are each a ribose sugar (2'-OH). Thus, for example, mA represents 2'-O-methyladenosine, xA represents a UNA nucleotide with an adenine nucleobase, eA represents an ENA nucleotide with an adenine nucleobase, and dA represents an adenosine deoxyribonucleotide.
[0187] The sgRNA designation may have one or more leading zeros immediately following the G. This does not affect the meaning of the designation. Thus, for example, G000282, G0282, G00282, and G282 refer to the same sgRNA. [Table 4]
[0188] definition The articles "a" and "an" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element, e.g., a plurality of elements.
[0189] The term "including" is used herein to mean, and is used interchangeably with, the phrase "including but not limited to," and the enumeration of items in a list does not exclude other similar items that may be substituted for or added to the listed items.
[0190] The term "or" is used herein to mean, and is used interchangeably with, the term "and / or," unless the context clearly indicates otherwise. For example, "the sense strand or the antisense strand" is understood as "the sense strand or the antisense strand, or the sense strand and the antisense strand."
[0191] The term "about" is used herein to mean within typical tolerances in the art. For example, "about" can be understood as about two standard deviations from the mean. In certain embodiments, about means +10%. In certain embodiments, about means +5%, +2%, or +1%. When about is before a series of numbers or ranges, it is understood that "about" may modify each number in the series or range. Each numerical parameter should, at the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, but at the very least, construed in light of the number of reported significant digits and by applying ordinary rounding techniques.
[0192] The term "at least" preceding a number or series of numbers is understood to include the number adjacent to the term "at least" and all subsequent numbers or integers that may be logically included, as is clear from the context. For example, the number of nucleotides in a nucleic acid molecule must be an integer. For example, "at least 17 nucleotides of a 20-nucleotide nucleic acid molecule" means that 17, 18, 19, or 20 nucleotides have the specified property. When "at least" is present before a series of numbers or a range, it is understood that "at least" can modify each of the numbers in the series or range.
[0193] As used herein, "less than" or "less than" is understood to refer to the expression and the logical lower zero or neighboring integer value that is logical from the context. For example, a duplex region of "2 nucleotide base pairs or less" has 2, 1, or 0 nucleotide base pairs. When "less than" or "less than" precedes a series of numbers or ranges, it is understood that each of the series or ranges is modified.
[0194] As used herein, ranges include both upper and lower limits.
[0195] As used herein, when the maximum amount of a value is represented by 100% (e.g., 100% inhibition), it is understood that the value is interpreted in light of the detection method, e.g., 100% inhibition is understood as inhibition to a level below the detection level of the assay.
[0196] As used herein, "editing efficiency" or "editing rate" or "percent editing" is the total number of sequence reads with nucleotide insertions, deletions, or base changes in the target region of interest relative to the total number of sequence reads after cleavage or nicking by a Cas RNP.
[0197] As used herein, a "region" refers to a portion of a nucleic acid. A region may also be referred to as a "module" or "domain." A region of an sgRNA may perform a specific function, such as directing the endonuclease activity of an RNP, or have a predicted structure, as described, for example, in Briner AE et al., Molecular Cell 56:333-339 (2014). Exemplary regions of sgRNAs are listed in Table 3.
[0198] As used herein, "hairpin" or "hairpin structure" refers to a nucleic acid duplex formed when a nucleic acid strand folds back and base pairs with another portion of the same strand. A hairpin may form a structure comprising a loop or U-shape. In some embodiments, a hairpin may be composed of an RNA loop. A hairpin may be formed when two complementary sequences within a single nucleic acid molecule bind, causing the molecule to fold back or pucker. In some embodiments, a hairpin comprises a stem or stem-loop structure. In some embodiments, a hairpin comprises a loop and a stem. As used herein, when there are two hairpins in a gRNA, "hairpin region" may refer to hairpin 1 and hairpin 2 in the conserved region of the sgRNA, and the intervening sequence (e.g., "n") between hairpin 1 and hairpin 2.
[0199] As used herein, "forming a duplex portion" is understood to mean being capable of or predicted to form an uninterrupted duplex portion, for example, by base pairing. A duplex portion may comprise two complementary sequences, such as a first hairpin stem region and a second hairpin stem region complementary to the first hairpin stem region. As used herein, a duplex portion has a length of at least two base pairs. A duplex portion optionally comprises 2 to 10 base pairs, and the two strands forming the duplex portion may be connected, for example, by a nucleotide loop. Base pairing in the duplex may include Watson-Crick base pairing, optionally combined with base stacking. As used herein, a duplex portion may comprise a single nucleotide discontinuity on one strand, where each consecutive nucleotide on one strand base pairs with a nucleotide on the complementary strand, and the complementary strand may have a single non-basepaired nucleotide discontinuity, such as nucleotide 96 of SEQ ID NO: 500 in Hairpin 1. Here, the discontinuity is flanked by Watson-Crick base pairs immediately at the 5' and 3' ends. This differs from unpaired nucleotides 36 and 65 in the repeat-antirepeat region and unpaired nucleotides 106-108 and 139 in hairpin 2, which constitute the discontinuities resulting in two duplex portions, as defined herein. RNA structures are well known in the art, and tools for RNA structure prediction are available (see, e.g., Sato et al., Nature Comm. 12:941 (2021); RNAstructure at rna.urmc.rochester.edu / RNAstructureWeb / Servers / Predict1 / Predict1.html, and RNAfold WebServer at rna.tbi.univie.ac.at / cgi-bin / RNAWebSuite / RNAfold.cgi). The bridge length and structural flexibility required to enable folding and form loops that allow sufficient access of the nucleobases for base pairing are well known in the art.
[0200] As used herein, "RNA-guided DNA binder" refers to a polypeptide or polypeptide complex, or a DNA-binding subunit of such a complex, that has RNA-binding and DNA-binding activity, and whose DNA-binding activity is sequence-specific and determined by the sequence of its RNA. Exemplary RNA-guided DNA binders include Cas cleavases (having double-strand cleavage activity), Cas nickases (having single-strand cleavage activity), and inactivated forms thereof ("dCas DNA binders"). As used herein, "Cas nuclease" encompasses Cas cleavases, Cas nickases, and dCas DNA binders. dCas DNA binders can be inactive nucleases containing a non-functional nuclease domain (RuvC or HNH domain). In some embodiments, Cas cleavases or Cas nickases include dCas DNA binders that have been modified to enable DNA cleavage, e.g., via fusion with a FokI domain. In some embodiments, the RNA-guided DNA binding agent has nuclease activity, eg, cleavase activity or nickase activity.
[0201] Exemplary nucleotide and polypeptide sequences of Cas9 molecules are provided below. Methods for identifying alternative nucleotide sequences encoding Cas9 polypeptide sequences (including alternative naturally occurring variants) are known in the art. Also contemplated are sequences having at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to any of the Cas9 nucleic acid sequences, amino acid sequences, or nucleic acid sequences encoding the amino acid sequences provided herein. An exemplary open reading frame for Cas9 is provided in Table 4A.
[0202] As used herein, "ribonucleoprotein" (RNP) or "RNP complex" refers to a guide RNA together with an RNA-guided DNA-binding agent, such as a Cas nuclease, e.g., a Cas cleavase, a Cas nickase, or a dCas DNA-binding agent (e.g., Cas9). In some embodiments, the guide RNA guides the RNA-guided DNA-binding agent, such as Cas9, to a target sequence; the guide RNA hybridizes to the target sequence; the binding agent binds to the target sequence; and, if the binding agent is a cleavase or nickase, can cleave or nick the target sequence after binding.
[0203] As used herein, "stem-loop" refers to a secondary structure of nucleotides that forms a "stem" of base pairs that ends in a loop of unpaired nucleic acid. A stem can be formed when two regions of the same nucleic acid strand are at least partially complementary in sequence when read in opposite directions. As used herein, "loop" refers to a region of non-base-pairing (i.e., non-complementary) nucleotides that may cover the stem. "Tetraloop" refers to a loop of four nucleotides. As used herein, the upper stem of an sgRNA may contain a tetraloop.
[0204] The terms "guide RNA," "gRNA," and "guide" are used interchangeably herein to refer to the combination of crRNA (also known as CRISPR RNA) and trRNA (also known as tracrRNA). The crRNA and trRNA can associate as a single RNA molecule (single guide RNA, sgRNA) or in two separate RNA molecules (dual guide RNA, dgRNA). "Guide RNA" or "gRNA" refer to each type. The trRNA may be a naturally occurring sequence or a trRNA sequence that has modifications or variations compared to the naturally occurring sequence. The guide RNA may include modified RNAs as described herein. In some embodiments, the guide RNA used herein does not include a non-nucleotide linker connecting two nucleotides in the guide RNA. Unless the context indicates otherwise, the guide RNAs described herein are suitable for use with Nme Cas9 (e.g., Nme1, Nme2, or Nme3 Cas9). For example, Figure 24 shows an exemplary schematic of an Nme2 sgRNA in possible secondary structures.
[0205] As used herein, for example, a nucleotide that is 6 nucleotides from the 5' end of a particular sgRNA segment is the sixth nucleotide of that segment, or "nucleotide 6" from the 5' end, e.g., XXXXXN, where N is the sixth nucleotide from the 5' end. A range of nucleotides located "at or after" 6 nucleotides from the 5' end begins at the sixth nucleotide and continues down the strand toward the 3' end. Similarly, for example, a nucleotide that is 5 nucleotides from the 3' end of the strand is the fifth nucleotide counting from the 3' end of the strand, e.g., NXXXX. Numerical positions or ranges within a guide region refer to positions determined from the 5' end unless another reference point is specified. For example, "nucleotide 5" within a guide region is the fifth nucleotide from the 5' end.
[0206] The term "conserved region" refers to a conserved region of the N. meningitidis Cas9 ("NmeCas9") gRNA, as shown in Table 3. Line 1 shows the nucleotide numbering, line 2 shows an exemplary sequence (e.g., SEQ ID NO: 500), and lines 3 and 4 show the region. A truncated conserved region lacks at least one nucleotide shown in Table 3 and is described in more detail below.
[0207] As used herein, a "truncated" region of a gRNA is a conserved region of a gRNA that lacks at least one nucleotide compared to the corresponding conserved region shown in Table 3. Similarly, "truncated" with respect to an sgRNA means that the conserved region contains fewer nucleotides than the sgRNA conserved region shown in Table 3. In no circumstance does "truncated" imply any particular limitation on the manufacturing process or method of the gRNA.
[0208] As used herein with respect to polynucleotides, "substituted" or "substitution" refers to a nucleic acid base modification that alters a base favored by Watson-Crick pairing or disrupts a base-stacking interaction. When a particular region of a guide RNA is "unsubstituted" as used herein, the sequence of that region can be aligned with gaps and matches only (i.e., no mismatches) to the sequence of the corresponding conserved region of the NmeCas9 sgRNA (e.g., SEQ ID NO: 500) or other gRNAs (e.g., portions of SEQ ID NOs: 1-19, 21-42, 301-494, and 931-946), where a base is considered to match if its preferred canonical partner base (A, C, G, or T / U) for Watson-Crick pairing is the same or if there is a paired base-stacking interaction as shown in Figure 25.
[0209] As used herein, "conservative substitution" with respect to a polynucleotide refers to a modification of a nucleic acid base, meaning that the position of a base pair nucleotide is exchanged so that base pairing is maintained, e.g., a GC pair becomes a CG pair, an AU pair becomes a UA pair, or other natural or modified base pair.
[0210] As used herein, "substituted" or the like with respect to unpaired nucleotides (e.g., the loop of a repeat / anti-repeat, hairpin 1, or hairpin 2 region, i.e., nucleotides 49-52, 87-90, and 122-125 of SEQ ID NO: 500, respectively, or other unpaired nucleotides) refers to replacing one or more nucleotides, e.g., 1, 2, 3, or 4 nucleotides, of a nucleotide sequence with different nucleotides that do not prevent the formation of a structure with the unpaired nucleotides (e.g., a bulge or loop), thereby allowing the formation of one or more duplex portions, e.g., in the repeat / anti-repeat, hairpin 1, or hairpin 2 region.
[0211] In some embodiments, a gRNA includes nucleotides that "match a modification pattern" at corresponding or designated nucleotides of a gRNA described herein. This means that the nucleotides that match the modification pattern have the same modification (e.g., phosphorothioate, 2'-fluoro, 2'-OMe, etc.) as the nucleotides at corresponding positions in a gRNA described herein, regardless of whether the nucleobases at those positions match. For example, if a first gRNA has a 2'-OMe modification and a phosphorothioate modification at nucleotides 5 and 6, respectively, this gRNA will have the same modification pattern as a second gRNA that has a 2'-OMe modification and a phosphorothioate modification at nucleotides 5 and 6, respectively, regardless of whether the nucleobases at positions 5 and 6 are the same or different in the first and second gRNAs. However, a 2'-OMe modification at nucleotide 6 but not nucleotide 7 will have a different modification pattern at nucleotides 6 and 7 than a 2'-OMe modification at nucleotide 7 but not nucleotide 6. Similarly, a modification pattern that matches at least 75% of the modification pattern of a gRNA described herein means that at least 75% of the nucleotides have the same modification as the corresponding positions in the gRNA described herein. Corresponding positions can be determined by pairwise or structural alignment.
[0212] As used herein, the terms "guide sequence" or "guide region" refer to a sequence within a guide RNA that is complementary to a target sequence and functions to guide the guide RNA to the target sequence for binding or modification (e.g., cleavage) by NmeCas9. A "guide sequence" is also referred to as a "targeting sequence" or "spacer sequence." The length of a guide sequence can be 20 to 25 nucleotides, and in the case of NmeCas9, for example, it can be 20, 21, 22, 23, 24, or 25 nucleotides in length.
[0213] Because the nucleic acid substrate of an RNA-guided DNA-binding agent is a double-stranded nucleic acid, the target sequence of the RNA-guided DNA-binding agent includes both the plus and minus strands of genomic DNA (i.e., a given sequence and its reverse complement). Thus, when a guide sequence is said to be "complementary to a target sequence," it is understood that the guide sequence can cause the guide RNA to bind to the sense or antisense strand (e.g., the reverse complement) of the target sequence. That is, in some embodiments, when a guide sequence binds to the reverse complement of a target sequence, the guide sequence is identical to a specific nucleotide of the target sequence (e.g., the target sequence without the PAM) except for the T-to-U substitution in the guide sequence.
[0214] As used herein, "5' end" refers to the first nucleotide of a gRNA, including a dgRNA (typically the 5' end of the crRNA of the dgRNA) and an sgRNA (i.e., the 5' end of the guide sequence that is not linked to another nucleotide at the 5' position).
[0215] As used herein, "5' end modified" refers to a gRNA that includes a guide region in which one or more of 1 to about 7 nucleotides, optionally about 4 nucleotides, at the 5' end of the gRNA have been modified, optionally with the first nucleotide (from the 5' end) of the gRNA being modified.
[0216] As used herein, "3' end" refers to the end or terminal nucleotide of a gRNA whose 3' position is not linked to another nucleotide. In some embodiments, the 3' end is within the 3' tail. In some embodiments, the 3' end is within a conserved region of the gRNA.
[0217] As used herein, "3' end modified" refers to a gRNA in which one or more of 1 to about 7 nucleotides, optionally about 4 nucleotides, at the 3' end are modified, optionally the last nucleotide (i.e., the 3'-most nucleotide) of the gRNA is modified. If a 3' tail is present, 1 to about 7 nucleotides, optionally about 4 nucleotides, may be present within the 3' tail. If a 3' tail is not present, 1 to about 7 nucleotides, optionally about 4 nucleotides, may be present within a conserved region of the sgRNA.
[0218] Nucleotides such as the "last," "second-to-last," and "third-to-last" refer to the 3'-most, second-to-last, and third-to-last nucleotides, respectively, in a particular sequence. For example, in the sequence 5'-AAACTG-3', the last, second-to-last, and third-to-last nucleotides are G, T, and C, respectively. The phrase "the last three nucleotides" refers to the last, second-to-last, and third-to-last nucleotides. More generally, the phrase "the last N nucleotides" refers to the last nucleotide through the Nth nucleotide. "The third-to-third nucleotide from the 3' end of the 3' end" is equivalent to "the third-to-last nucleotide." Similarly, "the third-to-fifth nucleotide from the 5' end of the 5' end" is equivalent to "the third-to-fifth nucleotide from the 5' end."
[0219] As used herein, a "protected end modification" (e.g., a protected 5' end modification or a protected 3' end modification) refers to the modification of one or more nucleotides, optionally of four of the seven nucleotides at the end of an sgRNA, which reduces degradation (e.g., exonucleolytic degradation) of the sgRNA. In some embodiments, the protected end modification comprises modification of at least two or at least three of the seven nucleotides at the end of an sgRNA, optionally of four of the seven nucleotides at the end of the sgRNA. In some embodiments, the modification comprises a phosphorothioate linkage, a 2' modification such as 2'-OMe or 2'-fluoro, 2'-H(DNA), ENA, UNA, or a combination thereof. In some embodiments, the modification comprises a phosphorothioate linkage and a 2'-OMe modification. In some embodiments, at least three terminal nucleotides are modified, e.g., with phosphorothioate linkages or a combination of phosphorothioate linkages and 2'-OMe modifications. In some embodiments, at least two terminal nucleotides are modified, e.g., with phosphorothioate linkages or a combination of phosphorothioate linkages and 2'-OMe modifications. Modifications known to those of skill in the art to reduce exonuclease degradation are included.
[0220] In some embodiments, the "3' tail" comprises about 1-10 nucleotides, optionally about 1-4 nucleotides, following the conserved region of the sgRNA at its 3' end.
[0221] Several Cas9 orthologs have been isolated from N. meningitidis (Esvelt et al., NAT. METHODS, Vol. 10, 2013, pp. 1116-1121; Hou et al., PNAS, Vol. 110, 2013, pp. 15644-15649) (Nme1Cas9, Nme2Cas9, and Nme3Cas9). The Nme2Cas9 ortholog functions efficiently in mammalian cells, recognizes the N4CC PAM, and can be used for in vivo editing (Ran et al., NATURE, Vol. 520, 2015, pp. 186-191; Kim et al., NAT. COMMUN., Vol. 8, 2017, pp. 14500). Nme2Cas9 has been shown to be naturally resistant to off-target editing (Lee et al., MOL. THER., vol. 24, 2016, pages 645-654; Kim et al., 2017). See, for example, WO2020081568 (e.g., pages 28 and 42), which describes Nme2Cas9 D16A nickase, the contents of which are incorporated herein by reference in their entirety. Furthermore, NmeCas9 mutants are known in the art; see, for example, Huang et al., Nature Biotech. 2022, doi.org / 10.1038 / s41587-022-01410-2, which describes a Cas9 mutant targeting a single nucleotide pyrimidine PAM.
[0222] As used herein, "NmeCas9" (sometimes referred to as "Cas9") includes NmeCas9, such as Nme1Cas9, Nme2Cas9, and Nme3Cas9, mutants of NmeCas9 listed herein, and equivalents thereof. See, e.g., Edraki et al., Mol. Cell 73:714-726, 2019. As used herein, "Cas nuclease," also referred to as "Cas protein," encompasses Cas cleavases and Cas nickases that further have RNA-guided DNA cleavage or nickase activity, as well as dCas DNA binders in which the cleavage / nickase activity has been inactivated. In some embodiments, NmeCas9 has double-strand cleavage activity. In some embodiments, NmeCas9 has nickase activity. In some embodiments, NmeCas9 comprises a dCas DNA-binding domain.
[0223] As used herein, a first sequence is considered to "contain a sequence having at least X% identity to" a second sequence if alignment of the first sequence to the second sequence indicates that X% or more of the positions of the second sequence overall match the first sequence. For example, the sequence AAGA contains a sequence having 100% identity to the sequence AAG, because alignment results in 100% identity in that all three positions of the second sequence match. Differences between RNA and DNA (generally, the exchange of uridine with thymidine or vice versa) and the presence of nucleoside analogs such as modified uridines do not contribute to differences in identity or complementarity between polynucleotides, as long as the related nucleotide (e.g., thymidine, uridine, or modified uridine) has the same complement (e.g., adenosine for all thymidine, uridine, or modified uridine; another example is cytosine and 5-methylcytosine, both of which have guanosine or modified guanosine as their complement). Thus, for example, in the sequence 5'-AXG, where X is any modified uridine, such as pseudouridine, N1-methylpseudouridine, or 5-methoxyuridine, it is considered 100% identical to AUG, since all are perfectly complementary to the same sequence (5'-CAU). Exemplary alignment algorithms are the Smith-Waterman and Needleman-Wunsch algorithms, which are well known in the art. Those skilled in the art will understand the appropriate selection of algorithm and parameter settings for a given pair of sequences to be aligned. For sequences that are approximately the same length and predicted to have greater than 50% amino acid identity or greater than 75% nucleotide identity, the Needleman-Wunsch algorithm (provided by the EBI on its web server at www.ebi.ac.uk) with the Needleman-Wunsch algorithm interface at default settings is generally appropriate.
[0224] "MRNA" is used herein to refer to a polynucleotide that is an RNA or modified RNA and contains an open reading frame that can be translated into a polypeptide (i.e., can be a substrate for translation by ribosomes and aminoacylated tRNAs). mRNA can contain a phosphate-sugar backbone that includes ribose residues or analogs thereof, such as 2'-methoxyribose residues. In some embodiments, the sugars of the nucleic acid phosphate-sugar backbone consist essentially of ribose residues, 2'-methoxyribose residues, or combinations thereof. Generally, mRNA does not contain significant amounts of thymidine residues (e.g., 0 residues, or fewer than 30, 20, 10, 5, 4, 3, or 2 thymidine residues; or a thymidine content of less than 10%, 9%, 8%, 7%, 6%, 5%, 4%, 4%, 3%, 2%, 1%, 0.5%, 0.2%, or 0.1%). mRNA can contain modified uridines at some or all of its uridine positions. Modified mRNAs contain at least one nucleotide in which one or more of the phosphate, sugar, or nucleobase differs from that of a standard adenosine, cytidine, guanidine, or uridine nucleotide.
[0225] As used herein, "subject" refers to any member of the animal kingdom. In some embodiments, "subject" refers to a human. In some embodiments, "subject" refers to a non-human animal. In some embodiments, "subject" refers to a primate. In some embodiments, "subject" refers to a non-human primate. In some embodiments, a subject includes, but is not limited to, a mammal, a bird, a reptile, an amphibian, a fish, an insect, or a worm, etc. In certain embodiments, a non-human subject is a mammal (e.g., a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a sheep, a cow, a primate, or a pig). In some embodiments, a subject may be a transgenic animal, a genetically engineered animal, or a clone. In certain embodiments of the invention, a subject is an adult, an adolescent, or an infant. In some embodiments, the terms "individual" or "patient" are used, which are intended interchangeably with "subject," and the subject is a human subject.
[0226] As used herein, "treatment" refers to any administration or application of a therapeutic agent to a disease or disorder in a subject, including delaying or arresting the onset or progression of a disease, alleviating one or more signs or symptoms of a disease, curing a disease, or preventing the recurrence of one or more symptoms of a disease.
[0227] As used herein, "delivery" and "administration" are used interchangeably and include ex vivo and in vivo applications.
[0228] As used herein, co-administration means that two or more agents are administered close enough in time that the agents act together. Co-administration includes administering the agents together in a single formulation, as well as administering the agents in separate formulations close enough in time that the agents act together.
[0229] As used herein, the term "pharmaceutically acceptable" means useful in preparing pharmaceutical compositions that are generally non-toxic, not biologically undesirable, and not otherwise unacceptable for pharmaceutical use. Pharmaceutically acceptable substances generally refer to non-pyrogenic substances. Pharmaceutically acceptable substances may refer to sterilized substances, particularly in the case of pharmaceutical substances for injection or infusion.
[0230] I. Guide RNAs with one or more truncated conserved regions Provided herein are guide RNAs (gRNAs) that include one or more shortened conserved regions.
[0231] In some embodiments, the gRNAs provided herein comprise a guide region and a conserved region comprising a repeat / anti-repeat region, a hairpin 1 region, and a hairpin 2 region, wherein one or more of the repeat / anti-repeat region, hairpin 1 region, and hairpin 2 region are truncated. In some embodiments, the gRNA is derived from N. meningitidis Cas9 (NmeCas9).
[0232] In some embodiments, the conserved region comprises one or more of the following: (a) a truncated repeat / anti-repeat region, wherein the truncated repeat / anti-repeat region lacks 2 to 24 nucleotides, wherein: (i) relative to SEQ ID NO: 500, one or more of nucleotides 37-48 and 53-64 are deleted, and optionally one or more of nucleotides 37-64 are substituted; and (ii) nucleotide 36 is connected to nucleotide 65 by at least two nucleotides; or (b) a truncated hairpin 1 region, wherein truncated hairpin 1 lacks 2 to 10 nucleotides, optionally 2 to 8 nucleotides, and wherein: (i) relative to SEQ ID NO: 500, one or more of nucleotides 82-86 and 91-95 are deleted, and optionally one or more of positions 82-96 are substituted; and (ii) nucleotide 81 is connected to nucleotide 96 by at least four nucleotides; or (c) a truncated hairpin 2 region, wherein the truncated hairpin 2 lacks 2 to 18 nucleotides, optionally 2 to 16 nucleotides, wherein: (i) relative to SEQ ID NO: 500, one or more of nucleotides 113-121 and 126-134 are deleted, and optionally one or more of nucleotides 113-134 are substituted; and (ii) nucleotide 112 is connected to nucleotide 135 by at least four nucleotides; wherein, relative to SEQ ID NO: 500, one or both of nucleotides 144-145 are optionally deleted; and wherein at least 10 nucleotides are modified nucleotides.
[0233] In some embodiments, the conserved region is a truncated repeat / anti-repeat region, wherein the truncated repeat / anti-repeat region lacks 2 to 24 nucleotides, (i) relative to SEQ ID NO: 500, one or more of nucleotides 37-48 and 53-64 are deleted, and optionally one or more of nucleotides 37-64 are substituted; and (ii) nucleotide 36 is connected to nucleotide 65 by at least two nucleotides; wherein, relative to SEQ ID NO: 500, one or both of nucleotides 144-145 are optionally deleted; At least 10 nucleotides within the conserved region are modified nucleotides.
[0234] In some embodiments, the conserved region is a truncated hairpin 1 region, wherein the truncated hairpin 1 lacks 2 to 10 nucleotides, optionally 2 to 8 nucleotides, wherein: (i) relative to SEQ ID NO: 500, one or more of nucleotides 82-86 and 91-95 are deleted, and optionally one or more of positions 82-96 are substituted; and (ii) nucleotide 81 is connected to nucleotide 96 by at least four nucleotides; wherein, relative to SEQ ID NO: 500, one or both of nucleotides 144-145 are optionally deleted; At least 10 nucleotides within the conserved region are modified nucleotides.
[0235] In some embodiments, the conserved region is a truncated hairpin 2 region, wherein the truncated hairpin 2 lacks 2 to 18 nucleotides, optionally 2 to 16 nucleotides, wherein (i) relative to SEQ ID NO: 500, one or more of nucleotides 113-121 and 126-134 are deleted, and optionally one or more of nucleotides 113-134 are substituted; and (ii) nucleotide 112 is connected to nucleotide 135 by at least four nucleotides; wherein, relative to SEQ ID NO: 500, one or both of nucleotides 144-145 are optionally deleted; At least 10 nucleotides within the conserved region are modified nucleotides.
[0236] In some embodiments, the conserved region is (a) a truncated repeat / anti-repeat region, wherein the truncated repeat / anti-repeat region lacks 2 to 24 nucleotides, wherein: (i) relative to SEQ ID NO: 500, one or more of nucleotides 37-48 and 53-64 are deleted, and optionally one or more of nucleotides 37-64 are substituted; and (ii) nucleotide 36 is connected to nucleotide 65 by at least two nucleotides; and (b) a truncated hairpin 1 region, wherein the truncated hairpin 1 lacks 2 to 10 nucleotides, optionally 2 to 8 nucleotides, and wherein: (i) relative to SEQ ID NO: 500, one or more of nucleotides 82-86 and 91-95 are deleted, and optionally one or more of positions 82-96 are substituted; and (ii) nucleotide 81 is connected to nucleotide 96 by at least four nucleotides; or wherein, relative to SEQ ID NO: 500, one or both of nucleotides 144-145 are optionally deleted; At least 10 nucleotides within the conserved region are modified nucleotides.
[0237] In some embodiments, the conserved region is (a) a truncated repeat / anti-repeat region, wherein the truncated repeat / anti-repeat region lacks 2 to 24 nucleotides, wherein: (i) relative to SEQ ID NO: 500, one or more of nucleotides 37-48 and 53-64 are deleted, and optionally one or more of nucleotides 37-64 are substituted; and (ii) nucleotide 36 is connected to nucleotide 65 by at least two nucleotides; and (b) a truncated hairpin 2 region, wherein the truncated hairpin 2 lacks 2 to 18 nucleotides, optionally 2 to 16 nucleotides, and wherein: (i) relative to SEQ ID NO: 500, one or more of nucleotides 113-121 and 126-134 are deleted, and optionally one or more of nucleotides 113-134 are substituted; and (ii) nucleotide 112 is connected to nucleotide 135 by at least four nucleotides; wherein, relative to SEQ ID NO: 500, one or both of nucleotides 144-145 are optionally deleted; At least 10 nucleotides within the conserved region are modified nucleotides.
[0238] In some embodiments, the conserved region is (a) a truncated hairpin 1 region, wherein truncated hairpin 1 lacks 2 to 10 nucleotides, optionally 2 to 8 nucleotides, and (i) relative to SEQ ID NO: 500, one or more of nucleotides 82-86 and 91-95 are deleted, and optionally one or more of positions 82-96 are substituted; and (ii) nucleotide 81 is connected to nucleotide 96 by at least four nucleotides; and (b) a truncated hairpin 2 region, wherein the truncated hairpin 2 lacks 2 to 18 nucleotides, optionally 2 to 16 nucleotides, and wherein: (i) relative to SEQ ID NO: 500, one or more of nucleotides 113-121 and 126-134 are deleted, and optionally one or more of nucleotides 113-134 are substituted; and (ii) nucleotide 112 is connected to nucleotide 135 by at least four nucleotides; wherein, relative to SEQ ID NO: 500, one or both of nucleotides 144-145 are optionally deleted; At least 10 nucleotides within the conserved region are modified nucleotides.
[0239] In some embodiments, the conserved region is (a) a truncated repeat / anti-repeat region, wherein the truncated repeat / anti-repeat region lacks 2 to 24 nucleotides, wherein: (i) relative to SEQ ID NO: 500, one or more of nucleotides 37-48 and 53-64 are deleted, and optionally one or more of nucleotides 37-64 are substituted; and (ii) nucleotide 36 is connected to nucleotide 65 by at least two nucleotides; (b) a truncated hairpin 1 region, wherein truncated hairpin 1 lacks 2 to 10 nucleotides, optionally 2 to 8 nucleotides, and wherein: (i) relative to SEQ ID NO: 500, one or more of nucleotides 82-86 and 91-95 are deleted, and optionally one or more of positions 82-96 are substituted; and (ii) nucleotide 81 is connected to nucleotide 96 by at least four nucleotides; and (c) a truncated hairpin 2 region, wherein the truncated hairpin 2 lacks 2 to 18 nucleotides, optionally 2 to 16 nucleotides, wherein: (i) relative to SEQ ID NO: 500, one or more of nucleotides 113-121 and 126-134 are deleted, and optionally one or more of nucleotides 113-134 are substituted; and (ii) nucleotide 112 is connected to nucleotide 135 by at least four nucleotides; wherein, relative to SEQ ID NO: 500, one or both of nucleotides 144-145 are optionally deleted; At least 10 nucleotides of the conserved region are modified nucleotides.
[0240] In some embodiments, the gRNAs described herein are sgRNAs.
[0241] In some embodiments, one or both of nucleotides 144-145 relative to SEQ ID NO:500 are deleted.
[0242] In some embodiments, at least 10 nucleotides of the conserved region are modified nucleotides.
[0243] In some embodiments, the repeat / anti-repeat region of the gRNA is a shortened repeat / anti-repeat region lacking 2-24 nucleotides, such as any of the repeat / anti-repeat regions shown in the numbered embodiments above or Tables 1-2, or described elsewhere herein, and can be combined with any of the shortened hairpin 1 or hairpin 2 regions described herein, including, but not limited to, combinations shown in the numbered embodiments above, represented by the sequences in Tables 1-2, or described elsewhere herein. In some embodiments, one or more of positions 49-52, 87-90, or 122-125 are substituted relative to SEQ ID NO:500. In some embodiments, all of positions 49-52, 87-90, or 122-125 are substituted relative to SEQ ID NO:500. In some embodiments, the 3' tail provided in Tables 1-2 or described herein is deleted.
[0244] In some embodiments, the truncated repeat / anti-repeat region of the gRNA lacks 18 nucleotides, hi some embodiments, the truncated repeat / anti-repeat region of the gRNA lacks 22 nucleotides.
[0245] In some embodiments, in the truncated repeat / anti-repeat region of the gRNA, nucleotide 36 is linked to nucleotide 65 by 6 nucleotides. In some embodiments, in the truncated repeat / anti-repeat region of the gRNA, nucleotide 36 is linked to nucleotide 65 by 7 nucleotides. In some embodiments, in the truncated repeat / anti-repeat region of the gRNA, nucleotide 36 is linked to nucleotide 65 by 8 nucleotides. In some embodiments, in the truncated repeat / anti-repeat region of the gRNA, nucleotide 36 is linked to nucleotide 65 by 9 nucleotides. In some embodiments, in the truncated repeat / anti-repeat region of the gRNA, nucleotide 36 is linked to nucleotide 65 by 10 nucleotides.
[0246] In some embodiments, the truncated repeat / anti-repeat region of the gRNA has nucleotides 38-48 and 53-63 deleted relative to SEQ ID NO: 500. In some embodiments, the truncated repeat / anti-repeat region of the gRNA has nucleotides 38, 41-48, 53-60, and 63 deleted relative to SEQ ID NO: 500.
[0247] In some embodiments, in the truncated repeat / anti-repeat region of the gRNA, nucleotide 36 is connected by 6 nucleotides to nucleotide 65. In some embodiments, in the truncated repeat / anti-repeat region of the gRNA, nucleotides 38-48 and 53-63 relative to SEQ ID NO:500 are deleted, and nucleotide 36 is connected to nucleotide 65 by nucleotides 37, 49-52, and 64.
[0248] In some embodiments, in the truncated repeat / anti-repeat region of the gRNA, nucleotide 36 is connected by 10 nucleotides to nucleotide 65. In some embodiments, in the truncated repeat / anti-repeat region of the gRNA, nucleotides 38, 41-48, 53-60, and 63 relative to SEQ ID NO:500 are deleted, and nucleotide 36 is connected to nucleotide 65 by nucleotides 37, 39, 40, 49-52, 61, 62, and 64.
[0249] In some embodiments, nucleotides 38-48 and all of nucleotides 53-63 of the upper stem of the truncated repeat / anti-repeat region are deleted relative to SEQ ID NO:500.
[0250] In some embodiments, nucleotides 39-48 and all of nucleotides 53-62 of the upper stem of the truncated repeat / anti-repeat region are deleted relative to SEQ ID NO:500, and nucleotides 38 and 63 are substituted.
[0251] In some embodiments, the truncated repeat / anti-repeat region has 14 modified nucleotides. In some embodiments, the truncated repeat / anti-repeat region has 15 modified nucleotides. In some embodiments, the truncated repeat / anti-repeat region has 16 modified nucleotides. In some embodiments, the truncated repeat / anti-repeat region has 17 modified nucleotides. In some embodiments, the truncated repeat / anti-repeat region has 18 modified nucleotides. In some embodiments, the truncated repeat / anti-repeat region has 19 modified nucleotides. In some embodiments, the truncated repeat / anti-repeat region has 20 modified nucleotides.
[0252] In some embodiments, the truncated hairpin 1 region lacks 2 nucleotides. In some embodiments, the truncated hairpin 1 region lacks 21 nucleotides. In some embodiments, the truncated hairpin 1 region lacks 2 nucleotides, with nucleotides 86 and 91 deleted relative to SEQ ID NO:500. In some embodiments, the truncated hairpin 1 region lacks 2 nucleotides, with nucleotides 85 and 92 deleted relative to SEQ ID NO:500. In some embodiments, in the truncated hairpin 1 region, nucleotide 81 is connected to nucleotide 96 by 12 nucleotides. In some embodiments, in the truncated hairpin 1 region, nucleotides 86 and 91 are deleted relative to SEQ ID NO:500, and nucleotide 81 is connected to nucleotide 96 by nucleotides 82-85, 87-90, and 92-95. In some embodiments, in the shortened hairpin 1 region, nucleotides 85 and 92 are deleted relative to SEQ ID NO:500, and nucleotide 81 is joined to nucleotide 96 by nucleotides 82-84, 86-91, and 93-95.
[0253] In some embodiments, the shortened hairpin 1 region has a duplex portion that is 7 base pair nucleotides in length. In some embodiments, the shortened hairpin 1 region has a duplex portion that is 8 base pair nucleotides in length.
[0254] The stem of the shortened hairpin 1 region is 7 base pair nucleotides in length. In some embodiments, nucleotides 85-86 and 91-92 of the shortened hairpin 1 region are deleted.
[0255] In some embodiments, the shortened hairpin 1 region has 13 modified nucleotides.
[0256] In some embodiments, truncated hairpin 2 lacks 18 nucleotides. In some embodiments, truncated hairpin 2 has 24 nucleotides. In some embodiments, truncated hairpin 2 has nucleotides 113-121 and 126-134 deleted relative to SEQ ID NO:500. In some embodiments, truncated hairpin 2 lacks 18 nucleotides, having nucleotides 113-121 and 126-134 deleted relative to SEQ ID NO:500. In some embodiments, in the truncated hairpin 2 region, nucleotide 112 is connected to nucleotide 135 by 4 nucleotides. In some embodiments, in the truncated hairpin 2 region, nucleotides 113-121 and 126-134 deleted relative to SEQ ID NO:500, and nucleotide 112 is connected to nucleotide 135 by nucleotides 122-125.
[0257] In some embodiments, the truncated repeat / anti-repeat region is 28 nucleotides in length. In some embodiments, the truncated repeat / anti-repeat region is 32 nucleotides in length.
[0258] In some embodiments, the upper stem of the truncated repeat / anti-repeat region comprises 1 base pair or less. In some embodiments, the upper stem of the truncated repeat / anti-repeat region comprises 3 base pairs or less.
[0259] In some embodiments, the shortened hairpin 2 region has 8 modified nucleotides.
[0260] In some embodiments, the guide RNA (gRNA) comprises a guide region and a conserved region, wherein the conserved region comprises: (a) a truncated repeat / anti-repeat region, wherein the truncated repeat / anti-repeat region lacks 18 to 22 nucleotides relative to SEQ ID NO: 500, wherein: (i) nucleotides 38 to 48 and 53 to 63 are deleted, and (ii) nucleotide 36 is connected to nucleotide 65 by 6 to 10 nucleotides; (b) a truncated hairpin 1 region, wherein the truncated hairpin 1 lacks two nucleotides, nucleotides 86 and 91 being deleted or nucleotides 85 and 92 being deleted relative to SEQ ID NO:500; and (c) a truncated hairpin 2 region, wherein truncated hairpin 2 lacks 18 nucleotides, nucleotides 113-121 and 126-134 deleted relative to SEQ ID NO: 500, and nucleotides 144-145 deleted relative to SEQ ID NO: 500, and at least 10 nucleotides are modified nucleotides.
[0261] In some embodiments, the guide RNA (gRNA) comprises a guide region and a conserved region, wherein the conserved region comprises: (a) a truncated repeat / anti-repeat region, wherein the truncated repeat / anti-repeat region lacks 18 to 22 nucleotides relative to SEQ ID NO: 500, wherein: (i) nucleotides 38, 41 to 48, 53 to 60, and 63 are deleted; and (ii) nucleotide 36 is connected to nucleotide 65 by 6 to 10 nucleotides; (b) a truncated hairpin 1 region, wherein the truncated hairpin 1 lacks two nucleotides, nucleotides 86 and 91 being deleted, or nucleotides 85 and 92 being deleted relative to SEQ ID NO:500; (c) a truncated hairpin 2 region, wherein the truncated hairpin 2 lacks 18 nucleotides, and nucleotides 113-121 and 126-134 are deleted relative to SEQ ID NO: 500; and wherein nucleotides 144-145 are deleted relative to SEQ ID NO: 500, At least 10 nucleotides are modified nucleotides.
[0262] In some embodiments, a guide RNA (gRNA) is provided, wherein the gRNA comprises a guide region and a conserved region, wherein the conserved region comprises one or more of the following: (a) a truncated repeat / anti-repeat region, wherein the truncated repeat / anti-repeat region lacks 18 to 22 nucleotides relative to SEQ ID NO: 500, wherein: (i) nucleotides 37-48 and 53-64 are deleted, and (ii) nucleotide 36 is connected to nucleotide 65 by 6 to 10 nucleotides; or (b) a truncated hairpin 1 region, wherein the truncated hairpin 1 lacks two nucleotides, with nucleotides 86 and 91 deleted or nucleotides 85 and 92 deleted relative to SEQ ID NO:500; or (c) a truncated hairpin 2 region, wherein the truncated hairpin 2 lacks 18 nucleotides, and nucleotides 113-121 and 126-134 are deleted relative to SEQ ID NO: 500; and wherein nucleotides 144-145 are deleted relative to SEQ ID NO: 500, At least 10 nucleotides are modified nucleotides.
[0263] In a further embodiment, in the truncated repeat / anti-repeat region, the truncated repeat / anti-repeat region lacks 22 nucleotides relative to SEQ ID NO: 500. In a further embodiment, nucleotide 36 is linked to nucleotide 65 by a sequence comprising the nucleotide sequence UGAAAC. In a further embodiment, nucleotide 36 is linked to nucleotide 65 by 10 nucleotides. In a further embodiment, nucleotide 36 is linked to nucleotide 65 by a sequence comprising the nucleotide sequence UUCGAAAGAC (SEQ ID NO: 950).
[0264] In some embodiments, the guide RNA (gRNA) of the foregoing embodiments comprises a guide region and a conserved region, wherein the conserved region comprises: (a) a truncated repeat / anti-repeat region, wherein the truncated repeat / anti-repeat region lacks 18 to 22 nucleotides, wherein: (i) nucleotides 37-48 and 53-64 are deleted relative to SEQ ID NO: 500; and (ii) nucleotide 36 is connected to nucleotide 65 by 6 to 10 nucleotides; (b) a truncated hairpin 1 region, wherein the truncated hairpin 1 lacks two nucleotides relative to SEQ ID NO: 500, wherein nucleotides 86 and 91 are deleted, or nucleotides 85 and 92 are deleted; (c) a truncated hairpin 2 region, wherein the truncated hairpin 2 lacks 18 nucleotides, and nucleotides 113-121 and 126-134 are deleted relative to SEQ ID NO: 500; and (d) wherein nucleotides 144-145 are deleted relative to SEQ ID NO: 500; At least 10 nucleotides are modified nucleotides.
[0265] In a further embodiment, in the truncated repeat / anti-repeat region, the truncated repeat / anti-repeat region lacks 22 nucleotides relative to SEQ ID NO: 500. In a further embodiment, nucleotide 36 is linked to nucleotide 65 by a sequence comprising the nucleotide sequence UGAAAC. In a further embodiment, nucleotide 36 is linked to nucleotide 65 by 10 nucleotides. In a further embodiment, nucleotide 36 is linked to nucleotide 65 by a sequence comprising the nucleotide sequence UUCGAAAGAC (SEQ ID NO: 950).
[0266] A. Truncated repeat / anti-repeat region In some embodiments, the gRNAs described herein comprise a conserved region that includes a truncated repeat / anti-repeat region. In some embodiments, the repeat / anti-repeat region comprises a hairpin structure between a first portion and a second portion of the repeat / anti-repeat region, and the first portion and the second portion of the repeat / anti-repeat region together form a duplex portion.
[0267] In some embodiments, the gRNAs described herein comprise a conserved region that includes a shortened upper stem region of the repeat / anti-repeat region. In some embodiments, the repeat / anti-repeat region comprises a loop (e.g., a tetraloop).
[0268] In some embodiments, the truncated repeat / anti-repeat region lacks 2 to 24 nucleotides, in some embodiments (i) one or more of nucleotides 37-48 and 53-64 are deleted, and optionally one or more of nucleotides 37-64 are substituted, relative to SEQ ID NO:500, and (ii) nucleotide 36 is connected to nucleotide 65 by at least four nucleotides.
[0269] In some embodiments, the truncated repeat / anti-repeat region lacks between 2 and 24 nucleotides.
[0270] In some embodiments, the length of the shortened repeat / anti-repeat region is 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides.
[0271] In some embodiments, the truncated repeat / anti-repeat region lacks 12 to 24 nucleotides, optionally 18 to 24 nucleotides. In some embodiments, the length of the truncated repeat / anti-repeat region is 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides. In some embodiments, the length of the truncated repeat / anti-repeat region is 28, 29, 30, 31, 32, 33, or 34 nucleotides. In some embodiments, the length of the truncated repeat / anti-repeat region is 28 nucleotides. In some embodiments, the length of the truncated repeat / anti-repeat region is 29 nucleotides. In some embodiments, the length of the truncated repeat / anti-repeat region is 30 nucleotides. In some embodiments, the length of the truncated repeat / anti-repeat region is 31 nucleotides. In some embodiments, the length of the truncated repeat / anti-repeat region is 32 nucleotides. In some embodiments, the truncated repeat / anti-repeat region is 33 nucleotides in length. In some embodiments, the truncated repeat / anti-repeat region is 34 nucleotides in length.
[0272] In some embodiments, nucleotides 37-64 of SEQ ID NO:500 form the upper stem, and one or more base pairs of the upper stem of the truncated repeat / anti-repeat region are deleted. In some embodiments, the upper stem of the truncated repeat / anti-repeat region contains no more than 1, no more than 2, no more than 3, or no more than 4 base pairs. In some embodiments, all of positions 38-48 and all of positions 53-63 of the upper stem of the truncated repeat / anti-repeat region are deleted. In some embodiments, nucleotides 37-48 and all of nucleotides 53-64 of the upper stem of the truncated repeat / anti-repeat region are deleted. As used herein, "base pair" or "base-paired nucleotide" or "Watson-Crick paired nucleotide" includes any pair capable of forming a Watson-Crick base pair, including AT, AU, TA, UA, CG, and GC pairs, as well as pairs containing modified versions of any of the foregoing nucleotides having the same base pairing preference. As used herein, base pairs or base-paired nucleotides also include base pairs generated by base stacking, such as nucleotides 25 and 76, 33 and 68, 34 and 67, and 37 and 64 in the repeat / anti-repeat region, and nucleotides 78 and 100, and 83 and 94 in the hairpin 1 region.
[0273] In some embodiments, one or more of positions 37-48 are deleted. In some embodiments, position 37 is deleted. In some embodiments, position 38 is deleted. In some embodiments, position 39 is deleted. In some embodiments, position 40 is deleted. In some embodiments, position 41 is deleted. In some embodiments, position 42 is deleted. In some embodiments, position 43 is deleted. In some embodiments, position 44 is deleted. In some embodiments, position 45 is deleted. In some embodiments, position 46 is deleted. In some embodiments, position 47 is deleted. In some embodiments, position 48 is deleted.
[0274] In some embodiments, one or more of positions 53-63 are deleted. In some embodiments, position 53 is deleted. In some embodiments, position 54 is deleted. In some embodiments, position 55 is deleted. In some embodiments, position 56 is deleted. In some embodiments, position 57 is deleted. In some embodiments, position 58 is deleted. In some embodiments, position 59 is deleted. In some embodiments, position 60 is deleted. In some embodiments, position 61 is deleted. In some embodiments, position 62 is deleted. In some embodiments, position 63 is deleted. In some embodiments, position 64 is deleted.
[0275] In some embodiments, the truncated repeat / anti-repeat region has a duplex portion that is 11 base pair nucleotides in length. In some embodiments, the truncated repeat / anti-repeat region has a single duplex portion.
[0276] In some embodiments, one or more base paired nucleotides within the repeat / anti-repeat region are deleted, in some embodiments, one or more base paired nucleotides selected from positions 37 and 53, positions 38 and 54, positions 39 and 55, positions 40 and 56, positions 41 and 57, positions 43 and 58, positions 43 and 59, positions 44 and 60, positions 45 and 61, positions 46 and 62, positions 47 and 63, and positions 48 and 64.
[0277] In some embodiments, the upper stem region of the repeat / anti-repeat region comprises 1 to 5 base pairs.
[0278] In some embodiments, the upper stem of the shortened repeat / anti-repeat region comprises one or more substitutions relative to SEQ ID NO:500.
[0279] In some embodiments, one or more substitutions are conservative substitutions that maintain the base pair(s). For example, a GC pair becomes a CG pair, or other natural or modified base pair, or an AU pair becomes a UA pair, or other natural or modified base pair. In some embodiments, one or more substitutions are conservative substitutions that exchange the positions of the base pair nucleotides (e.g., a GC pair becomes a CG pair, or an AU pair becomes a UA pair).
[0280] In some embodiments, one or more of nucleotides 49-52 are substituted relative to SEQ ID NO: 500. In some embodiments, the truncated repeat / anti-repeat region is not substituted.
[0281] In some embodiments, the truncated repeat / anti-repeat region has between 12 and 22 modified nucleotides.
[0282] B. The shortened hairpin 1 region In some embodiments, the gRNAs described herein comprise a conserved region that includes a shortened hairpin 1 region. In some embodiments, the hairpin 1 region comprises a hairpin structure between a first portion and a second portion of the hairpin 1 region, and the first portion and the second portion of the hairpin 1 region together form a duplex portion.
[0283] In some embodiments, the gRNAs described herein comprise a conserved region that includes a shortened upper stem region of the hairpin 1 region. In some embodiments, hairpin 1 comprises a loop (e.g., a tetraloop).
[0284] In some embodiments, shortened hairpin 1 lacks 2-10 nucleotides. In some embodiments, shortened hairpin 1 lacks 2-8 nucleotides. In some embodiments, shortened hairpin 1 lacks 2-4 nucleotides. In some embodiments, shortened hairpin 1 lacks 2 nucleotides. In some embodiments, shortened hairpin 1 lacks 3 nucleotides. In some embodiments, shortened hairpin 1 lacks 4 nucleotides. In some embodiments, shortened hairpin 1 lacks 5 nucleotides. In some embodiments, shortened hairpin 1 lacks 6 nucleotides. In some embodiments, shortened hairpin 1 lacks 7 nucleotides. In some embodiments, shortened hairpin 1 lacks 8 nucleotides. In some embodiments, shortened hairpin 1 lacks 9 nucleotides. In some embodiments, shortened hairpin 1 lacks 10 nucleotides. In some embodiments, (i) relative to SEQ ID NO: 500, one or more of nucleotides 82-86 and 91-95 are deleted, and optionally one or more of positions 82-95 are substituted, and (ii) nucleotide 81 is connected to nucleotide 96 by at least four nucleotides.
[0285] In some embodiments, the shortened hairpin 1 region lacks 2-10 nucleotides. In some embodiments, the length of the shortened hairpin 1 region is 13, 14, 15, 16, 17, 18, 19, 20, or 21 nucleotides. In some embodiments, the shortened hairpin 1 region has a duplex portion 7-8 base pairs nucleotides in length. As used herein, nucleotide 96 is not considered to interrupt the duplex portion of hairpin 1 if one or more of base pairs 82 and 95, 83 and 94, 85 and 93, and 86 and 92 are present.
[0286] In some embodiments, the truncated hairpin 1 region has a single duplex portion, hi some embodiments, in the truncated hairpin 1 region, positions 78 and 100, and positions 83 and 94 have base-stacking interactions and do not constitute a discontinuity in the duplex portion.
[0287] In some embodiments, one or two base pairs of the shortened Hairpin 1 region are deleted. In some embodiments, the stem of the shortened Hairpin 1 region comprises 1, 2, 3, 4, 5, 6, 7, or 8 base pairs. In some embodiments, the stem of the shortened Hairpin 1 region is 7 or 8 base pair nucleotides in length.
[0288] In some embodiments, one or more of positions 85-86 and one or more of nucleotides 91-92 of the shortened hairpin 1 region are deleted. In some embodiments, nucleotides 86 and 91 of the shortened hairpin 1 region are deleted. In some embodiments, nucleotides 85 and 92 of the shortened hairpin 1 region are deleted. In some embodiments, one or more of nucleotides 82-95 of the shortened hairpin 1 region are substituted relative to SEQ ID NO:500. In some embodiments, one or more of nucleotides 87-91 are substituted relative to SEQ ID NO:500.
[0289] In some embodiments, the shortened hairpin 1 region is unsubstituted. In some embodiments, the shortened hairpin 1 region has between 6 and 15 modified nucleotides.
[0290] C. The shortened hairpin 2 region In some embodiments, the gRNAs described herein comprise a conserved region that includes a shortened hairpin 2 region. In some embodiments, the hairpin 2 region comprises a hairpin structure between a first portion and a second portion of the hairpin 2 region, and the first portion and the second portion of the hairpin 1 region together form a duplex portion.
[0291] In some embodiments, (c) a shortened hairpin 2 region, wherein the shortened hairpin 2 lacks 2-16 nucleotides. In some embodiments, (i) relative to SEQ ID NO: 500, one or more of nucleotides 113-121 and 126-134 are deleted, and optionally one or more of nucleotides 113-134 are substituted, and (ii) nucleotide 112 is connected to nucleotide 135 by at least four nucleotides.
[0292] In some embodiments, the conserved region of a gRNA described herein comprises a shortened upper stem region of the hairpin 2 region. In some embodiments, hairpin 1 comprises a loop (e.g., a tetraloop). In some embodiments, the shortened hairpin 2 region lacks 2-16 nucleotides. In some embodiments, the length of the shortened hairpin 2 region is 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides. In some embodiments, the length of the shortened hairpin 2 region is 28, 29, 30, 31, 32, 33, or 34 nucleotides. In some embodiments, one or more of positions 113-121 and one or more of nucleotides 126-134 of the shortened hairpin 2 region are deleted.
[0293] The shortened hairpin 2 region contains unpaired regions, i.e., nucleotides 106-108 and 139 on the opposite strand, that cause the duplex portion in hairpin 2 to be discontinuous, providing two duplex portions, i.e., nucleotides 102-105 and 140-143, and nucleotides 109-112 and 135-138.
[0294] In some embodiments, the shortened hairpin 2 region has two duplex portions. In some embodiments, the shortened hairpin 2 region has a duplex portion 4 base pair nucleotides in length. In some embodiments, the shortened hairpin 2 region has a duplex portion 4 to 8 base pair nucleotides in length. In some embodiments, the shortened hairpin 2 region has a duplex portion 4 to 6 base pair nucleotides in length. In some embodiments, the upper stem of the shortened hairpin 2 region comprises 1, 2, 3, or 4 base pairs. In some embodiments, at least one pair of nucleotides 113 and 134, nucleotides 114 and 133, nucleotides 115 and 132, nucleotides 116 and 131, nucleotides 117 and 130, nucleotides 118 and 129, nucleotides 119 and 128, nucleotides 120 and 127, and nucleotides 121 and 126 are deleted. In some embodiments, all of positions 113-121 and 126-134 of the shortened hairpin 2 region are deleted.
[0295] In some embodiments, one or more of nucleotides 113-134 of the shortened hairpin 2 region are substituted relative to SEQ ID NO: 500. In some embodiments, one or more of nucleotides 122-125 are substituted relative to SEQ ID NO: 500.
[0296] In some embodiments, the shortened hairpin 2 region is unsubstituted. In some embodiments, the shortened hairpin 2 region has between 6 and 15 modified nucleotides.
[0297] D.3' tail In some embodiments, the gRNA comprises a 3' tail. In some embodiments, the 3' tail is 1-20 nucleotides in length and is linked to the 3' end of the conserved region of the gRNA by a phosphodiester or phosphorothioate linkage. In some embodiments, the 3' tail comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides. In some embodiments, the 3' tail comprises 1, 2, 3, 4, or 5 nucleotides. In some embodiments, the 3' tail comprises 1 or 2 nucleotides.
[0298] In some embodiments, the length of the 3' tail is 1-10 nucleotides, 1-5 nucleotides, 1-4 nucleotides, 1-3 nucleotides, and 1-2 nucleotides. In some embodiments, the 3' tail comprises about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides. In some embodiments, the length of the 3' tail is 1 nucleotide. In some embodiments, the length of the 3' tail is 2 nucleotides. In some embodiments, the length of the 3' tail is 3 nucleotides. In some embodiments, the length of the 3' tail is 4 nucleotides. In some embodiments, the length of the 3' tail is 1-2 nucleotides.
[0299] In some embodiments, the 3' tail terminates with a nucleotide containing uracil or a modified uracil. In some embodiments, the 3' tail is 1 nucleotide in length. In some embodiments, the 3' tail is composed of nucleotides containing uracil or a modified uracil. In some embodiments, the 3' tail includes a modification to any one or more of the nucleotides present in the 3' tail. In further embodiments, the modification of the 3' tail is one or more of 2'-O-methyl (2'-OMe) modified nucleotides and internucleotide phosphorothioate (PS) linkages.
[0300] In some embodiments, the 3' tail is fully modified.
[0301] In some embodiments, the 3' nucleotide of the gRNA is a nucleotide containing uracil or a modified uracil.
[0302] In some embodiments, one or more of nucleotides 144 and 145 are deleted relative to SEQ ID NO: 500. In some embodiments, both nucleotides 144 and 145 are deleted relative to SEQ ID NO: 500.
[0303] In some embodiments, the gRNA does not comprise a 3' tail. In some embodiments, the 3' end of the guide without a 3' tail terminates with a nucleotide containing uracil or a modified uracil. In some embodiments, the 3' tail is composed of nucleotides containing uracil or a modified uracil. In some embodiments, the 3' terminal nucleotide is a modified nucleotide. In some embodiments, the modification at the 3' end is one or more of a 2'-O-methyl (2'-OMe) modified nucleotide and a phosphorothioate (PS) linkage between the terminal nucleotide and the penultimate nucleotide.
[0304] In some embodiments, the 3' end, i.e., the end of hairpin 2 without any further tails, or the end of the 3' tail, comprises or further comprises one or more modifications, such as, for example, internucleotide phosphorothioate (PS) linkages, 2'-OMe modified nucleotides, 2'-O-moe modified nucleotides, 2'-F modified nucleotides, inverted abasic modified nucleotides, and combinations thereof. In some embodiments, the 3' end comprises or further comprises one or more modifications, such as, for example, internucleotide phosphorothioate (PS) linkages, 2'-OMe modified nucleotides, 2'-F modified nucleotides, and combinations thereof. In some embodiments, the 3' end comprises a phosphorothioate (PS) linkage between nucleotides 141 and 142 and between nucleotides 142 and 143, and comprises a 2'-OMe modified nucleotide at each of positions 142 and 143.
[0305] In some embodiments, the 3' end, i.e., the end of hairpin 2 without any further tails, or the end of the 3' tail, comprises or further comprises one or more phosphorothioate (PS) linkages between nucleotides. In some embodiments, the 3' end comprises or further comprises one or more 2'-OMe modified nucleotides. In some embodiments, the 3' end comprises or further comprises one or more 2'-Ome modified nucleotides. In some embodiments, the 3' end comprises or further comprises one or more 2'-F modified nucleotides. In some embodiments, the 3' end comprises or further comprises one or more inverted abasic modified nucleotides. In some embodiments, the 3' end comprises or further comprises one or more protected end modifications. In some embodiments, the 3' end comprises or further comprises one or more combinations of phosphorothioate (PS) linkages between nucleotides, 2'-OMe modified nucleotides, 2'-O-moe modified nucleotides, 2'-F modified nucleotides, and inverted abasic modified nucleotides.
[0306] E. Guide Sequence In some embodiments, the gRNA further comprises a guide sequence. In some embodiments, the guide sequence comprises 20, 21, 22, 23, 24, or 25 nucleotides, optionally 22, 23, 24, or 25 nucleotides from the 5' to the 5'-most nucleotide of the repeat / anti-repeat region. In some embodiments, the guide sequence comprises 22, 23, 24, 25, or more nucleotides. In some embodiments, the guide sequence is 24 nucleotides in length. In some embodiments, the guide sequence is 23 nucleotides in length. In some embodiments, the guide sequence is 22 nucleotides in length. In some embodiments, the guide sequence is 21 nucleotides in length. In some embodiments, the guide sequence is 20 nucleotides in length.
[0307] In some embodiments, the guide region (i) has a 1 nucleotide insertion or 1-4 nucleotide deletion within positions 1-24 relative to SEQ ID NO:500, or (ii) is 24 nucleotides in length.
[0308] In some embodiments, the selection of the guide sequence is determined based on the target sequence within the gene of interest for editing. For example, in some embodiments, the sgRNA comprises a guide sequence that is complementary to the target sequence within the gene of interest.
[0309] In some embodiments, the target sequence in the gene of interest may be complementary to the guide sequence of the gRNA. In some embodiments, the degree of complementarity or identity between the guide sequence of the gRNA and its corresponding target sequence in the gene of interest may be about 90%, 95%, or 100%. In some embodiments, the guide region of the gRNA and the target region in the gene of interest may be 100% complementary or identical. In other embodiments, the guide sequence of the gRNA and the target sequence in the gene of interest may contain at least one mismatch. For example, the guide sequence of the gRNA and the target sequence in the gene of interest may contain one, optionally two, or three mismatches, where the total length of the target sequence is at least about 22, 23, 24, or more nucleotides. In some embodiments, the guide sequence of the gRNA and the target region in the gene of interest may contain one, optionally two, or three mismatches, where the guide sequence comprises about 24 nucleotides. In certain embodiments, the guide sequence does not contain any mismatches, i.e., is fully complementary to the target sequence. The 5' end may contain nucleotides that are not considered a guide region (i.e., do not function to guide the Cas9 protein to the target nucleic acid).
[0310] II. Modified guide RNA (gRNA) Disclosed herein are guide RNAs that contain modifications at various positions. In some embodiments, the positions of the gRNA that contain modifications are modified by one or more of the following types of modifications: The term "modified gRNA" generally refers to a gRNA that has modifications to the chemical structure of one or more of the base, sugar, phosphodiester linkage, or backbone moiety (including the phosphate of a nucleotide), all of which are detailed and exemplified herein.
[0311] In some embodiments, the guide region of the gRNA comprises at least one modified nucleotide.
[0312] In some embodiments, the guide region of the gRNA comprises at least two modified nucleotides, and optionally at least four modified nucleotides, where each modification independently optionally comprises a modified nucleotide selected from 2'-O-methyl (2'-OMe) modified nucleotides, 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotides, 2'-fluoro (2'-F) modified nucleotides, internucleotide phosphorothioate (PS) linkages, inverted abasic modified nucleotides, or a combination thereof.
[0313] In some embodiments, the guide region of the gRNA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 modified nucleotides. In some embodiments, the guide region of the gRNA comprises 1, 2, or 3 modified nucleotides. In some embodiments, the guide region of the gRNA comprises 4, 5, 6, 7, 8, 9, 10, 11, or 12 modified nucleotides. In some embodiments, the guide region of the gRNA comprises 6, 7, 8, 9, 10, 11, or 12 modified nucleotides.
[0314] In some embodiments, the gRNA comprises a 5' end modification. In some embodiments, the gRNA further comprises a 3' end modification.
[0315] In some embodiments, the guide region does not include 3' modified nucleotides in the first three nucleotides of the guide region.
[0316] In some embodiments, the guide region does not contain modified nucleotides.
[0317] In some embodiments, the gRNA comprises a 3'-end modification. In some embodiments, the gRNA comprises a modification in the upper stem region of the repeat / anti-repeat region. In some embodiments, the gRNA comprises a modification in the hairpin 1 region. In some embodiments, the gRNA comprises a modification in the hairpin 2 region. In some embodiments, the gRNA comprises a 3'-end modification and a modification in the upper stem region of the repeat / anti-repeat region. In some embodiments, the gRNA comprises a 3'-end modification and a modification in the hairpin 1 region. In some embodiments, the gRNA comprises a 3'-end modification and a modification in the hairpin 2 region. In some embodiments, the gRNA comprises a 5'-end modification and a modification in the upper stem region of the repeat / anti-repeat region. In some embodiments, the gRNA comprises a 5'-end modification and a modification in the hairpin 1 region. In some embodiments, the gRNA comprises a 5'-end modification and a modification in the hairpin 2 region. In some embodiments, the gRNA comprises a 5'-end modification, a modification in the upper stem region of the repeat / anti-repeat region, and a 3'-end modification. In some embodiments, the gRNA comprises a 5'-end modification, a modification in the hairpin 1 region, and a 3'-end modification. In some embodiments, the gRNA comprises a 5'-end modification, a modification in the hairpin 1 region, a modification in the hairpin 2 region, and a 3'-end modification. In some embodiments, the gRNA comprises a 5'-end modification, a modification in the repeat / anti-repeat region, a modification in the hairpin 1 region, a modification in the hairpin 2 region, and a 3'-end modification.
[0318] In some embodiments, the gRNA does not comprise a modification at position 76. In some embodiments, the gRNA does not comprise a PS modification at position 76, i.e., a PS modification between nucleotides 76 and 77.
[0319] In some embodiments, the gRNA comprises one or more, i.e., 1, 2, 3, or 4, modifications at positions 106-109. In some embodiments, the gRNA comprises modifications at positions 106-109. In some embodiments, the modifications comprise 2'-O-methyl (2'-O-Me) modified nucleotides.
[0320] In some embodiments, the gRNA comprises 2'-O-methyl (2'-O-Me) modified nucleotides. In some embodiments, the gRNA comprises 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotides. In some embodiments, the gRNA comprises 2'-fluoro (2'-F) modified nucleotides. In some embodiments, the gRNA comprises phosphorothioate (PS) linkages between nucleotides.
[0321] In some embodiments, the gRNA comprises a 5'-end modification, a 3'-end modification, or a 5'-end and a 3'-end modification (such as a blocked end modification). In some embodiments, the 5'-end modification comprises an internucleotide phosphorothioate (PS) linkage. In some embodiments, the 5'-end modification comprises a 2'-O-methyl (2'-O-Me), 2'-O-(2-methoxyethyl) (2'-O-moe), or 2'-fluoro (2'-F) modified nucleotide. In some embodiments, the 5'-end modification comprises at least one phosphorothioate (PS) linkage and one or more of a 2'-O-methyl (2'-O-Me), 2'-O-(2-methoxyethyl) (2'-O-moe), or 2'-fluoro (2'-F) modified nucleotide. Terminal modifications may include phosphorothioate (PS), 2'-O-methyl (2'-O-Me), 2'-O-(2-methoxyethyl) (2'-O-moe), or 2'-fluoro (2'-F) modifications. Equivalent terminal modifications are also included in the embodiments described herein. In some embodiments, the gRNA includes a terminal modification in combination with modifications of one or more regions of the gRNA.
[0322] Exemplary patterns of modifications are shown in Tables 1-2. In certain embodiments, exemplary modifications include the patterns of modifications shown in Tables 1-2, with the 3' tail, if present, deleted. Additional exemplary patterns are described below.
[0323] Types of chemical modifications described herein 2'-O-methyl modification Modified sugars are thought to control the wrinkles in the nucleotide sugar ring, a physical property that affects the binding affinity of an oligonucleotide to its complementary strand, duplex formation, and interaction with nucleases. Therefore, substitutions in the sugar ring can alter the structure and shape of these wrinkles. For example, 2'-O-methyl (2'-OMe) modifications can increase the binding affinity and nuclease stability of oligonucleotides, although, as shown in the Examples, the effect of modifications at specific positions in an oligonucleotide must be empirically determined.
[0324] The terms "mA," "mC," "mU," or "mG" may be used to refer to 2'-OMe modified nucleotides.
[0325] Ribonucleotides and modified 2'-O-methylribonucleotides can be represented as follows: [ka]
[0326] 2'-O-(2-methoxyethyl) modification In some embodiments, the modification may be 2'-O-(2-methoxyethyl) (2'-O-moe). The modified 2'-O-moe ribonucleotide can be represented as follows: [ka]
[0327] The terms "moeA," "moeC," "moeU," or "moeG" may be used to refer to nucleotides modified with 2'-O-moe.
[0328] 2'-Fluoro modification Another chemical modification shown to affect the sugar ring of nucleotides is halogen substitution: for example, 2'-fluoro (2'-F) substitution on the nucleotide sugar ring improves oligonucleotide binding affinity and nuclease stability.
[0329] In this application, the terms "fA," "fC," "fU," or "fG" may be used to refer to a 2'-F substituted nucleotide.
[0330] Ribonucleotides with and without 2'-F substitutions can be represented as follows: [ka]
[0331] phosphorothioate modification Phosphorothioate (PS) linkage or bond refers to a phosphodiester bond, e.g., a bond between nucleotides, in which one non-bridging phosphate oxygen is replaced with sulfur. When phosphorothioates are used to generate oligonucleotides, the modified oligonucleotides are also called S-oligos.
[0332] A "*" may be used to indicate a PS modification. In this application, the terms A*, C*, U*, or G* may be used to indicate a nucleotide that is linked to the following (e.g., 3') nucleotide by a PS bond. Throughout this application, PS modifications are grouped with nucleotides whose 3' carbon is linked to a phosphorothioate. Thus, indicating that a PS modification is at position 1 means that a phosphorothioate is attached to the 3' carbon of nucleotide 1 and the 5' carbon of nucleotide 2.
[0333] In the present application, the terms "mA*," "mC*," "mU*," or "mG*" may be used to refer to a nucleotide that is substituted with 2'-OMe and linked to the following (e.g., 3') nucleotide by a PS linkage (sometimes referred to as a "PS bond"). Similarly, the terms "fA*," "fC*," "fU*," or "fG*" may be used to refer to a nucleotide that is substituted with 2'-F and linked to the following (e.g., 3') nucleotide by a PS linkage. Equivalents of PS linkages or bonds are encompassed by the embodiments described herein.
[0334] The diagram below shows the substitution of S- for a non-bridging phosphate oxygen, creating a PS linkage instead of a phosphodiester linkage: [ka]
[0335] Inverted abasic modification An abasic nucleotide is a nucleotide lacking a nitrogenous base. The diagram below shows an oligonucleotide with an abasic site lacking a base (in this case, shown as apurinic; an abasic site can also be an apyrimidinic site, where the description of the abasic site usually refers to Watson-Crick base pairing; for example, an apurinic site refers to a site lacking a nitrogenous base and usually base-pairing with a pyrimidine site). This base may be replaced at the 1' position of the furan ring with another moiety (e.g., a hydroxyl group, as shown below, to form a ribose or deoxyribose moiety, or a hydrogen, as shown below). [ka]
[0336] An inverted base refers to a base having a linkage that is inverted from the normal 5' to 3' linkage (i.e., either a 5' to 5' linkage or a 3' to 3' linkage). For example, [ka]
[0337] The abasic nucleotide can be linked by an inverted linkage. For example, the abasic nucleotide can be linked to the terminal 5' nucleotide via a 5'-to-5' linkage, or the abasic nucleotide can be linked to the terminal 3' nucleotide via a 3'-to-3' linkage. An inverted abasic nucleotide at either the terminal 5' or 3' nucleotide is also called an inverted abasic end cap. In this application, the term "invd" refers to an inverted abasic nucleotide linkage.
[0338] Deoxyribonucleotides Deoxyribonucleotides (those in which the sugar comprises the 2'-deoxy position) are considered modified in the context of gRNA in that the nucleotide is modified relative to standard RNA by replacing the hydroxyl at the 2' position with a proton. Unless otherwise specified, deoxyribonucleotide modifications at U positions in unmodified RNA also include substitution of a U nucleobase with a T.
[0339] Bicyclic ribose analogs Exemplary bicyclic ribose analogs include locked nucleic acids (LNA), ENA, bridged nucleic acids (BNA), or other LNA-like modifications. In some cases, the bicyclic ribose analogs are connected at the 2' and 4' positions via a linker. The linker has the formula -X-(CH2) n -, where n is 1 or 2, X is O, NR, or S, and R is H or C. 1-3and alkyl (e.g., methyl). Examples of bicyclic ribose analogs include LNAs containing the 2'-O-CH2-4' bicyclic structure (oxy-LNA) (see WO98 / 39352 and WO99 / 14226); 2'-NH-CH2-4' or 2'-N(CH3)-CH2-4' (amino-LNA) (Singh et al., J. Org. Chem. 63:10035-10039 (1998); Singh et al., J. Org. Chem. 63:6078-6079 (1998)); and 2'-S-CH2-4' (thio-LNA) (Singh et al., J. Org. Chem. 63:6078-6079 (1998); Kumar et al. al., Biorg. Med. Chem. Lett. 8:2219-2222 (1998)).
[0340] ENA ENA modification refers to a nucleotide containing a 2'-O, 4'-C-ethylene modification. An exemplary structure of an ENA nucleotide is shown below. The wavy line indicates the connection to the adjacent nucleotide (or the terminal position, as the case may be). However, it should be understood that when the 3'-terminal nucleotide is an ENA nucleotide, the 3'-position may contain a hydroxyl instead of a phosphate. For more information about ENA nucleotides, see, for example, Koizumi et al., Nucleic Acids Res. 31: 3267-3273 (2003). [ka]
[0341] UNA UNA or unlocked nucleic acid modification refers to a nucleotide containing a 2',3'-seco-RNA modification in which the 2' and 3' carbons are not directly linked to each other. An exemplary structure of a UNA nucleotide is shown below. The wavy line indicates the connection to the adjacent phosphate or the modification replacing the phosphate (or in some cases, the terminal position). For more information about UNA nucleotides, see, for example, Snead et al., Molecular Therapy 2:e103, doi:10.1038 / mtna.2013.36 (2013). [ka]
[0342] Base modification Base modifications are modifications that alter the structure of a nucleic acid base or its attachment to the backbone, including isomerization (e.g., pseudouridine). In some embodiments, the base modification includes inosine. In some embodiments, modifications include base modifications that reduce RNA endonuclease activity, for example, by interfering with RNase recognition of the cleavage site or by stabilizing an RNA structure (e.g., secondary structure) that reduces the accessibility of the cleavage site by RNase. Exemplary base modifications that can stabilize RNA structure include pseudouridine and 5-methylcytosine. See Peacock et al., J Org Chem. 76:7295-7300 (2011). In some embodiments, base modifications can increase or decrease the melting temperature (Tm) of a nucleic acid, for example, by increasing hydrogen bonding in Watson-Crick base pairs, forming non-canonical base pairs, or generating mismatched base pairs.
[0343] The above modifications and their equivalents are included within the scope of the embodiments described herein.
[0344] 3' end modification In some embodiments, the terminal (i.e., last) 1, 2, 3, or 4, optionally 5, 6, or 7 nucleotides of the 3'-terminus are modified. Throughout, this modification may be referred to as a "3'-end modification." In some embodiments, the terminal (i.e., last) 1, 2, 3, or 4, optionally 5, 6, or 7 nucleotides of the 3'-terminus comprise multiple modifications. In some embodiments, at least one of the terminal (i.e., last) 1, 2, 3, or 4, optionally 5, 6, or 7 nucleotides of the 3'-terminus is modified. In some embodiments, at least two of the terminal (i.e., last) 1, 2, 3, or 4, optionally 5, 6, or 7 nucleotides of the 3'-terminus are modified. In some embodiments, at least three of the terminal (i.e., last) 1, 2, 3, or 4, optionally 5, 6, or 7 nucleotides of the 3'-terminus are modified. In some embodiments, the modification comprises a PS linkage. In some embodiments, the modification to the 3'-terminus is a 3'-protecting end modification. In some embodiments, the 3' end modification comprises a 3' blocking end modification.
[0345] In some embodiments, the 3' end modification comprises modified nucleotides selected from 2'-O-methyl (2'-O-Me) modified nucleotides, 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotides, 2'-fluoro (2'-F) modified nucleotides, phosphorothioate internucleotide (PS) linkages, or inverted abasic modified nucleotides; and optionally, the gRNA comprises at least two 3' end modifications independently selected from 2'-O-methyl (2'-OMe) modified nucleotides, 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotides, 2'-fluoro (2'-F) modified nucleotides, phosphorothioate internucleotide (PS) linkages, and inverted abasic modified nucleotides.
[0346] In some embodiments, the 3'-end modification comprises or further comprises a 2'-O-methyl (2'-O-Me) modified nucleotide.
[0347] In some embodiments, the 3'-end modification comprises or further comprises a 2'-fluoro (2'-F) modified nucleotide.
[0348] In some embodiments, the 3'-end modification comprises or further comprises an internucleotide phosphorothioate (PS) linkage.
[0349] In some embodiments, the 3' terminal modification comprises or further comprises an inverted abasic modified nucleotide.
[0350] In some embodiments, the 3'-end modifications include or further include 2'-O-methyl (2'-O-Me) modified nucleotides and internucleotide phosphorothioate (PS) linkages.
[0351] In some embodiments, the 3'-terminal modification comprises or further comprises a modification of any one or more of the last 1, 2, 3, or 4, optionally 5, 6, or 7 nucleotides. In some embodiments, the 3'-terminal modification comprises or further comprises one modified nucleotide. In some embodiments, the 3'-terminal modification comprises or further comprises two modified nucleotides. In some embodiments, the 3'-terminal modification comprises or further comprises three modified nucleotides. In some embodiments, the 3'-terminal modification comprises or further comprises four modified nucleotides. In some embodiments, the 3'-terminal modification comprises or further comprises five modified nucleotides. In some embodiments, the 3'-terminal modification comprises or further comprises six modified nucleotides. In some embodiments, the 3'-terminal modification comprises or further comprises seven modified nucleotides.
[0352] In some embodiments, the 3' terminal modification comprises or further comprises modifications of 1 to 7 or 14 nucleotides.
[0353] In some embodiments, the 3' end modification comprises, or further comprises, modification of 1, 2, 3, or 4, optionally 5, 6, or 7 nucleotides at the 3' end of the gRNA.
[0354] In some embodiments, the 3' end modification comprises or further comprises a modification of about 1 to 3, 1 to 4, or 1 to 5 nucleotides at the 3' end of the gRNA.
[0355] In some embodiments, the 3'-end modification comprises or further comprises any one or more of an internucleotide phosphorothioate (PS) linkage, a 2'-O-Me modified nucleotide, a 2'-O-moe modified nucleotide, a 2'-F modified nucleotide, an inverted abasic modified nucleotide, and combinations thereof.
[0356] In some embodiments, the 3' end modification comprises or further comprises 1, 2, 3, or 4, optionally 5, 6, or 7 PS linkages between nucleotides.
[0357] In some embodiments, the 3'-end modification comprises or further comprises at least one 2'-O-Me, 2'-O-moe, inverted abasic, or 2'-F modified nucleotide. In some embodiments, the 3'-terminal modification comprises or further comprises one PS linkage, which is between the last and penultimate nucleotide. In some embodiments, the 3'-terminal modification comprises or further comprises two PS linkages between the last three nucleotides. In some embodiments, the 3'-terminal modification comprises or further comprises four PS linkages between the last four nucleotides.
[0358] In some embodiments, the 3'-terminal modification comprises or further comprises a PS linkage between any one or more of the last four nucleotides. In some embodiments, the 3'-terminal modification comprises or further comprises a PS linkage between any one or more of the last three nucleotides. In some embodiments, the 3'-terminal modification comprises or further comprises a PS linkage between any one or more of the last 2, 3, or 4, optionally 5, 6, or 7 nucleotides.
[0359] In some embodiments, the 3'-terminal modification includes, or further includes, one or more modifications of the last 1 to 4, optionally 1 to 7, nucleotides, where the modifications are a PS linkage, an inverted abasic nucleotide, 2'-OMe, 2'-O-moe, 2'-F, or a combination thereof.
[0360] In some embodiments, the 3'-end modification includes, or further includes, a modification to the last nucleotide with 2'-OMe, 2'-O-moe, 2'-F, or a combination thereof, and, optionally, one or two PS linkages to the next or first nucleotide at the 3'-end.
[0361] In some embodiments, the 3'-end modification comprises, or further comprises, a modification to the last or penultimate nucleotide with 2'-OMe, 2'-O-moe, 2'-F, or a combination thereof, and optionally one or more PS linkages.
[0362] In some embodiments, the 3'-end modification comprises, or further comprises, a modification to the last, second to last, or third to last nucleotide with 2'-OMe, 2'-O-moe, 2'-F, or a combination thereof, and optionally one or more PS linkages.
[0363] In some embodiments, the 3'-end modification comprises, or further comprises, a modification of the last, second to last, third to last, or fourth to last nucleotide with 2'-OMe, 2'-O-moe, 2'-F, or a combination thereof, and optionally one or more PS linkages.
[0364] In some embodiments, the 3'-end modification comprises or further comprises a modification of the last, second to last, third to last, fourth to last, or fifth to last nucleotide with 2'-OMe, 2'-O-moe, 2'-F, or a combination thereof, and optionally one or more PS linkages.
[0365] In some embodiments, the gRNA comprising a 3'-end modification comprises or further comprises a 3' tail, wherein the 3' tail comprises a modification to any one or more of the nucleotides present in the 3' tail. In some embodiments, the 3' tail is fully modified. In some embodiments, the 3' tail comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9, or 1-10 nucleotides, optionally with any one or more of these nucleotides modified. In some embodiments, the 3' tail comprises 1-4 nucleotides, optionally 1-2 nucleotides.
[0366] In some embodiments, gRNAs are provided that include a 3' end modification, wherein the 3' end modification includes a 3' end modification set forth in any one of SEQ ID NOs: 4-9 and 301-494. In some embodiments, gRNAs are provided that include a 5' end modification, wherein the 5' end modification includes a 5' end modification set forth in any one of SEQ ID NOs: 4-9 and 301-494. In some embodiments, gRNAs are provided that include a 3' protected end modification.
[0367] In some embodiments, the gRNA comprises a 5' end modification and a 3' end modification.
[0368] 5' end modification In some embodiments, the 5' end is modified, e.g., the first 1, 2, 3, or 4, optionally 5, 6, or 7 nucleotides of the gRNA are modified. Throughout, this modification may be referred to as a "5' end modification." In some embodiments, the first 1, 2, 3, or 4, optionally 5, 6, or 7 nucleotides of the 5' end comprise multiple modifications. In some embodiments, at least one of the terminal (i.e., first) 1, 2, 3, or 4, optionally 5, 6, or 7 nucleotides of the 5' end is modified. In some embodiments, at least two of the terminal 1, 2, 3, or 4, optionally 5, 6, or 7 nucleotides of the 5' end are modified. In some embodiments, at least three of the terminal 1, 2, 3, or 4, optionally 5, 6, or 7 nucleotides of the 5' end are modified. In some embodiments, the 5' end modification is a 5' protected end modification.
[0369] In some embodiments, both the 5' and 3' ends of the gRNA are modified. In some embodiments, only the 5' end of the gRNA is modified. In some embodiments, only the 3' end of the conserved region of the gRNA is modified.
[0370] In some embodiments, the gRNA comprises modifications in 1, 2, 3, or 4, optionally 5, 6, or 7, and optionally the first 7 nucleotides of the first 4 nucleotides of the 5'-terminal region of the gRNA. In some embodiments, the gRNA comprises modifications in 1, 2, 3, or 4, optionally 5, 6, or 7, and optionally 7, of the four terminal nucleotides at the 3'-end. In some embodiments, 1, 2, 3, or 4 of the first 4 nucleotides at the 5'-end or 1, 2, 3, or 4 of the four nucleotides at the 3'-end are modified. In some embodiments, 2, 3, or 4 of the first 4 nucleotides at the 5'-end are linked with phosphorothioate (PS) linkages.
[0371] In some embodiments, the modification to the 5' or 3' end comprises a 2'-O-methyl (2'-O-Me) or a 2'-O-(2-methoxyethyl) (2'-O-moe) modification. In some embodiments, the modification comprises a 2'-fluoro (2'-F) modification to the nucleotide. In some embodiments, the modification comprises a phosphorothioate (PS) internucleotide linkage. In some embodiments, the modification comprises an inverted abasic nucleotide. In some embodiments, the modification comprises a protected end modification. In some embodiments, the modification comprises multiple modifications selected from a protected end modification, 2'-O-Me, 2'-O-moe, 2'-fluoro (2'-F), a phosphorothioate (PS) internucleotide linkage, and an inverted abasic nucleotide. In some embodiments, equivalent modifications are encompassed.
[0372] In some embodiments, the gRNA comprises one or more phosphorothioate (PS) linkages within the first 1, 2, 3, 4, 5, 6, or 7 nucleotides at the 5' end. In some embodiments, the gRNA comprises one or more PS linkages within the last 1, 2, 3, or 4, optionally 5, 6, or 7 nucleotides at the 3' end. In some embodiments, the gRNA comprises one or more PS linkages within both the last 1, 2, 3, or 4, optionally 5, 6, or 7 nucleotides at the 3' end and the first 1, 2, 3, or 4, optionally 5, 6, or 7 nucleotides from the 5' end of the 5' end. In some embodiments, in addition to the PS linkages, the 5'- and 3'-terminal nucleotides may comprise 2'-O-Me, 2'-O-moe, or 2'-F modified nucleotides.
[0373] In some embodiments, the gRNA comprises a 5' end modification, for example, the first nucleotide of the guide region is modified. In some embodiments, the gRNA comprises a 5' end modification, and the first nucleotide of the guide region comprises a 5' blocking end modification.
[0374] In some embodiments, the 5' end modification comprises modified nucleotides selected from 2'-O-methyl (2'-O-Me) modified nucleotides, 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotides, 2'-fluoro (2'-F) modified nucleotides, phosphorothioate internucleotide (PS) linkages, inverted abasic modified nucleotides, and optionally, the gRNA comprises at least two 5' end modifications independently selected from 2'-O-methyl (2'-OMe) modified nucleotides, 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotides, 2'-fluoro (2'-F) modified nucleotides, phosphorothioate internucleotide (PS) linkages, and inverted abasic modified nucleotides.
[0375] In some embodiments, the 5'-end modification comprises or further comprises a 2'-O-methyl (2'-O-Me) modified nucleotide.
[0376] In some embodiments, the 5'-end modification comprises or further comprises a 2'-fluoro (2'-F) modified nucleotide.
[0377] In some embodiments, the 5'-end modification comprises or further comprises an internucleotide phosphorothioate (PS) linkage.
[0378] In some embodiments, the 5' end modification comprises or further comprises an inverted abasic modified nucleotide.
[0379] In some embodiments, the 5'-end modifications include or further include 2'-O-methyl (2'-O-Me) modified nucleotides and internucleotide phosphorothioate (PS) linkages.
[0380] In some embodiments, the 5'-end modification comprises, or further comprises, a modification of any one or more of nucleotides 1-4, and optionally nucleotides 1-7, of the guide region of the gRNA. In some embodiments, the 5'-end modification comprises, or further comprises, one modified nucleotide. In some embodiments, the 5'-end modification comprises, or further comprises, two modified nucleotides. In some embodiments, the 5'-end modification comprises, or further comprises, three modified nucleotides. In some embodiments, the 5'-end modification comprises, or further comprises, four modified nucleotides. In some embodiments, the 5'-end modification comprises, or further comprises, five modified nucleotides. In some embodiments, the 5'-end modification comprises, or further comprises, six modified nucleotides. In some embodiments, the 5'-end modification comprises, or further comprises, seven modified nucleotides.
[0381] In some embodiments, the 5' end modification comprises or further comprises modifications of 1 to 7, 1 to 5, 1 to 4, 1 to 3, or 1 to 2 nucleotides.
[0382] In some embodiments, the 5' terminal modification comprises or further comprises a modification 1, 2, 3, or 4, optionally 5, 6, or 7 nucleotides from the 5' end, hi some embodiments, the 5' terminal modification comprises or further comprises a modification about 1-3, 1-4, 1-5, 1-6, or 1-7 nucleotides from the 5' end.
[0383] In some embodiments, the 5'-end modification comprises, or further comprises, modification of the first nucleotide at the 5'-end of the gRNA. In some embodiments, the 5'-end modification comprises, or further comprises, modification of the first and second nucleotides from the 5'-end of the gRNA. In some embodiments, the 5'-end modification comprises, or further comprises, modification of the first, second, and third nucleotides from the 5'-end of the gRNA. In some embodiments, the 5'-end modification comprises, or further comprises, modification of the first, second, third, and fourth nucleotides from the 5'-end of the gRNA. In some embodiments, the 5'-end modification comprises, or further comprises, modification of the first, second, third, fourth, and fifth nucleotides from the 5'-end of the gRNA. In some embodiments, the 5'-end modification comprises, or further comprises, modification of the first, second, third, fourth, and fifth nucleotides from the 5'-end of the gRNA. In some embodiments, the 5' end modification comprises or further comprises modification of the first, second, third, fourth, fifth, sixth, and seventh nucleotide from the 5' end of the gRNA.
[0384] In some embodiments, the 5'-end modification comprises, or further comprises, an internucleotide phosphorothioate (PS) linkage, or a 2'-O-Me modified nucleotide, or a 2'-O-moe modified nucleotide, or a 2'-F modified nucleotide, or an inverted abasic modified nucleotide, or a combination thereof.
[0385] In some embodiments, the 5'-terminal modification comprises or further comprises 1, 2, 3, 4, 5, 6, or 7 PS linkages between nucleotides, hi some embodiments, the 5'-terminal modification comprises or further comprises about 1-2, 1-3, 1-4, 1-5, 1-6, or 1-7 PS linkages between nucleotides.
[0386] In some embodiments, the 5' end modification comprises or further comprises at least one PS linkage, where if there is one, the PS linkage is between nucleotide 1 and nucleotide 2 of the guide region.
[0387] In some embodiments, the 5' end modification comprises or further comprises at least two PS linkages, one between nucleotide 1 and nucleotide 2 and one between nucleotide 2 and nucleotide 3 of the guide region.
[0388] In some embodiments, the 5' end modification comprises or further comprises a PS linkage between any one or more of nucleotides 1 and 2, 2 and 3, and 3 and 4 of the guide region.
[0389] In some embodiments, the 5' end modification comprises or further comprises a PS linkage between any one or more of nucleotides 1 and 2, 2 and 3, 3 and 4, and 4 and 5 of the guide region.
[0390] In some embodiments, the 5' end modification comprises, or further comprises, a PS linkage between any one or more of nucleotides 1 and 2, 2 and 3, 3 and 4, 4 and 5, and 5 and 6 of the guide region.
[0391] In some embodiments, the 5' end modification comprises, or further comprises, a PS linkage between any one or more of nucleotides 1 and 2, 2 and 3, 3 and 4, 4 and 5, 5 and 6, and 7 and 8 of the guide region.
[0392] In some embodiments, the 5'-end modification includes, or further includes, one or more modifications of nucleotides 1-7 of the guide region, where the modification is a PS linkage, an inverted abasic nucleotide, 2'-O-Me, 2'-O-moe, 2'-F, or a combination thereof.
[0393] In some embodiments, the 5' end modification includes, or further includes, a modification to the first nucleotide of the guide region with 2'-O-Me, 2'-O-moe, 2'-F, or a combination thereof, and an optional PS linkage to the next nucleotide.
[0394] In some embodiments, the 5' end modification comprises, or further comprises, a modification to the first or second nucleotide of the guide region with 2'-O-Me, 2'-O-moe, 2'-F, or a combination thereof, and, optionally, one or more PS linkages between the first and second nucleotides or the second and third nucleotides.
[0395] In some embodiments, the 5' end modification comprises, or further comprises, a modification to the first, second, or third nucleotide of the variable region with 2'-O-Me, 2'-O-moe, 2'-F, or a combination thereof, and, optionally, one or more PS linkages between the first and second nucleotides, the second and third nucleotides, or the third and fourth nucleotides.
[0396] In some embodiments, the 5'-end modification comprises, or further comprises, a modification to the first, second, third, or fourth nucleotide of the variable region with 2'-O-Me, 2'-O-moe, 2'-F, or a combination thereof, and, optionally, one or more PS linkages between the first and second nucleotides, between the second and third nucleotides, between the third and fourth nucleotides, or between the fourth and fifth nucleotides.
[0397] In some embodiments, the 5' end modification comprises, or further comprises, a modification to the first, second, third, fourth, or fifth nucleotide of the variable region with 2'-O-Me, 2'-O-moe, 2'-F, or a combination thereof, and, optionally, one or more PS linkages between the first and second nucleotide, the second and third nucleotide, the third and fourth nucleotide, the fourth and fifth nucleotide, or the fifth and sixth nucleotide.
[0398] In some embodiments, a gRNA is provided that comprises a 5' end modification, wherein the 5' end modification comprises a 5' end modification set forth in any one of SEQ ID NOs: 4-9, 301-494, and 931-946.
[0399] In some embodiments, the sgRNA comprises a 5' end modification, including a 5' protected end modification. In some embodiments, a gRNA is provided that comprises a 5' end modification, wherein the 5' end modification comprises a 2'-OMe modified nucleotide at nucleotide 1, nucleotide 2, and nucleotide 3 of the guide region.
[0400] In some embodiments, gRNAs are provided that comprise 5' end modifications, including 2'-OMe modified nucleotides at nucleotide 1, nucleotide 2, and nucleotide 3 of the guide region, and PS linkages between nucleotides 1 and 2, between nucleotides 2 and 3, and between nucleotides 3 and 4 of the guide region.
[0401] In some embodiments, a gRNA is provided that comprises a 5' end modification, wherein the 5' end modification comprises a 2'-OMe modified nucleotide at nucleotide 1, nucleotide 2, nucleotide 3, nucleotide 4, and nucleotide 5 of the guide region.
[0402] In some embodiments, gRNAs are provided that comprise 5' end modifications, including 2'-OMe modified nucleotides at nucleotide 1, nucleotide 2, nucleotide 3, nucleotide 4, and nucleotide 5 of the guide region, and PS linkages between nucleotides 1 and 2, between nucleotides 2 and 3, and between nucleotides 3 and 4 of the guide region.
[0403] In some embodiments, gRNAs are provided that contain 5' and 3' end modifications. In some embodiments, the gRNAs contain modified nucleotides at the 5' and 3' ends and in one or more other regions listed in Table 3.
[0404] In some embodiments, the sgRNA comprises modified nucleotides that are not at the 5' or 3' end. Exemplary patterns of modification are described below and shown in Table 1.
[0405] Repeat / anti-repeat modifications In some embodiments, a gRNA is provided that comprises a repeat / anti-repeat region modification, wherein the repeat / anti-repeat region modification comprises a modification to any one or more of nucleotides 25-76 of the upper stem region.
[0406] In some embodiments, gRNAs are provided that include repeat / anti-repeat region modifications, wherein the upper stem modification comprises modification of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotides within the repeat / anti-repeat region.
[0407] In some embodiments, gRNAs are provided that comprise upper stem modifications, which comprise modifications of about 1-18, 1-16, 1-15, 5-18, 5-15, 8-18, 8-15, 10-18, 10-15, or 12-15 nucleotides within the repeat / anti-repeat region.
[0408] In some embodiments, gRNAs are provided that comprise repeat / anti-repeat modifications, wherein the repeat / anti-repeat modifications comprise 2'-OMe modified nucleotides. In some embodiments, gRNAs are provided that comprise repeat / anti-repeat modifications, wherein the repeat / anti-repeat modifications comprise 2'-O-moe modified nucleotides. In some embodiments, gRNAs are provided that comprise repeat / anti-repeat modifications, wherein the repeat / anti-repeat modifications comprise 2'-F modified nucleotides.
[0409] In some embodiments, gRNAs are provided that comprise repeat / anti-repeat modifications, wherein the repeat / anti-repeat modifications comprise 2'-OMe modified nucleotides, 2'-O-moe modified nucleotides, 2'-F modified nucleotides, or combinations thereof.
[0410] In some embodiments, the sgRNA comprises a repeat / anti-repeat modification as set forth in any one of the sequences in Table 1 or 2. In some embodiments, the gRNA does not comprise a modification at position 76 of the repeat / anti-repeat region. In some embodiments, the gRNA does not comprise a PS modification at position 76.
[0411] In some embodiments, such repeat / anti-repeat modifications are combined with a 5'-protected end modification, for example, as shown for the corresponding sequence in Table 1 or Table 2. In some embodiments, such repeat / anti-repeat modifications are combined with a 3'-protected end modification, for example, as shown for the corresponding sequence in Table 1 or Table 2. In some embodiments, such repeat / anti-repeat modifications are combined with a 5'-end modification and a 3'-end modification, for example, as shown for the corresponding sequence in Table 1 or Table 2.
[0412] In some embodiments, the gRNA comprises a 5'-end modification and a repeat / anti-repeat modification. In some embodiments, the gRNA comprises a 3'-end modification and a repeat / anti-repeat modification. In some embodiments, the gRNA comprises a 5'-end modification, a 3'-end modification, and a repeat / anti-repeat modification.
[0413] Hairpin modification In some embodiments, the gRNA comprises a modification in the hairpin region (e.g., hairpin 1 region or hairpin 2 region). In some embodiments, the modification in the hairpin region comprises at least one modified nucleotide selected from 2'-O-methyl (2'-OMe) modified nucleotides, 2'-fluoro (2'-F) modified nucleotides, or a combination thereof.
[0414] In some embodiments, the modification of the hairpin region is in the hairpin 1 region. In some embodiments, the modification of the hairpin region is in the hairpin 2 region. In some embodiments, the modification is in the hairpin 1 region and the hairpin 2 region, and optionally the nucleotides between hairpin 1 and hairpin 2 are also modified.
[0415] In some embodiments, the hairpin modification comprises or further comprises 2'-O-methyl (2'-OMe) modified nucleotides.
[0416] In some embodiments, the hairpin modification comprises or further comprises 2'-fluoro (2'-F) modified nucleotides.
[0417] In some embodiments, the modification of the hairpin region comprises at least one modified nucleotide selected from 2'H-modified nucleotides (DNA), PS-modified nucleotides, 2'-O-methyl (2'-O-Me)-modified nucleotides, 2'-fluoro (2'-F)-modified nucleotides, or a combination thereof.
[0418] In some embodiments, the gRNA comprises one or more, i.e., 1, 2, 3, or 4, modifications at positions 106-109 of the hairpin 2 region. In some embodiments, the gRNA comprises modifications at positions 106-109. In some embodiments, the modifications comprise 2'-O-methyl (2'-O-Me) modified nucleotides.
[0419] In some embodiments, the gRNA comprises a 3'-end modification and a modification in the hairpin region. In some embodiments, the 3'-end modification is within the hairpin region, i.e., within hairpin 2.
[0420] In some embodiments, the gRNA comprises a 5' end modification and a modification in the hairpin region.
[0421] In some embodiments, the gRNA comprises repeat / anti-repeat modifications and modifications in the hairpin region.
[0422] In some embodiments, the gRNA comprises a hairpin modification as shown in any one of the sequences in Table 1 or Table 2. In some embodiments, such a hairpin modification is combined with a 5'-end modification as shown for the corresponding sequence in Table 1 or Table 2. In some embodiments, such a hairpin modification is combined with a 3'-end modification as shown for the corresponding sequence in Table 1 or Table 2. In some embodiments, such a hairpin modification is combined with a 5'-end modification and a 3'-end modification as shown for the corresponding sequence in Table 1 or Table 2.
[0423] In some embodiments, the gRNA comprises a 3' end modification, a modification in the hairpin region, a repeat / anti-repeat modification, and a 5' end modification.
[0424] Exemplary guide RNAs In some embodiments, gRNAs are provided that include a 5' end modification and one or more modifications in one or more of the repeat / anti-repeat region, hairpin 1 region, and hairpin 2 region, wherein the one or more modifications are at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 85%, 80%, 75%, or 70% identical to the modification pattern set forth in the reference sequence identifiers in Tables 1-2.
[0425] In some embodiments, the gRNAs described herein comprise any of the sequences shown in Tables 1-2. In some embodiments, the gRNAs described herein consist of any of the sequences shown in Tables 1-2. In some embodiments, the gRNAs described herein consist of any of the sequences shown in Tables 1-2 with the 3' tail sequence removed. Additionally, gRNAs containing modifications of any of the sequences shown in Tables 1 or 2 and identified therein by SEQ ID NO: are also encompassed. That is, the nucleotides may be the same or different, but the modification pattern shown may be the same or similar to the modification pattern of the guide sequences in Tables 1-2. The modification pattern includes the relative position and identity of the modifications on the gRNA.
[0426] In some embodiments, the modification pattern comprises at least 50%, 55%, 60%, 70%, 75%, preferably at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of the modifications of any one of the sequences shown in the sequence columns of Tables 1-2, or modifications across one or more regions of the sequences. In some embodiments, the modification pattern is at least 50%, 55%, 60%, 70%, 75%, preferably at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the modification pattern of any one of the sequences shown in the sequence columns of Tables 1-2. In some embodiments, the modification pattern is at least 50%, 55%, 60%, 70%, 75%, preferably at least 80%, 85%, 90%, or 95% identical to a pattern in Tables 1-2 over one or more (e.g., 1, 2, 3, 4, or 5) regions of the sequence shown in Table 3.
[0427] For example, some embodiments include gRNAs in which the modification pattern is at least 50%, 55%, 60%, 70%, 75%, preferably at least 80%, 85%, 90%, or 95% identical to the modification pattern of the sequence on the guide sequence. Some embodiments include gRNAs in which the modification pattern is at least 50%, 55%, 60%, 70%, 75%, preferably at least 80%, 85%, 90%, or 95% identical across the repeat / anti-repeat region. Some embodiments include gRNAs in which the modification pattern is at least 50%, 55%, 60%, 70%, 75%, preferably at least 80%, 85%, 90%, or 95% identical across the hairpin 1 region. In some embodiments, gRNAs are encompassed in which the modification pattern is at least 50%, 55%, 60%, 70%, 75%, 80%, preferably at least 85%, 90%, 95%, 96%, 97%, 98%, and 99% identical across the hairpin 2 region. In some embodiments, gRNAs are encompassed in which the modification pattern is at least 50%, 55%, 60%, 70%, 80%, or 90% identical across the 3' tail. In some embodiments, the modification pattern differs by 0, 1, 2, 3, 4, 5, or 6 nucleotides from the modification pattern of a sequence in Tables 1-2, or a region set forth in Table 3 of such a sequence. In some embodiments, the gRNA comprises a modification that differs from the modification of a sequence in Tables 1-2 in 0, 1, 2, 3, 4, 5, or 6 nucleotides. In some embodiments, the gRNA comprises a modification that differs from the modification of a region set forth in Table 3 of a sequence in Tables 1-2 in 0, 1, 2, 3, 4, 5, or 6 nucleotides.
[0428] In some embodiments, gRNAs are provided that comprise any one of the sequences set forth in SEQ ID NOs: 1-19, 21-42, 301-494, 931-946, 951, and 952. In some embodiments, gRNAs are provided that consist of any one of the sequences set forth in SEQ ID NOs: 1-19, 21-42, 301-494, 931-946, 951, and 952. In some embodiments, gRNAs are provided that comprise any one of the sequences set forth in SEQ ID NOs: 1-19, 21-42, 301-494, 931-946, 951, and 952, including the modifications shown in Tables 1-2. In some embodiments, gRNAs are provided that consist of any one of the sequences set forth in SEQ ID NOs: 1-19, 21-42, 301-494, 931-946, 951, and 952, including the modifications shown in Tables 1-2. In some embodiments, a gRNA is provided that comprises or consists of any one of the sequences set forth in SEQ ID NOs: 1-19, 21-42, 301-494, 931-946, 951, and 952, including the modifications shown in Tables 1-2, wherein the 3' tail, if present, has been deleted.
[0429] In some embodiments, a gRNA is provided that comprises any one of the sequences of SEQ ID NOs: 6 or 9, wherein the gRNA further comprises a guide sequence that is complementary to the target sequence and directs Cas9 to the target for cleavage. In some embodiments, a gRNA is provided that comprises a nucleic acid having at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 85%, 80%, 75%, or 70% identity to a nucleic acid of any one of SEQ ID NOs: 6 or 9, wherein the modification pattern is identical to the modification pattern shown in the reference sequence identifiers in Tables 1-2.
[0430] Figures 25, 37, and 38 show exemplary sgRNAs in possible secondary structures.
[0431] In some embodiments, the single guide RNA (sgRNA) 2'-O-Me modified nucleotides in the first four nucleotides 1–4; PS linkages between nucleotides 1-2, 2-3, and 3-4; and a guide sequence comprising 2'-O-Me modified nucleotides at nucleotides 5, 8, 9, 11, 13, 18, and 22 of the guide sequence; 2'-O-Me modified nucleotides at nucleotides 25, 29, 30, 31, 32, 37, 49-52, 64, 65, 69, 70, and 73; and a truncated repeat / anti-repeat region in which nucleotides 38-48 and 53-63 have been deleted relative to SEQ ID NO: 500, including a PS linkage between nucleotides 76-77 between the truncated repeat / anti-repeat region and the truncated hairpin 1 region; 2'-O-Me modified nucleotides at nucleotides 80, 81, 83, 84, 85, 87-90, 92-94, and 99; and a truncated Hairpin 1 region, with nucleotides 86 and 91 deleted relative to SEQ ID NO:500, including a 2'-O-Me modified nucleotide at nucleotide 101 between the truncated Hairpin 1 region and the truncated Hairpin 2 region; 2'-O-Me modified nucleotides at nucleotides 104, 110, 111, 122 to 125, 142, and 143, and a truncated hairpin 2 region in which nucleotides 112-120 and 127-134 are deleted relative to SEQ ID NO: 500, including PS linkages between nucleotides 141-142 and 142-143; With respect to SEQ ID NO: 500, one or both of nucleotides 144-145 are optionally deleted.
[0432] In some embodiments, 2'-O-Me modified nucleotides in the first four nucleotides 1–4; PS linkages between nucleotides 1-2, 2-3, and 3-4; and a guide region comprising 2'-O-Me modified nucleotides at nucleotides 5, 8, 9, 11, 13, 18, and 22 of the guide region; 2'-O-Me modified nucleotides at nucleotides 25, 29, 30, 31, 32, 37, 49-52, 64, 65, 69, 70, and 73; and a truncated repeat / anti-repeat region in which nucleotides 38-48 and 53-63 have been deleted relative to SEQ ID NO: 500, including a PS linkage between nucleotides 76-77 between the truncated repeat / anti-repeat region and the truncated hairpin 1 region; 2'-O-Me modified nucleotides at nucleotides 80, 81, 83, 84, 85, 87-90, 92-94, and 99; and a truncated Hairpin 1 region, with nucleotides 86 and 91 deleted relative to SEQ ID NO:500, including a 2'-O-Me modified nucleotide at nucleotide 101 between the truncated Hairpin 1 region and the truncated Hairpin 2 region; 2'-O-Me modified nucleotides at nucleotides 104, 110, 111, 122 to 125, 142, and 143, and and a truncated hairpin 2 region, wherein nucleotides 112-120 and 127-134 are deleted relative to SEQ ID NO: 500, comprising a PS linkage between nucleotides 141-142 and 142-143; With respect to SEQ ID NO: 500, one or both of nucleotides 144-145 are optionally deleted.
[0433] In some embodiments, 2'-O-Me modified nucleotides in the first four nucleotides 1–4; PS linkages between nucleotides 1-2, 2-3, and 3-4; and a guide region comprising 2'-O-Me modified nucleotides at nucleotides 5, 8, 9, 11, 13, 18, and 22 of the guide region; 2'-O-Me modified nucleotides at nucleotides 25, 29, 30, 31, 32, 37, 48, 49-52, 64, 65, 69, 70, and 73; and a truncated repeat / anti-repeat region in which nucleotides 38-47 and 54-63 have been deleted relative to SEQ ID NO: 500, including a PS linkage between nucleotides 76-77 between the truncated repeat / anti-repeat region and the truncated hairpin 1 region; 2'-O-Me modified nucleotides at nucleotides 80, 81, 83, 84, 85, 87-90, 92-94, and 99; and a truncated Hairpin 1 region, with nucleotides 86 and 91 deleted relative to SEQ ID NO:500, including a 2'-O-Me modified nucleotide at nucleotide 101 between the truncated Hairpin 1 region and the truncated Hairpin 2 region; 2'-O-Me modified nucleotides at nucleotides 104, 110, 111, 122 to 125, 142, and 143, and and a truncated hairpin 2 region, wherein nucleotides 112-120 and 127-134 are deleted relative to SEQ ID NO: 500, comprising a PS linkage between nucleotides 141-142 and 142-143; With respect to SEQ ID NO: 500, one or both of nucleotides 144-145 are optionally deleted.
[0434] In some embodiments, the single guide RNA (sgRNA) 2'-O-Me modified nucleotides in the first two nucleotides 1-2; the PS linkage between nucleotides 1 and 2; and a guide region comprising 2'-O-Me modified nucleotides at nucleotides 10 and 13 of the guide region; 2'-O-Me modified nucleotides at nucleotides 25, 29, 30, 31, 32, 37, 49-52, 64, 65, 69, 70, and 73; and a truncated repeat / anti-repeat region in which nucleotides 38-48 and 53-63 have been deleted relative to SEQ ID NO: 500, including a PS linkage between nucleotides 76-77 between the truncated repeat / anti-repeat region and the truncated hairpin 1 region; 2'-O-Me modified nucleotides at nucleotides 80, 81, 83, 84, 85, 87-90, 92-94, and 99; and a truncated Hairpin 1 region, with nucleotides 86 and 91 deleted relative to SEQ ID NO:500, including a 2'-O-Me modified nucleotide at nucleotide 101 between the truncated Hairpin 1 region and the truncated Hairpin 2 region; 2'-O-Me modified nucleotides at nucleotides 102 to 105, 110, 111, 122 to 125, 135, 136, 138, 139, and 141 to 143, and a shortened hairpin 2 region in which nucleotides 112-120 and 127-134 are deleted relative to SEQ ID NO: 500, which contains three PS linkages between nucleotides 140-141, 141-142, and 142-143; Here, the sgRNA does not contain a 3' tail.
[0435] In some embodiments, the single guide RNA (sgRNA) 2'-O-Me modified nucleotides in the first four nucleotides 1–4; PS linkages between nucleotides 1-2, 2-3, and 3-4; and a guide sequence comprising 2'-O-Me modified nucleotides at nucleotides 5, 8, 9, 11, 13, 18, and 22 of the guide sequence; 2'-O-Me modified nucleotides at nucleotides 25, 29, 30, 31, 32, 37, 49-52, 64, 65, 69, 70, and 73; and a truncated repeat / anti-repeat region in which nucleotides 38-48 and 53-63 have been deleted relative to SEQ ID NO: 500, including a PS linkage between nucleotides 76-77 between the truncated repeat / anti-repeat region and the truncated hairpin 1 region; 2'-O-Me modified nucleotides at nucleotides 80, 81, 83, 84, 85, 87-90, 92-94, and 99; and a truncated Hairpin 1 region, with nucleotides 86 and 91 deleted relative to SEQ ID NO:500, including a 2'-O-Me modified nucleotide at nucleotide 101 between the truncated Hairpin 1 region and the truncated Hairpin 2 region; 2'-O-Me modified nucleotides at nucleotides 104, 110, 111, 122 to 125, 142, and 143, and a truncated hairpin 2 region in which nucleotides 112-120 and 127-135 are deleted relative to SEQ ID NO: 500, including PS linkages between nucleotides 141-142 and 142-143; With respect to SEQ ID NO: 500, one or both of nucleotides 144-145 are optionally deleted.
[0436] In some embodiments, 2'-O-Me modified nucleotides in the first four nucleotides 1–4; PS linkages between nucleotides 1-2, 2-3, and 3-4; and a guide region comprising 2'-O-Me modified nucleotides at nucleotides 5, 8, 9, 11, 13, 18, and 22 of the guide region; 2'-O-Me modified nucleotides at nucleotides 25, 29, 30, 31, 32, 37, 49-52, 64, 65, 69, 70, and 73; and a truncated repeat / anti-repeat region in which nucleotides 38-48 and 53-63 have been deleted relative to SEQ ID NO: 500, including a PS linkage between nucleotides 76-77 between the truncated repeat / anti-repeat region and the truncated hairpin 1 region; 2'-O-Me modified nucleotides at nucleotides 80, 81, 83, 84, 85, 87-90, 92-94, and 99; and a truncated Hairpin 1 region, with nucleotides 86 and 91 deleted relative to SEQ ID NO:500, including a 2'-O-Me modified nucleotide at nucleotide 101 between the truncated Hairpin 1 region and the truncated Hairpin 2 region; 2'-O-Me modified nucleotides at nucleotides 104, 110, 111, 122 to 125, 142, and 143, and and a truncated hairpin 2 region, wherein nucleotides 112-120 and 127-135 are deleted relative to SEQ ID NO: 500, comprising a PS linkage between nucleotides 141-142 and 142-143; With respect to SEQ ID NO: 500, one or both of nucleotides 144-145 are optionally deleted.
[0437] In some embodiments, 2'-O-Me modified nucleotides in the first four nucleotides 1–4; PS linkages between nucleotides 1-2, 2-3, and 3-4; and a guide region comprising 2'-O-Me modified nucleotides at nucleotides 5, 8, 9, 11, 13, 18, and 22 of the guide region; 2'-O-Me modified nucleotides at nucleotides 25, 29, 30, 31, 32, 37, 48, 49-52, 64, 65, 69, 70, and 73; and a truncated repeat / anti-repeat region in which nucleotides 38-47 and 54-63 have been deleted relative to SEQ ID NO: 500, including a PS linkage between nucleotides 76-77 between the truncated repeat / anti-repeat region and the truncated hairpin 1 region; 2'-O-Me modified nucleotides at nucleotides 80, 81, 83, 84, 85, 87-90, 92-94, and 99; and a truncated Hairpin 1 region, with nucleotides 86 and 91 deleted relative to SEQ ID NO:500, including a 2'-O-Me modified nucleotide at nucleotide 101 between the truncated Hairpin 1 region and the truncated Hairpin 2 region; 2'-O-Me modified nucleotides at nucleotides 104, 110, 111, 122 to 125, 142, and 143, and and a truncated hairpin 2 region, wherein nucleotides 112-120 and 127-135 are deleted relative to SEQ ID NO: 500, comprising a PS linkage between nucleotides 141-142 and 142-143; With respect to SEQ ID NO: 500, one or both of nucleotides 144-145 are optionally deleted.
[0438] In some embodiments, the single guide RNA (sgRNA) 2'-O-Me modified nucleotides in the first two nucleotides 1-2; the PS linkage between nucleotides 1 and 2; and a guide region comprising 2'-O-Me modified nucleotides at nucleotides 10 and 13 of the guide region; 2'-O-Me modified nucleotides at nucleotides 25, 29, 30, 31, 32, 37, 49-52, 64, 65, 69, 70, and 73; and a truncated repeat / anti-repeat region in which nucleotides 38-48 and 53-63 have been deleted relative to SEQ ID NO: 500, including a PS linkage between nucleotides 76-77 between the truncated repeat / anti-repeat region and the truncated hairpin 1 region; 2'-O-Me modified nucleotides at nucleotides 80, 81, 83, 84, 85, 87-90, 92-94, and 99; and a truncated Hairpin 1 region, with nucleotides 86 and 91 deleted relative to SEQ ID NO:500, including a 2'-O-Me modified nucleotide at nucleotide 101 between the truncated Hairpin 1 region and the truncated Hairpin 2 region; 2'-O-Me modified nucleotides at nucleotides 102 to 105, 110, 111, 122 to 125, 135, 136, 138, 139, and 141 to 143, and a shortened hairpin 2 region in which nucleotides 112-120 and 127-135 are deleted relative to SEQ ID NO: 500, which contains three PS linkages between nucleotides 140-141, 141-142, and 142-143; Here, the sgRNA does not contain a 3' tail.
[0439] In some embodiments, the single guide RNA (sgRNA) 2'-O-Me modified nucleotides in the first four nucleotides 1–4; PS linkages between nucleotides 1-2, 2-3, and 3-4; and a guide sequence comprising 2'-O-Me modified nucleotides at nucleotides 5, 8, 9, 11, 13, 18, and 22 of the guide sequence; 2'-O-Me modified nucleotides at nucleotides 25, 29, 30, 31, 32, 37, 39-40, 49-52, 61-62, 64, 65, 69, 70, and 73; and a truncated repeat / anti-repeat region in which nucleotides 38, 41-48, 53-60, and 63 have been deleted relative to SEQ ID NO: 500, including a PS linkage between nucleotides 76-77 between the truncated repeat / anti-repeat region and the truncated hairpin 1 region; 2'-O-Me modified nucleotides at nucleotides 80, 81, 83, 84, 85, 87-90, 92-94, and 99; and a truncated Hairpin 1 region, with nucleotides 86 and 91 deleted relative to SEQ ID NO:500, including a 2'-O-Me modified nucleotide at nucleotide 101 between the truncated Hairpin 1 region and the truncated Hairpin 2 region; 2'-O-Me modified nucleotides at nucleotides 104, 110, 111, 122 to 125, 142, and 143, and a truncated hairpin 2 region in which nucleotides 112-120 and 127-135 are deleted relative to SEQ ID NO: 500, including PS linkages between nucleotides 141-142 and 142-143; With respect to SEQ ID NO: 500, one or both of nucleotides 144-145 are optionally deleted.
[0440] In some embodiments, the single guide RNA (sgRNA) 2'-O-Me modified nucleotides in the first four nucleotides 1–4; PS linkages between nucleotides 1-2, 2-3, and 3-4; and a guide sequence comprising 2'-O-Me modified nucleotides at nucleotides 5, 8, 9, 11, 13, 18, and 22 of the guide sequence; a truncated repeat / anti-repeat region, wherein nucleotides 38-48 and 53-63 are deleted relative to SEQ ID NO: 500, and wherein nucleotides 25, 29, 30, 31, 32, 37, 49-52, 64, 65, 69, 70, and 73 are 2'-O-Me modified nucleotides; 2'-O-Me modified nucleotides at nucleotides 80, 81, 83, 84, 85, 87-90, 92-94, and 99; and a truncated Hairpin 1 region, with nucleotides 86 and 91 deleted relative to SEQ ID NO:500, including a 2'-O-Me modified nucleotide at nucleotide 101 between the truncated Hairpin 1 region and the truncated Hairpin 2 region; 2'-O-Me modified nucleotides at nucleotides 104, 110, 111, 122 to 125, 142, and 143, and a truncated hairpin 2 region in which nucleotides 112-120 and 127-135 are deleted relative to SEQ ID NO: 500, including PS linkages between nucleotides 141-142 and 142-143; With respect to SEQ ID NO: 500, one or both of nucleotides 144-145 are optionally deleted.
[0441] In some embodiments, the single guide RNA (sgRNA) 2'-O-Me modified nucleotides in the first four nucleotides 1–4; PS linkages between nucleotides 1-2, 2-3, and 3-4; and a guide sequence comprising 2'-O-Me modified nucleotides at nucleotides 5, 8, 9, 11, 13, 18, and 22 of the guide sequence; 2'-O-Me modified nucleotides at nucleotides 25, 29, 30, 31, 32, 37, 49-52, 64, 65, 69, 70, and 73; and a truncated repeat / anti-repeat region in which nucleotides 38-48 and 53-63 have been deleted relative to SEQ ID NO: 500, including a PS linkage between nucleotides 76-77 between the truncated repeat / anti-repeat region and the truncated hairpin 1 region; 2'-O-Me modified nucleotides at nucleotides 80, 81, 83, 84, 85, 87-90, 92-94, and 99; and a truncated Hairpin 1 region, with nucleotides 86 and 91 deleted relative to SEQ ID NO:500, including a 2'-O-Me modified nucleotide at nucleotide 101 between the truncated Hairpin 1 region and the truncated Hairpin 2 region; 2'-O-Me modified nucleotides at nucleotides 104, 106 to 109, 110, 111, 122 to 125, 142, and 143, and a truncated hairpin 2 region in which nucleotides 112-120 and 127-135 are deleted relative to SEQ ID NO: 500, including PS linkages between nucleotides 141-142 and 142-143; With respect to SEQ ID NO: 500, one or both of nucleotides 144-145 are optionally deleted.
[0442] In some embodiments, the single guide RNA (sgRNA) 2'-O-Me modified nucleotides in the first four nucleotides 1–4; PS linkages between nucleotides 1-2, 2-3, and 3-4; and a guide sequence comprising 2'-O-Me modified nucleotides at nucleotides 5, 8, 9, 11, 13, 18, and 22 of the guide sequence; a truncated repeat / anti-repeat region, wherein nucleotides 38-48 and 53-63 are deleted relative to SEQ ID NO: 500, and wherein nucleotides 25, 29, 30, 31, 32, 37, 49-52, 64, 65, 69, 70, and 73 are 2'-O-Me modified nucleotides; 2'-O-Me modified nucleotides at nucleotides 80, 81, 83, 84, 85, 87-90, 92-94, and 99; and a truncated Hairpin 1 region, with nucleotides 86 and 91 deleted relative to SEQ ID NO:500, including a 2'-O-Me modified nucleotide at nucleotide 101 between the truncated Hairpin 1 region and the truncated Hairpin 2 region; 2'-O-Me modified nucleotides at nucleotides 104, 106 to 109, 110, 111, 122 to 125, 142, and 143, and a truncated hairpin 2 region in which nucleotides 112-120 and 127-135 are deleted relative to SEQ ID NO: 500, including PS linkages between nucleotides 141-142 and 142-143; With respect to SEQ ID NO: 500, one or both of nucleotides 144-145 are optionally deleted.
[0443] In some embodiments, the single guide RNA (sgRNA) 2'-O-Me modified nucleotides in the first four nucleotides 1–4; PS linkages between nucleotides 1-2, 2-3, and 3-4; and a guide sequence comprising 2'-O-Me modified nucleotides at nucleotides 5, 8, 9, 11, 13, 18, and 22 of the guide sequence; a truncated repeat / anti-repeat region, wherein nucleotides 38, 41-48, 53-60, and 63 are deleted relative to SEQ ID NO: 500, and wherein nucleotides 25, 29, 30, 31, 32, 37, 39-40, 49-52, 61-62, 64, 65, 69, 70, and 73 are 2'-O-Me modified nucleotides; 2'-O-Me modified nucleotides at nucleotides 80, 81, 83, 84, 85, 87-90, 92-94, and 99; and a truncated Hairpin 1 region, with nucleotides 86 and 91 deleted relative to SEQ ID NO:500, including a 2'-O-Me modified nucleotide at nucleotide 101 between the truncated Hairpin 1 region and the truncated Hairpin 2 region; 2'-O-Me modified nucleotides at nucleotides 104, 110, 111, 122 to 125, 142, and 143, and a truncated hairpin 2 region in which nucleotides 112-120 and 127-135 are deleted relative to SEQ ID NO: 500, including PS linkages between nucleotides 141-142 and 142-143; With respect to SEQ ID NO: 500, one or both of nucleotides 144-145 are optionally deleted.
[0444] In some embodiments, the single guide RNA (sgRNA) 2'-O-Me modified nucleotides in the first four nucleotides 1–4; PS linkages between nucleotides 1-2, 2-3, and 3-4; and a guide sequence comprising 2'-O-Me modified nucleotides at nucleotides 5, 8, 9, 11, 13, 18, and 22 of the guide sequence; 2'-O-Me modified nucleotides at nucleotides 25, 29, 30, 31, 32, 37, 39-40, 49-52, 61-62, 64, 65, 69, 70, and 73; and a truncated repeat / anti-repeat region in which nucleotides 38, 41-48, 53-60, and 63 have been deleted relative to SEQ ID NO: 500, including a PS linkage between nucleotides 76-77 between the truncated repeat / anti-repeat region and the truncated hairpin 1 region; 2'-O-Me modified nucleotides at nucleotides 80, 81, 83, 84, 85, 87-90, 92-94, and 99; and a truncated Hairpin 1 region, with nucleotides 86 and 91 deleted relative to SEQ ID NO:500, including a 2'-O-Me modified nucleotide at nucleotide 101 between the truncated Hairpin 1 region and the truncated Hairpin 2 region; 2'-O-Me modified nucleotides at nucleotides 104, 106 to 109, 110, 111, 122 to 125, 142, and 143, and a truncated hairpin 2 region in which nucleotides 112-120 and 127-135 are deleted relative to SEQ ID NO: 500, including PS linkages between nucleotides 141-142 and 142-143; With respect to SEQ ID NO: 500, one or both of nucleotides 144-145 are optionally deleted.
[0445] In some embodiments, the single guide RNA (sgRNA) 2'-O-Me modified nucleotides in the first four nucleotides 1–4; PS linkages between nucleotides 1-2, 2-3, and 3-4; and a guide sequence comprising 2'-O-Me modified nucleotides at nucleotides 5, 8, 9, 11, 13, 18, and 22 of the guide sequence; a truncated repeat / anti-repeat region, wherein nucleotides 38, 41-48, 53-60, and 63 are deleted relative to SEQ ID NO: 500, and wherein nucleotides 25, 29, 30, 31, 32, 37, 39-40, 49-52, 61-62, 64, 65, 69, 70, and 73 are 2'-O-Me modified nucleotides; 2'-O-Me modified nucleotides at nucleotides 80, 81, 83, 84, 85, 87-90, 92-94, and 99; and a truncated Hairpin 1 region, with nucleotides 86 and 91 deleted relative to SEQ ID NO:500, including a 2'-O-Me modified nucleotide at nucleotide 101 between the truncated Hairpin 1 region and the truncated Hairpin 2 region; 2'-O-Me modified nucleotides at nucleotides 104, 106 to 109, 110, 111, 122 to 125, 142, and 143, and a truncated hairpin 2 region in which nucleotides 112-120 and 127-135 are deleted relative to SEQ ID NO: 500, including PS linkages between nucleotides 141-142 and 142-143; With respect to SEQ ID NO: 500, one or both of nucleotides 144-145 are optionally deleted.
[0446] Compositions and Kits Compositions comprising any of the gRNAs described herein and a carrier, excipient, diluent, etc. are encompassed. Optionally, the excipient or diluent is inert. Optionally, the excipient or diluent is not inert. In certain embodiments, the carrier, excipient, or diluent is non-pyrogenic. In certain embodiments, the carrier, excipient, or diluent is sterile. In some embodiments, a pharmaceutical formulation is provided comprising any of the gRNAs described herein and a pharmaceutically acceptable carrier, excipient, diluent, etc. In some embodiments, the pharmaceutical formulation further comprises a LNP. In some embodiments, the pharmaceutical formulation further comprises a Cas9 protein or an mRNA encoding a Cas9 protein. In some embodiments, the pharmaceutical formulation comprises a gRNA, a LNP, and one or more of a Cas protein or an mRNA encoding a Cas protein. In some embodiments, the gRNA is an sgRNA. In some embodiments, the Cas protein is a monomeric Cas protein, e.g., a Cas9 protein. In some embodiments, the Cas protein is an Nme Cas protein. In some embodiments, the Cas protein comprises multiple subunits.
[0447] Also provided are kits that include one or more gRNAs, compositions, or pharmaceutical preparations described herein. In some embodiments, the kits further include one or more of a solvent, solution, or buffer, apart from the composition or pharmaceutical preparation, instructions, or desiccant.
[0448] Compositions comprising RNA-guided DNA-binding agents or mRNA encoding RNA-guided DNA-binding agents In some embodiments, compositions or pharmaceutical formulations are provided that include at least one gRNA, preferably an sgRNA, as described herein, and an RNA-guided DNA-binding agent or a nucleic acid (e.g., mRNA) encoding the RNA-guided DNA-binding agent. In some embodiments, the RNA-guided DNA-binding agent is a Cas protein. In some embodiments, the gRNA, together with the Cas protein or a nucleic acid (e.g., mRNA) encoding the Cas protein, is referred to as a Cas RNP. In some embodiments, the RNA-guided DNA-binding agent cooperates with the gRNA to guide the RNA-guided DNA-binding agent to a target nucleic acid sequence. In some embodiments, the RNA-guided DNA-binding agent is a Cas protein from a type II CRISPR / Cas system. In some embodiments, the Cas protein is Cas9. In some embodiments, the Cas9 protein is wild-type Cas9. In some embodiments, the Cas9 protein is derived from Neisseria meningitidis Cas9 (NmeCas9). In some embodiments, compositions are provided that include at least one gRNA and an mRNA encoding a nuclease or NmeCas9. In some embodiments, compositions are provided that include at least one gRNA and an mRNA encoding a nuclease or NmeCas9. In some embodiments, the Cas induces a double-strand break in the target DNA. NmeCas9 and its homologs and mutant equivalents, as well as other Cas proteins disclosed herein, are encompassed by the embodiments described herein.
[0449] RNA-guided DNA-binding agents, including Cas9, include modifications and variants thereof. Modified versions with an inactive RuvC or HNH catalytic domain are called "nickases." Nickases cleave only one strand of target DNA, generating a single-strand break. A single-strand break is also called a "nick." In some embodiments, compositions and methods include a nickase. In some embodiments, compositions and methods include a nickase RNA-guided DNA-binding agent, such as a nickase Cas, e.g., nickase Cas9, that induces a nick rather than a double-strand break in target DNA.
[0450] In some embodiments, a nuclease, such as an RNA-guided DNA binder, can be modified to contain only one functional nuclease domain. For example, an RNA-guided DNA binder can be modified such that one of the nuclease domains is mutated or completely or partially deleted to reduce its nucleic acid cleavage activity. In some embodiments, a nickase Cas with a RuvC domain that has reduced activity is used. In some embodiments, a nickase Cas with an inactive RuvC domain is used. In some embodiments, a nickase Cas with an HNH domain that has reduced activity is used. In some embodiments, a nickase Cas with an inactive HNH domain is used.
[0451] In some embodiments, conserved amino acids within the RNA-guided DNA binder nuclease domain are substituted to reduce or alter nuclease activity. In some embodiments, the Cas protein may comprise an amino acid substitution in the RuvC or RuvC-like nuclease domain. An exemplary amino acid substitution in the RuvC or RuvC-like nuclease domain is H588A (based on the N. meningitidis Cas9 protein). In some embodiments, the Cas protein may comprise an amino acid substitution in the HNH or HNH-like nuclease domain. An exemplary amino acid substitution in the HNH or HNH-like nuclease domain is D16A (based on the NmeCas9 protein).
[0452] In some embodiments, the RNP complexes described herein include a nickase or an mRNA encoding a nickase and a pair of gRNAs (one or both of which can be sgRNAs) that are complementary to the sense and antisense strands of the target sequence, respectively. In this embodiment, the gRNA (e.g., sgRNA) guides the nickase to the target sequence, creating a nick in the opposite strand of the target sequence (i.e., double nicking), thereby introducing a double-strand break (DSB). In some embodiments, the use of double nicking can improve specificity and reduce off-target effects. In some embodiments, a nickase RNA-guided DNA-binding agent is used with two separate gRNAs (e.g., sgRNAs) selected to be in close proximity to generate a double nick in the target DNA.
[0453] In some embodiments, chimeric Cas proteins are used in which one domain or region is replaced with a portion of a different protein. In some embodiments, the Cas nuclease domain may be replaced with a domain from a different nuclease, such as Fok1. In some embodiments, the Cas protein may be a modified nuclease.
[0454] In some embodiments, the nuclease, eg, an RNA-guided DNA binder, can be modified to induce point mutations or base changes, eg, deamination.
[0455] In some embodiments, the Cas protein is a nickase or comprises a fusion protein comprising a catalytically inactive Cas nuclease (e.g., Cas9) linked to a heterologous functional domain. In some embodiments, the Cas protein comprises a fusion protein comprising a catalytically inactive Cas nuclease (e.g., Cas9) linked to a heterologous functional domain (see, e.g., WO2014152432). In some embodiments, the catalytically inactive Cas9 is a catalytically inactive N. meningitidis Cas9. In some embodiments, the catalytically inactive Cas comprises a mutation that inactivates the Cas. In some embodiments, the heterologous functional domain is a domain that modifies gene expression, histones, or DNA. In some embodiments, the heterologous functional domain is a transcriptional activation domain or a transcriptional repression domain. In some embodiments, the nuclease is a catalytically inactive Cas nuclease, such as dCas9.
[0456] In some embodiments, the heterologous functional domain is a deaminase, such as cytidine deaminase or adenine deaminase. In certain embodiments, the heterologous functional domain is a C to T base conversion (cytidine deaminase), such as apolipoprotein B mRNA editing enzyme (APOBEC) deaminase. A heterologous functional domain, such as a deaminase, can be part of a fusion protein with a Cas nuclease with nickase activity or a catalytically inactive Cas nuclease.
[0457] In some embodiments, the target sequence may be adjacent to a PAM. In some embodiments, the PAM may be adjacent to or within 1, 2, 3, or 4 nucleotides of the 3' end of the target sequence. The length and sequence of the PAM may vary depending on the Cas protein used. For example, the PAM may be selected from consensus or specific PAM sequences for a particular NmeCas9 protein or NmeCas9 ortholog (Edraki et al., 2019). In some embodiments, the NmeCas9 PAM may comprise 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides in length. Non-limiting exemplary PAM sequences include NCC, N4GAYW, N4GYTT, N4GTCT, NNNNCC(a), and NNNNCAAA (where N is defined as any nucleotide, W is defined as either A or T, R is defined as either A or G, and (a) preferably, but not necessarily, an A after the second C). In some embodiments, the PAM sequence may be NCC.
[0458] In some embodiments, the heterologous functional domain can facilitate the transport of the RNA-guided DNA binding agent into the cell nucleus. For example, the heterologous functional domain can be a nuclear localization signal (NLS). In some embodiments, the RNA-guided DNA binding agent can be fused with 1 to 10 NLS(s). In some embodiments, the RNA-guided DNA binding agent can be fused with 1 to 5 NLS(s). In some embodiments, the RNA-guided DNA binding agent can be fused with one NLS. When one NLS is used, the NLS is preferably fused at the N-terminus of the RNA-guided DNA binding agent sequence. The NLS can also be inserted within the RNA-guided DNA binding agent sequence. In other embodiments, the RNA-guided DNA binding agent can be fused with multiple NLSs. In some embodiments, the RNA-guided DNA binding agent can be fused with two, three, four, or five NLSs. In some embodiments, the RNA-guided DNA binding agent can be fused with two NLSs. In some embodiments, the NLS may be fused to the N-terminus of the sequence of the RNA-guided DNA binding agent. In some embodiments, the NLS may be fused only to the N-terminus of the sequence of the RNA-guided DNA binding agent. In some embodiments, the RNA-guided DNA binding agent may not have an NLS inserted into the sequence of the RNA-guided DNA binding agent. In certain embodiments, the NLS may not be present at the C-terminus of the sequence of the RNA-guided DNA binding agent.
[0459] In some embodiments, the RNA-guided DNA binding agent may be fused with two NLSs. In certain circumstances, the two NLSs may be the same (e.g., two SV40 NLSs) or different. In some embodiments, the RNA-guided DNA binding agent is fused to two NLS sequences (e.g., SV40) at the amino terminus. In some embodiments, the RNA-guided DNA binding agent may be fused with two NLSs, one fused at the N-terminus and one fused at the C-terminus. In some embodiments, the RNA-guided DNA binding agent may be fused with three NLSs. In some embodiments, the RNA-guided DNA binding agent is not fused to an NLS at the C-terminus. In some embodiments, the RNA-guided DNA binding agent does not have an NLS inserted within the sequence of the RNA-guided DNA binding agent. An NLS may be fused to the C-terminus of the RNA-guided DNA binding agent. One or more linkers are optionally included at the fusion site.
[0460] In some embodiments, the NLS can be a monopartite sequence (e.g., the SV40 NLS, such as PKKKRKV (SEQ ID NO: 669) or PKKKRRV (SEQ ID NO: 670)). In some embodiments, the NLS can be a bipartite sequence, such as the nucleoplasmin NLS, KRPAATKKAGQAKKKK (SEQ ID NO: 682). In some embodiments, the NLS sequence can include LAAKRSRTT (SEQ ID NO: 671), QAAKRSRTT (SEQ ID NO: 672), PAPAKRERTT (SEQ ID NO: 673), QAAKRPRTT (SEQ ID NO: 674), RAAKRPRTT (SEQ ID NO: 675), AAAKRSWSMAA (SEQ ID NO: 676), AAAKRVWSMAF (SEQ ID NO: 677), AAAKRSWSMAF (SEQ ID NO: 678), AAAKRKYFAA (SEQ ID NO: 679), RAAKRKAFAA (SEQ ID NO: 680), or RAAKRKYFAV (SEQ ID NO: 681). The NLS can be Snapportin 1 importin β (IBB domain, e.g., SPN1-impβ sequence). See Huber et al., 2002, J. Cell Bio., 156, 467-479. In a specific embodiment, it is a single PKKKRKV (SEQ ID NO: 669). In some embodiments, the first and second NLSs are independently selected from an SV40 NLS, a nucleoplasmic NLS, a bipartite NLS, a c-myc-like NLS, and an NLS comprising the sequence KTRAD. In certain embodiments, the first and second NLSs can be the same (e.g., two SV40 NLSs). In certain embodiments, the first and second NLSs can be different.
[0461] In some embodiments, the first NLS is an SV40 NLS and the second NLS is a nucleoplasmic NLS.
[0462] In some embodiments, the SV40 NLS comprises the sequence of SEQ ID NO: 683 or 684. In some embodiments, the nucleoplasmic NLS comprises the sequence of SEQ ID NO: 682. In some embodiments, the bipartite NLS comprises the sequence of SEQ ID NO: 685. In some embodiments, the c-myc-like NLS comprises the sequence of SEQ ID NO: 686.
[0463] In some embodiments, the RNA-guided DNA binding agent comprises an amino acid sequence having at least 90%, 93%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 100% identity to any one of SEQ ID NOs: 600-603, 605, 607-620, or 707-712 (as shown in Table 4A).
[0464] In some embodiments, the polynucleotide encoding the RNA-guided DNA binder comprises a nucleotide sequence having at least 90%, 93%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 100% identity to any one of SEQ ID NOs: 621-623, 626-643, 645, 647-668, 701-706, and 713-718 (NmeCas9 mRNA and ORFs shown in Table 4A).
[0465] In some embodiments, the mRNA encoding the RNA-guided DNA binding agent comprises an open reading frame (ORF) comprising a sequence having at least 90%, 93%, 95%, 96%, 97%, 98%, or 99%, or 100% identity to any one of SEQ ID NOs: 621-623, 626-639, and 713-718, as set forth in Table 4A.
[0466] How to use In some embodiments, any one or more of the gRNAs (e.g., sgRNAs), compositions, or pharmaceutical formulations described herein are used in the preparation of a medicament for treating or preventing a disease or disorder of a subject.
[0467] In some embodiments, the invention includes methods of treating or preventing a disease or disorder in a subject comprising administering any one or more of the gRNAs (e.g., sgRNAs), compositions, or pharmaceutical formulations described herein.
[0468] In some embodiments, the present invention includes methods or uses for modifying target DNA, comprising administering or delivering any one or more of the gRNAs (e.g., sgRNAs), compositions, or pharmaceutical formulations described herein.
[0469] In some embodiments, the present invention includes a method or use for regulating a target gene, comprising administering or delivering any one or more of the gRNAs (e.g., sgRNAs), compositions, or pharmaceutical formulations described herein. In some embodiments, the regulation is editing of the target gene. In some embodiments, the regulation is a change in expression of a protein encoded by the target gene.
[0470] As used herein, "gene editing" or "genetic modification" refers to a change at the DNA level, for example, induced by a gRNA / Cas complex. Gene editing or genetic modification can typically include insertion, deletion, or substitution (base substitution, e.g., C to T, or point mutation) within a defined sequence or genomic locus. Genetic modification changes the nucleic acid sequence of DNA. Genetic modification may occur at a single nucleotide position. Genetic modification can involve multiple nucleotides, for example, 2, 3, 4, 5, or more nucleotides, typically adjacent to each other, e.g., consecutive nucleotides.
[0471] In some embodiments, the method or use results in gene editing. In some embodiments, the method or use generates a double-strand break in the target gene. In some embodiments, the method or use generates an indel mutation during non-homologous end joining of the DSB. In some embodiments, the method or use generates a nucleotide insertion or deletion in the target gene. In some embodiments, the nucleotide insertion or deletion in the target gene results in a frameshift mutation or a premature stop codon, resulting in a non-functional protein. In some embodiments, the nucleotide insertion or deletion in the target gene leads to knockdown or elimination of expression of the target gene. In some embodiments, the method or use includes homology-guided repair of the DSB. In some embodiments, the method or use further includes delivering a template to a cell, wherein at least a portion of the template is incorporated into the target DNA at or near the site of the nuclease-induced double-strand break. In some embodiments, the method or use generates a single-strand break in the target gene. In some embodiments, the method or use generates a base change in the target gene, for example, by deamination. Gene editing typically occurs within or adjacent to a portion of the target gene where the spacer sequence forms a duplex.
[0472] In some embodiments, the method or use is used to regulate genes. In some embodiments, the gene regulation is an increase or decrease in gene expression, a change in DNA methylation status, or a modification of histone subunits. In some embodiments, the method or use results in an increase or decrease in the expression of the protein encoded by the target gene.
[0473] The efficacy of gRNAs can be tested in vitro and in vivo. In some embodiments, the invention comprises one or more gRNAs, compositions, or pharmaceutical formulations described herein, wherein the gRNA, when provided to a cell along with a Cas nuclease, e.g., Cas9, or an mRNA encoding Cas9, results in gene regulation. In some embodiments, the efficacy of a gRNA can be measured in vitro or in vivo.
[0474] In some embodiments, the activity of a Cas RNP containing a gRNA is compared to the activity of a Cas RNP containing an unmodified sgRNA, or to the activity of a reference sgRNA that lacks modifications present in the sgRNA, such as one or more internal linkers or a truncated region. In some embodiments, the sgRNA does not contain an internal linker.
[0475] In some embodiments, the efficiency of a gRNA to increase or decrease expression of a target protein is determined by measuring the amount of the target protein.
[0476] In some embodiments, the efficiency of editing by a particular gRNA is determined by the edits present at the target location in the genome after delivery of the Cas nuclease and gRNA. In some embodiments, the efficiency of editing by a particular gRNA is measured by next-generation sequencing (NGS). In some embodiments, the editing rate of the target region of interest is determined. In some embodiments, the total number of sequence reads with sequence alterations, such as nucleotide insertions or deletions (indels), or base alterations without insertions or deletions, in the target region of interest relative to the total number of sequence reads after delivery of the gRNA and Cas nuclease is measured.
[0477] In some embodiments, the efficiency of editing by a particular gRNA is measured by the presence of sequence alterations, such as insertions or deletions, or base substitutions, or nucleotide point mutations, introduced by successful gene editing. In some embodiments, the activity of the Cas nuclease and gRNA is tested in a biochemical assay. In some embodiments, the activity of the Cas nuclease and gRNA is tested in a cell-free cleavage assay. In some embodiments, the activity of the Cas nuclease and gRNA is tested in Neuro2A cells. In some embodiments, the activity of the Cas nuclease and gRNA is tested in primary cells, such as primary hepatocytes.
[0478] In some embodiments, the activity of the modified gRNA is measured after in vivo administration of an LNP comprising the modified gRNA and a Cas protein or an mRNA encoding a Cas protein.
[0479] In some embodiments, the in vivo efficacy of a gRNA or composition provided herein is determined by the editing efficacy measured in DNA extracted from tissue (e.g., liver tissue) following administration of the gRNA and Cas nuclease.
[0480] In some embodiments, activation of the subject's immune response is measured by serum concentration of cytokine(s) after in vivo administration of the sgRNA together with the Cas nuclease mRNA or protein (e.g., formulated in LNPs). In some embodiments, the cytokine is interferon alpha (IFN-α), interleukin 6 (IL-6), monocyte chemotactic protein 1 (MCP-1), or tumor necrosis factor alpha (TNF-α).
[0481] In some embodiments, administration of a Cas RNP or Cas nuclease mRNA together with a modified gRNA (e.g., sgRNA) results in lower serum concentration(s) of immune cytokines compared to administration of an unmodified sgRNA. In some embodiments, the invention includes methods comprising administering to a subject any one of the gRNAs disclosed herein, wherein the gRNA induces lower concentrations of immune cytokines in the serum of the subject compared to a similarly unmodified control gRNA.
[0482] Guide RNA delivery In some embodiments, the gRNA compositions, compositions, or pharmaceutical formulations described herein are administered alone or encoded on one or more vectors, formulated in or via lipid nanoparticles, see e.g., WO2017 / 173054, the entire contents of which are incorporated herein by reference.
[0483] Lipids; Formulations; Delivery Disclosed herein are various embodiments that utilize lipid nucleic acid assembly compositions comprising the nucleic acid(s) or composition(s) described herein. In some embodiments, the lipid nucleic acid assembly composition comprises a gRNA described herein, e.g., a gRNA comprising a guide region and a conserved region, wherein the conserved region comprises one or more of the following: (a) a truncated repeat / anti-repeat region, wherein the truncated repeat / anti-repeat region lacks 2-24 nucleotides, wherein (i) one or more of nucleotides 37-48 and 53-64 are deleted, optionally with one or more substitutions of nucleotides 37-64 relative to SEQ ID NO: 500, and (ii) nucleotide 36 is connected to nucleotide 65 by at least two nucleotides; or (b) a truncated hairpin 1 region, wherein the truncated hairpin 1 lacks 2-10 nucleotides, optionally 2-8 nucleotides, and wherein (i) one of nucleotides 82-86 and 91-95 or (c) a truncated hairpin 2 region, wherein truncated hairpin 2 lacks 2 to 18 nucleotides, optionally 2 to 16 nucleotides, and wherein (i) one or more of nucleotides 113-121 and 126-134 are deleted, and optionally one or more of nucleotides 113-134 are substituted relative to SEQ ID NO:500, and (ii) nucleotide 112 is connected to nucleotide 135 by at least 4 nucleotides; wherein one or both of nucleotides 144-145 are optionally deleted and at least 10 nucleotides are modified nucleotides relative to SEQ ID NO:500.
[0484] As used herein, "lipid-nucleic acid assembly composition" refers to lipid-based delivery compositions, including lipid nanoparticles (LNPs) and lipoplexes. LNPs refer to lipid nanoparticles of less than 100 nM. LNPs are formed by precisely mixing a lipid component (e.g., in ethanol) with an aqueous nucleic acid component, and LNPs are uniform in size. Lipoplexes are particles formed by mixing lipid and nucleic acid components in large quantities, and are approximately 100 nm to 1 micron in size. In certain embodiments, the lipid-nucleic acid assembly is an LNP. As used herein, a "lipid-nucleic acid assembly" comprises multiple (i.e., two or more) lipid molecules physically associated with each other through intermolecular forces. Lipid-nucleic acid assembly can comprise bioavailable lipids with pKa values less than 7.5 or less than 7. Lipid-nucleic acid assembly can be formed by mixing an aqueous nucleic acid-containing solution with an organic solvent-based lipid solution (e.g., 100% ethanol). Suitable solutions or solvents may include or contain water, PBS, Tris buffer, NaCl, citrate buffer, ethanol, chloroform, diethyl ether, cyclohexane, tetrahydrofuran, methanol, isopropanol. Pharmaceutically acceptable buffers may be optionally included in pharmaceutical formulations containing lipid-nucleic acid assemblies, for example, for ex vivo treatment. In some embodiments, the aqueous solution comprises a gRNA as described herein. In some embodiments, the aqueous solution further comprises an mRNA encoding an RNA-guided DNA-binding agent, such as Cas9.
[0485] As used herein, lipid nanoparticles (LNPs) refer to particles comprising a plurality (i.e., two or more) of lipid molecules physically associated with each other by intermolecular forces. LNPs can be, for example, microspheres (including unilamellar and multilamellar vesicles, e.g., "liposomes," which have a lamellar phase lipid bilayer, which in some embodiments are substantially spherical and, in certain embodiments, can include an aqueous core containing, for example, a substantial portion of RNA molecules), the dispersed phase of an emulsion, a micelle, or the internal phase of a suspension. Emulsions, micelles, and suspensions can be compositions suitable for topical and / or localized delivery. See, for example, WO2017173054A1, the contents of which are incorporated herein by reference in their entirety. Any LNP known to those skilled in the art to be capable of delivering nucleotides to a subject can be utilized with the guide RNAs, RNA-guided nickase-encoding nucleic acids, and cytidine deaminase-encoding nucleic acids described herein.
[0486] In some embodiments, the aqueous solution comprises a gRNA as described herein, and optionally further comprises an mRNA encoding an RNA-guided DNA-binding agent, such as Cas9. Pharmaceutical formulations comprising lipid-nucleic acid assembly compositions can optionally comprise a pharmaceutically acceptable buffer.
[0487] In some embodiments, lipid-nucleic acid assembly compositions include "amine lipids" (sometimes referred to herein or elsewhere as "ionizable lipids" or "biodegradable lipids"), along with optional "helper lipids," "neutral lipids," and stealth lipids such as PEG lipids. In some embodiments, the amine lipids or ionizable lipids are cationic depending on pH.
[0488] Amine lipids In some embodiments, the lipid-nucleic acid assembly composition comprises an "amine lipid," which is an ionizable lipid such as, for example, lipid A or its equivalents, including the acetal analog of lipid A.
[0489] In some embodiments, the amine lipid is lipid A, which is (9Z,12Z)-3-((4,4-bis(octyloxy)butanoyl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)propyl octadeca-9,12-dienoate, also referred to as 3-((4,4-bis(octyloxy)butanoyl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)propyl(9Z,12Z)-octadeca-9,12-dienoate. [ka] It can be expressed as:
[0490] Lipid A can be synthesized according to WO2015 / 095340 (e.g., pp. 84-86). In some embodiments, the amine lipid is equivalent to lipid A.
[0491] In some embodiments, the amine lipid is an analog of lipid A. In some embodiments, the analog of lipid A is an acetal analog of lipid A. In certain lipid nucleic acid assembly compositions, the acetal analog is a C4-C12 acetal analog. In some embodiments, the acetal analog is a C5-C12 acetal analog. In additional embodiments, the acetal analog is a C5-C10 acetal analog. In further embodiments, the acetal analog is selected from C4, C5, C6, C7, C9, C10, C11, and C12 acetal analogs.
[0492] Amine lipids and other "biodegradable lipids" suitable for use in the lipid-nucleic acid assemblies described herein are biodegradable in vivo or ex vivo. Amine lipids have low toxicity (e.g., are tolerated in animal models without adverse effects at doses of 10 mg / kg or greater). In some embodiments, lipid-nucleic acid assemblies comprising amine lipids include those in which at least 75% of the amine lipids are cleared from plasma or engineered cells within 8, 10, 12, 24, or 48 hours, or within 3, 4, 5, 6, 7, or 10 days. In some embodiments, lipid-nucleic acid assemblies comprising amine lipids include those in which at least 50% of the nucleic acid, e.g., mRNA or gRNA, is cleared from plasma within 8, 10, 12, 24, or 48 hours, or within 3, 4, 5, 6, 7, or 10 days. In some embodiments, lipid nucleic acid assemblies comprising amine lipids include those in which at least 50% of the lipid nucleic acid assemblies are cleared from plasma within 8, 10, 12, 24, or 48 hours, or within 3, 4, 5, 6, 7, or 10 days, as determined, for example, by measuring lipid (e.g., amine lipid), nucleic acid (e.g., RNA / mRNA), or other components. In some embodiments, the lipid-encapsulated lipid versus free lipid, RNA, or nucleic acid components of the lipid nucleic acid assemblies are measured.
[0493] Biodegradable lipids include, for example, those in WO / 2020 / 219876, WO / 2020 / 118041, WO / 2020 / 072605, WO / 2019 / 067992, WO / 2017 / 173054, WO2015 / 095340, and WO2014 / 136086, and LNPs include the LNP compositions described herein, which lipids and compositions are incorporated herein by reference.
[0494] Lipid clearance can be measured as described in the literature. See Maier, MA, et al. Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics. Mol. Ther. 2013, 21(8), 1570-78 ("Maier"). For example, Maier administered an LNP-siRNA system containing siRNA targeting luciferase at 0.3 mg / kg via intravenous bolus injection through the lateral tail vein to 6-8 week-old male C57Bl / 6 mice. Blood, liver, and spleen samples were collected at 0.083, 0.25, 0.5, 1, 2, 4, 8, 24, 48, 96, and 168 hours post-administration. Mice were perfused with saline before tissue collection, and blood samples were processed to obtain plasma. All samples were processed and analyzed by LC-MS. Maier also describes procedures for assessing the toxicity of LNP-siRNA formulations after administration. For example, 0, 1, 3, 5, or 10 mg / kg of siRNA targeting luciferase was administered to male Sprague-Dawley rats (5 rats per group) via a single intravenous bolus injection at a dose of 5 mL / kg. After 24 hours, approximately 1 mL of blood was collected from the jugular vein of conscious animals, and serum was separated. Seventy-two hours after administration, all animals were euthanized for necropsy. Clinical signs, body weight, serum chemistry, organ weight, and histopathology were evaluated. While Maier describes methods for evaluating siRNA-LNP formulations, these methods can be applied to assess the clearance, pharmacokinetics, and toxicity of the lipid-nucleic acid assembly compositions of the present disclosure.
[0495] Suitable for LNP delivery of nucleic acid known in the art is ionizable and bioavailable lipid.Lipid can be ionized according to the pH of the medium in which it is contained.For example, in a slightly acidic medium, lipid such as amine lipid can be protonated and therefore have positive charge.On the other hand, in a slightly basic medium, such as blood, whose pH is approximately 7.35, lipid such as amine lipid can not be protonated and therefore have no charge.
[0496] The ability of a lipid to carry a charge is related to its inherent pKa. In some embodiments, the amine lipids of the present disclosure can each independently have a pKa in the range of about 5.1 to about 7.4. In some embodiments, the bioavailable lipids of the present disclosure can each independently have a pKa in the range of about 5.1 to about 7.4, e.g., about 5.5 to about 6.6, about 5.6 to about 6.4, about 5.8 to about 6.2, or about 5.8 to about 6.5. For example, the amine lipids of the present disclosure can each independently have a pKa in the range of about 5.8 to about 6.5. Lipids with a pKa in the range of about 5.1 to about 7.4 are effective for in vivo cargo delivery, for example, to the liver. Furthermore, lipids with a pKa in the range of about 5.3 to about 6.4 have been found to be effective for in vivo delivery, for example, to tumors. See, e.g., WO2014 / 136086.
[0497] Additional fats "Neutral lipids" suitable for use in the lipid nucleic acid assembly compositions of the present disclosure include, for example, a variety of neutral lipids, uncharged lipids, or zwitterionic lipids. Examples of neutral phospholipids suitable for use in the present disclosure include 5-heptadecylbenzene-1,3-diol (resorcinol), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), phosphocholine (DOPC), dimyristoylphosphatidylcholine (DMPC), phosphatidylcholine (PLPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DAPC), phosphatidylethanolamine (PE), egg phosphatidylcholine (EPC), dilauryloylphosphatidylcholine (DLPC), dimyristoylphosphatidylcholine (DMPC), 1-myristoyl-2-palmitoylphosphatidylcholine (MPPC), 1-palmitoyl-2-myristoylphosphatidylcholine (PMPC), 1-palmitoyl-2-stearoylphosphatidylcholine (PMP ...
[0039] Examples of suitable phosphatidylcholine include, but are not limited to, palmitoyl oleoyl phosphatidylcholine (PSPC), 1,2-diarachidoyl-sn-glycero-3-phosphocholine (DBPC), 1-stearoyl-2-palmitoylphosphatidylcholine (SPPC), 1,2-dieicosenoyl-sn-glycero-3-phosphocholine (DEPC), palmitoyloleoylphosphatidylcholine (POPC), lysophosphatidylcholine, dioleoylphosphatidylethanolamine (DOPE), dilinoleoylphosphatidylcholine, distearoylphosphatidylethanolamine (DSPE), dimyristoylphosphatidylethanolamine (DMPE), dipalmitoylphosphatidylethanolamine (DPPE), palmitoyloleoylphosphatidylethanolamine (POPE), lysophosphatidylethanolamine, and combinations thereof. In one embodiment, the neutral phospholipid may be selected from the group consisting of distearoylphosphatidylcholine (DSPC) and dimyristoylphosphatidylethanolamine (DMPE). In another embodiment, the neutral phospholipid may be distearoylphosphatidylcholine (DSPC).
[0498] "Helper lipids" include steroids, sterols, and alkylresorcinols. Helper lipids suitable for use in the present disclosure include, but are not limited to, cholesterol, 5-heptadecylresorcinol, and cholesterol hemisuccinate. In one embodiment, the helper lipid can be cholesterol. In one embodiment, the helper lipid can be cholesterol hemisuccinate.
[0499] A "stealth lipid" is a lipid that alters the length of time that nanoparticles can persist in vivo (e.g., in blood). Stealth lipids can aid in the formulation process, for example, by reducing particle aggregation and controlling particle size. Stealth lipids used herein can modulate the pharmacokinetic properties of lipid-nucleic acid aggregates or enhance the stability of nanoparticles ex vivo. Stealth lipids suitable for use in the lipid-nucleic acid aggregate compositions of the present disclosure include, but are not limited to, stealth lipids having a hydrophilic head group attached to the lipid moiety. Information regarding stealth lipids suitable for use in the lipid-nucleic acid aggregate compositions of the present disclosure and the biochemistry of such lipids can be found in Romberg et al., Pharmaceutical Research, Vol. 25, No. 1, 2008, pp. 55-71 and Hoekstra et al., Biochimica et Biophysica Acta 1660 (2004) 41-52. Additional suitable PEG lipids are disclosed, for example, in WO 2006 / 007712.
[0500] In one embodiment, the hydrophilic head group of the stealth lipid comprises a polymer moiety selected from PEG-based polymers. The stealth lipid may comprise a lipid moiety. In some embodiments, the stealth lipid is a PEG lipid.
[0501] In one embodiment, the stealth lipid comprises a polymer moiety selected from polymers based on PEG (sometimes called poly(ethylene oxide)), poly(oxazoline), poly(vinyl alcohol), poly(glycerol), poly(N-vinylpyrrolidone), polyamino acids, and poly[N-(2-hydroxypropyl)methacrylamide].
[0502] In one embodiment, the PEG lipid comprises a polymer moiety based on PEG (sometimes referred to as poly(ethylene oxide)).
[0503] The PEG-lipid further comprises a lipid moiety. In some embodiments, the lipid moiety may be derived from a diacylglycerol or diacylglycamide, e.g., a dialkylglycerol or dialkylglycamide group, independently, having an alkyl chain length of about C4 to about C40 saturated or unsaturated carbon atoms, and the chain may include one or more functional groups, such as amides or esters. In some embodiments, the alkyl chain length includes about C10 to C20. The dialkylglycerol or dialkylglycamide group may further include one or more substituted alkyl groups. The chain length may be symmetric or asymmetric.
[0504] Unless otherwise specified, the term "PEG" as used herein refers to polyethylene glycol or other polyalkylene ether polymers. In one embodiment, PEG is a linear or branched polymer, optionally substituted with ethylene glycol or ethylene oxide. In one embodiment, PEG is unsubstituted. In one embodiment, PEG is substituted, for example, with one or more alkyl, alkoxy, acyl, hydroxy, or aryl groups. In one embodiment, the term includes PEG copolymers, such as PEG-polyurethane or PEG-polypropylene (see, e.g., J. Milton Harris, Poly(ethylene glycol) chemistry: biotechnical and biomedical applications (1992)). In another embodiment, the term does not include PEG copolymers. In one embodiment, the molecular weight of PEG is from about 130 to about 50,000, and in a subembodiment, from about 150 to about 30,000, and in a subembodiment, from about 150 to about 20,000, and in a subembodiment, from about 150 to about 15,000, and in a subembodiment, from about 150 to about 10,000, and in a subembodiment, from about 150 to about 6,000, and in a subembodiment, from about 150 to about 5,000, and in a subembodiment, from about 150 to about 4,000, and in a subembodiment, from about 150 to about 3,000, and in a subembodiment, from about 300 to about 3,000, and in a subembodiment, from about 1,000 to about 3,000, and in a subembodiment, from about 1,500 to about 2,500.
[0505] In some embodiments, the PEG (e.g., conjugated to a lipid moiety or lipid, such as a stealth lipid) is "PEG-2K," also known as "PEG2000," and has an average molecular weight of about 2,000 daltons. PEG-2K is represented herein by the following formula (I): [ka] However, other embodiments of PEG known in the art may be used, including, for example, those having a number average degree of polymerization of about 23 subunits (n=23) and / or 68 subunits (n=68). In some embodiments, n may range from about 30 to about 60. In some embodiments, n may range from about 35 to about 55. In some embodiments, n may range from about 40 to about 50. In some embodiments, n may range from about 42 to about 48. In some embodiments, n may be 45. In some embodiments, R may be selected from H, substituted alkyl, and unsubstituted alkyl. In some embodiments, R may be unsubstituted alkyl. In some embodiments, R may be methyl.
[0506] In any of the embodiments described herein, the PEG lipid may be PEG-dilauroylglycerol, PEG-dimyristoylglycerol (e.g., 1,2-dimyristoyl-rac-glycero-3-methylpolyethylene glycol-2000 (PEG2k-DMG) or PEG-DMG) (Catalog No. GM-020, manufactured by NOF, Tokyo, Japan), PEG-dipalmitoylglycerol, PEG-distearoylglycerol (PEG-DSPE) (Catalog No. DSPE-020CN, manufactured by NOF, Tokyo, Japan), PEG-dilaurylglycamide, PEG-dimyristylglycamide, PEG-dipalmitoylglycamide, and PEG-distearoylglycamide, PEG-cholesterol (1-[8'-(cholest-5-ene-3[beta]-oxy)carboxamido-3',6'-dioxaotanyl]carbamoyl-[omega]-methyl-poly(ethylene glycol), PEG-DMB (3,4-ditetradecoxylbenzyl-[omega]-methyl-poly(ethylene glycol) ether), 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG2k-DMG) (catalog no. 880150P, Avanti Polar Lipids (Alabaster, Alabama, USA), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG2k-DSPE) (catalog number 880120C, Avanti Polar Lipids (Alabaster, Alabama, USA)), 1,2-distearoyl-sn-glycerol, methoxypolyethylene glycol (PEG2k-DSG; GS-020, NOF Tokyo, Japan), poly(ethylene glycol)-2000-dimethacrylate (PEG2k-DMA), and 1,2-distearyloxypropyl-3-amine-N-[methoxy(polyethylene glycol)-2000] (PEG2k-DSA). In one embodiment, the PEG lipid is 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene glycol-2000 (PEG2k-DMG).In one embodiment, the PEG lipid can be PEG2k-DMG. In one embodiment, the PEG lipid can be PEG2k-DMG. In some embodiments, the PEG lipid can be PEG2k-DSG. In one embodiment, the PEG lipid can be PEG2k-DSPE. In one embodiment, the PEG lipid can be PEG2k-DMA. In one embodiment, the PEG lipid can be PEG2k-C-DMA. In one embodiment, the PEG lipid can be compound S027, disclosed in WO 2016 / 010840 (paragraphs
[0240] to
[0244] ). In one embodiment, the PEG lipid can be PEG2k-DSA. In one embodiment, the PEG lipid can be PEG2k-C11. In some embodiments, the PEG lipid can be PEG2k-C14. In some embodiments, the PEG lipid can be PEG2k-C16. In some embodiments, the PEG lipid can be PEG2k-C18.
[0507] In a preferred embodiment, the PEG lipid comprises a glycerol group. In a preferred embodiment, the PEG lipid comprises a dimyristoylglycerol (DMG) group. In a preferred embodiment, the PEG lipid comprises PEG-2k. In a preferred embodiment, the PEG lipid is PEG-DMG. In a preferred embodiment, the PEG lipid is PEG-2k-DMG. In a preferred embodiment, the PEG lipid is 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol 2000. In a preferred embodiment, the PEG-2k-DMG is 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000.
[0508] LNP delivery of gRNA Lipid nanoparticles (LNPs) are well-known means for delivering nucleotide and protein cargoes and may be used to deliver the gRNAs (e.g., sgRNAs), compositions, or pharmaceutical formulations disclosed herein. In some embodiments, LNPs deliver nucleic acids, proteins, or nucleic acids and proteins. As used herein, lipid nanoparticles (LNPs) refer to particles comprising a plurality (i.e., two or more) of lipid molecules physically associated with one another by intermolecular forces. LNPs can be, for example, microspheres (which include unilamellar and multilamellar vesicles, e.g., "liposomes," lamellar phase lipid bilayers, which in some embodiments are substantially spherical and, in certain embodiments, can include an aqueous core containing, for example, a substantial portion of RNA molecules), the dispersed phase of an emulsion, a micelle, or the internal phase of a suspension (see, e.g., WO2017173054, the entire contents of which are incorporated herein by reference). Any LNP known to those of skill in the art to be capable of delivering nucleotides to a subject can be utilized.
[0509] In some embodiments, the invention includes methods of delivering any one of the gRNAs disclosed herein to a subject, wherein the gRNA is associated with a LNP. In some embodiments, the gRNA / LNP is also associated with a Cas nuclease or a polynucleotide (e.g., mRNA or DNA) encoding the Cas nuclease.
[0510] In some embodiments, the invention includes a composition comprising any one of the disclosed gRNAs and a LNP. In some embodiments, the composition further comprises Cas9 or a polynucleotide (e.g., mRNA or DNA) encoding Cas9.
[0511] In some embodiments, provided herein are methods of delivering any of the guide RNAs described herein to a cell or cell population, including a cell or cell population in a subject in vivo, or to a subject, wherein any one or more of the components are associated with an LNP. In some embodiments, the method further comprises an RNA-guided DNA binding agent (e.g., Cas9 or a polynucleotide (e.g., mRNA or DNA) encoding Cas9).
[0512] In some embodiments, provided herein are compositions comprising any of the guide RNAs described herein or donor constructs disclosed herein, alone or in combination, together with LNPs. In some embodiments, the compositions further comprise an RNA-guided DNA binding agent (e.g., Cas9 or a polynucleotide (e.g., mRNA or DNA) encoding Cas9).
[0513] In some embodiments, the LNPs comprise a cationic lipid. In some embodiments, the LNPs comprise (9Z,12Z)-3-((4,4-bis(octyloxy)butanoyl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)propyl octadeca-9,12-dienoate (also known as 3-((4,4-bis(octyloxy)butanoyl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)propyl(9Z,12Z)-octadeca-9,12-dienoate). In some embodiments, the LNPs comprise a cationic lipid amine:RNA phosphate molar ratio (N:P) of about 4.5. In some embodiments, the LNPs comprise 8-((7,7-bis(octyloxy)heptyl)(2-hydroxyethyl)amino)nonyl octanoate. In some embodiments, the LNPs have a molar ratio of cationic lipid amine to RNA phosphate (N:P) of about 4.5 to 6.5. In some embodiments, the LNPs have a molar ratio of cationic lipid amine to RNA phosphate (N:P) of about 4.5. In some embodiments, the LNPs have a molar ratio of cationic lipid amine to RNA phosphate (N:P) of about 6.0.
[0514] In some embodiments, the gRNA-associated LNPs disclosed herein are for use in preparing a medicament for treating a disease or disorder.
[0515] Electroporation is a well-known means for cargo delivery, and any electroporation method can be used to deliver any one of the gRNAs disclosed herein. In some embodiments, electroporation can be used to deliver any one of the gRNAs disclosed herein and Cas9 or a polynucleotide (e.g., mRNA or DNA) encoding Cas9.
[0516] In some embodiments, the present invention includes a method for delivering any one of the gRNAs disclosed herein to an ex vivo cell, wherein the gRNA is associated with an LNP or is not associated with an LNP. In some embodiments, the gRNA / LNP or gRNA is also associated with Cas9 or a polynucleotide (e.g., mRNA or DNA) encoding Cas9. (See, e.g., PCT / US2021 / 029446, which is incorporated herein by reference.)
[0517] In some embodiments, the vector comprises one or more nucleotide sequence(s) encoding an mRNA encoding an RNA-guided DNA nuclease, which may be a Cas nuclease (e.g., NmeCas9). In some embodiments, the vector comprises an mRNA encoding an RNA-guided DNA nuclease, which may be a Cas protein (e.g., Cas9). In one embodiment, the Cas9 is NmeCas9.
[0518] In some embodiments, components can be introduced as naked nucleic acid, as nucleic acid complexed with an agent such as liposomes or poloxamers, or delivered by viral vectors (e.g., adenovirus, AAV, herpesvirus, retrovirus, lentivirus). Methods and compositions for non-viral delivery of nucleic acids include electroporation, lipofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, LNPs, polycation or lipid:nucleic acid conjugates, naked nucleic acid (e.g., naked DNA / RNA), artificial virions, and drug-enhanced DNA uptake. Sonoporation, for example, using the Sonitron 2000 system (Rich-Mar), can also be used to deliver nucleic acids.
[0519] In some embodiments, the gRNA-associated LNPs disclosed herein are for use in preparing a medicament for treating a disease or disorder. ***
[0520] This description and exemplary embodiments should not be construed as limiting. For purposes of this specification and the appended claims, unless otherwise specified, all numbers expressing quantities, percentages, or ratios, as well as other numerical values used in the specification and claims, unless already so modified, should be understood as modified in all instances by the term "about." [Table 5-1] [Table 5-2] [Table 5-3] [Table 5-4] [Table 5-5]
Table 5-6
Table 5-7
Table 5-8
Table 5-9
Table 5-10
Table 5-11
Table 5-12
Table 5-13
Table 5-14
Table 5-15
Table 5-16
Table 5-17
Table 5-18
Table 5-19
Table 5-20
Table 5-21
Table 5-22
Table 5-23
Table 5-24
Table 5-25
Table 5-26
Table 5-27
Table 5-28
Table 5-29
Table 5-30
Table 5-31
Table 5-32
Table 5-33
Table 5-34
Table 5-35
Table 5-36
Table 5-37
Table 5-38
Table 5-39
Table 5-40
Table 5-41
Table 5-42
Table 5-43
Table 5-44
Table 5-45
Table 5-46
Table 5-47
Table 5-48
Table 5-49
Table 5-50
Table 5-51
Table 5-52
Table 5-53
Table 5-54
Table 5-55
Table 5-56
Table 5-57
Table 5-58
Table 5-59
Table 5-60
Table 5-61
Table 5-62
Table 5-63
Table 5-64
Table 5-65
Table 5-66
Table 5-67
Table 5-68
Table 5-69
Table 5-70
Table 5-71
Table 5-72
Table 5-73
Table 5-74
Table 5-75
Table 5-76
Table 5-77
Table 6-1
Table 6-2
Table 6-3
Table 6-4
Table 6-5
Table 6-6
Table 6-7
Table 6-8
Table 6-9
Table 6-10
Table 6-11
[0521] When a DNA sequence (containing T) is referred to herein in relation to RNA, it is understood that T should be replaced with U (which may or may not be modified depending on the context), and vice versa.
[0522] Nucleotide modifications are indicated in Table 4 as follows: m: 2'-OMe; *: PS linkage; f: 2'-fluoro; (invd): inverted abasic; moe: 2'-moe; e: ENA; d: deoxyribonucleotide (note also that T is always a deoxyribonucleotide); x: UNA. In the sgRNA-modified sequence, in certain embodiments, A, C, G, U, and N are each independently a ribose sugar (2'-OH). In certain embodiments, A, C, G, U, and N are each a ribose sugar (2'-OH). Thus, for example, mA represents 2'-O-methyladenosine, xA represents a UNA nucleotide with an adenine nucleobase, eA represents an ENA nucleotide with an adenine nucleobase, and dA represents an adenosine deoxyribonucleotide. As used herein, (L1) refers to an internal linker having a bridge length of approximately 15-21 atoms.
[0523] The sgRNA designation may have one or more leading zeros immediately following the G, without affecting the meaning of the designation. Thus, for example, G000282, G0282, G00282, and G282 refer to the same sgRNA. Similarly, the crRNA and / or trRNA designation may have one or more leading zeros immediately following CR or TR, respectively, without affecting the meaning of the designation. Thus, for example, CR000100, CR00100, CR0100, and CR100 refer to the same crRNA, and TR000200, TR00200, TR0200, and TR200 refer to the same trRNA. [Example]
[0524] The following examples are provided to illustrate certain disclosed embodiments and should not be construed in any way as limiting the scope of the disclosure.
[0525] Example 1. Materials and Methods In vitro transcription ("IVT") of nuclease mRNA Capped and polyadenylated mRNA containing N1-methylpseudo-U was generated by in vitro transcription using conventional methods. For example, plasmid DNA containing the T7 promoter, transcription sequence, and polyadenylation region was linearized with XbaI according to the manufacturer's protocol. XbaI was inactivated by heating. The linearized plasmid was purified from enzymes and buffer salts. An IVT reaction to generate modified mRNA was performed by incubating 50 ng / μL of linearized plasmid; 2–5 mM each of GTP, ATP, CTP, and N1-methylpseudo-UTP (Trilink); 10–25 mM ARCA (Trilink); 5 U / μL T7 RNA polymerase; 1 U / μL mouse RNase inhibitor (NEB); 0.004 U / μL inorganic E. coli pyrophosphatase (NEB); and 1x reaction buffer at 37°C. TURBO DNase (Thermo Fisher) was added to a final concentration of 0.01 U / μL, and the reaction was incubated at 37°C to remove the DNA template.
[0526] mRNA was purified using the MegaClear Transcription Clean-up Kit (Thermo Fisher) or the RNeasy Maxi Kit (Qiagen) according to the manufacturer's instructions. Alternatively, mRNA was purified using a precipitation protocol (occasionally followed by HPLC-based purification). Briefly, after DNase digestion, mRNA was purified using LiCl, ammonium acetate, and sodium acetate precipitations. For HPLC-purified mRNA, after LiCl precipitation and reconstitution, mRNA was purified by RP-IP HPLC (see, e.g., Kariko, et al. Nucleic Acids Research, 2011, Vol. 39, No. 21 el42). Fractions selected for pooling were combined and desalted by sodium acetate / ethanol precipitation as described above. In a further alternative method, mRNA was purified by LiCl precipitation followed by further purification by tangential flow filtration. RNA concentrations were determined by measuring absorbance at 260 nm (Nanodrop) and transcripts were analyzed by capillary electrophoresis on a Bioanalyzer (Agilent).
[0527] Streptococcus pyogenes ("Spy") Cas9 mRNA was generated from plasmid DNA encoding an open reading frame according to SEQ ID NOs: 661-665 (see sequences in Table 4A). When the sequences cited in this paragraph are referred to below in reference to RNA, it is understood that T should be replaced with U (which may be a modified nucleoside as described above). The messenger RNA used in the examples includes a 5' cap and a 3' polyadenylation sequence (e.g., up to 100 nt), which are identified in Table 4A. Guide RNAs are chemically synthesized by methods known in the art.
[0528] Guide RNAs are either chemically synthesized by commercial vendors or synthesized using standard in vitro synthesis techniques using modified nucleotides.
[0529] Hepatocyte preparation Primary mouse hepatocytes (PMH), primary rat hepatocytes (PRH), primary human hepatocytes (PHH), and primary cynomolgus monkey hepatocytes (PCH) were prepared as follows: PMH (Gibco, MCM837, unless otherwise specified), PRH (Gibco, RS977, unless otherwise specified), PCH (In Vitro ADMET Laboratories, 10136011, unless otherwise specified), and PHH (Gibco, Hu8284, unless otherwise specified) were thawed and resuspended in 50 mL of cryopreserved hepatocyte recovery medium (CHRM) (Invitrogen, CM7000) followed by centrifugation. Cells were resuspended in hepatocyte medium containing plating supplements such as Williams' E Medium Plating Supplements with FBS (Gibco, catalog A13450). Cells were pelleted by centrifugation, resuspended in medium, and seeded at a density of 20,000 cells / well for PMH and 30,000 cells / well for PHH on Bio-coat collagen I-coated 96-well plates (Corning #354407). Seeded cells were allowed to adhere for 4–6 hours in a tissue culture incubator at 37°C and 5% CO2. After incubation, cells were checked for monolayer formation, washed once, and seeded in 100 μL of Hepatocyte Maintenance Medium: Williams' E Medium (Gibco, Cat. A12176-01) plus supplement pack (Gibco, Cat. CM3000).
[0530] Preparation of HEK cells HEK-293 cells (ATCC, CRL-1573, unless otherwise specified) were thawed and resuspended in serum-free Dulbecco's Modified Eagle Medium (Corning #10-013-CV) containing 10% FBS (Gibco #A31605-02) and 1% penicillin-streptomycin (Gibco #15070063). Cells were counted and seeded onto 96-well tissue culture plates (Falcon, #353072) in Dulbecco's Modified Eagle Medium (Corning #10-013-CV) containing 10% FBS (Gibco #A31605-02). The seeded cells were allowed to adhere for 18 hours in a tissue culture incubator at 37°C in a 5% CO atmosphere.
[0531] Preparation of LNP formulations containing sgRNA and Cas9 mRNA Generally, lipid nanoparticle components were dissolved in 100% ethanol at various molar ratios. RNA cargo (e.g., Cas9 mRNA and sgRNA) was dissolved in 25 mM citric acid, 100 mM NaCl, pH 5.0, to a concentration of approximately 0.45 mg / mL of RNA cargo. The LNP used was 3-((4,4-bis(octyloxy)butanoyl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)propyl(9Z,12Z)-octadeca-9,12-dienoate), also referred to herein as lipid A, containing the ionizable lipid ((9Z,12Z)-3-((4,4-bis(octyloxy)butanoyl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)propyloctadeca-9,12-dienoate), cholesterol, distearoylphosphatidylcholine (DSPC), and 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene glycol. The LNPs contained 50% lipid A, 38% cholesterol, 9% DSPC, and 3% PEG2k-DMG (2000) in a molar ratio of 50% lipid A, 38% cholesterol, 9% DSPC, and 3% PEG2k-DMG. The LNPs were formulated to have a lipid amine to RNA phosphate (N:P) molar ratio of approximately 6. The LNPs used contain single RNA species, such as Cas9 mRNA and sgRNA. LNPs are also prepared with a mixture of Cas9 mRNA and guide RNA.
[0532] LNPs were prepared using a cross-flow technique that utilizes impinging jet mixing of lipid-containing ethanol with two volumes of RNA solution and one volume of water. First, lipid-containing ethanol was mixed with two volumes of RNA solution through a mixing cross. Next, a fourth stream of water was mixed with the outlet stream from the cross via an in-line T-junction (see Figure 2 in WO2016010840). The LNPs were held at room temperature for 1 hour and further diluted with water (approximately 1:1 v / v). The diluted LNPs were buffer-exchanged into 50 mM Tris, 45 mM NaCl, 5% (w / v) sucrose, pH 7.5 (TSS) and, if necessary, concentrated by methods known in the art. The resulting mixture was then filtered using a 0.2 μm sterile filter. The final LNPs were characterized to determine encapsulation efficiency, polydispersity index, and mean particle size. The final LNPs were stored at 4°C or -80°C until further use.
[0533] sgRNA and Cas9 mRNA lipofection A premixed lipid formulation was used for lipofection of Cas9 mRNA and gRNA. The lipofection reagent contained ionizable lipid A, cholesterol, DSPC, and PEG2k-DMG in the following molar ratios: lipid A 50%, cholesterol 38%, DSPC 9%, PEG2k-DMG 3%. This mixture was reconstituted in 100% ethanol and then mixed with RNA (e.g., Cas9 mRNA and gRNA) at a lipid amine to RNA phosphate (N:P) molar ratio of approximately 6.0.
[0534] Next-generation sequencing ("NGS") and editing efficiency analysis Genomic DNA was extracted using a commercially available kit, such as QuickExtract™ DNA Extraction Solution (Lucigen, catalog QE09050), according to the manufacturer's protocol. To quantitatively determine the efficiency of editing at the target location in the genome, deep sequencing was used to identify the presence of insertions and deletions introduced by gene editing. PCR primers were designed based on the target site within the gene of interest (e.g., TRAC) to amplify the genomic region of interest. Primer sequences were designed using standard techniques in the art.
[0535] An additional PCR was performed according to the manufacturer's (Illumina) protocol, and sequencing chemistry was added. The amplicons were sequenced on an Illumina MiSeq instrument. After removing reads with low quality scores, the reads were aligned against the human reference genome (e.g., hg38). Reads overlapping the target region of interest were realigned to the local genome sequence to improve alignment. Next, the number of wild-type reads was calculated relative to the number of reads containing C-to-T mutations, C-to-A / G mutations, or indels. Insertions and deletions were scored in a 20-bp region centered around the predicted Cas9 cleavage site. The indel rate is defined as the total number of sequence reads with one or more base insertions or deletions within the 20-bp scoring region divided by the total number of sequence reads containing wild-type mutations. C-to-T mutations or C-to-A / G mutations were scored in a 40-bp region encompassing 10 bp upstream and 10 bp downstream of the 20-bp sgRNA target sequence. The C to T editing rate is defined as the total number of sequence reads with one or more C to T mutations within a 40-bp region divided by the total number of sequence reads containing the wild type. The percentage of C to A / G mutations was calculated similarly.
[0536] Example 2. In vitro editing using truncated NmeCas9 guides in human embryonic kidney (HEK) cells Truncated Nme-Cas9 sgRNAs targeting the SEAP gene were designed and tested to assess the impact of each modification on guide function. Guide modifications that maintained editing efficacy were considered well tolerated and were included in future studies.
[0537] Example 2.1 Plasmid evaluation of sgRNA modification patterns Preparation of HEK cells HEK-Blue™ cells (Invivogen, catalog hkb-il1b), a HEK reporter cell line with a SEAP reporter, were thawed and resuspended in 15 mL growth medium (DMEM, 4.5 g / L glucose, 2 mM L-glutamine, 10% (v / v) fetal bovine serum (FBS), 50 U / ml penicillin, 50 mg / ml streptomycin, 100 mg / ml Normocin™) and centrifuged. The supernatant was discarded, and the pelleted cells were resuspended in growth medium. Cells were seeded at a density of 10,000 cells / well in 96-well tissue culture plates (Falcon, #353072) using test medium (DMEM, 4.5 g / l glucose, 2 mM L-glutamine, 10% (v / v), heat-inactivated FBS (56°C for 30 minutes), 50 U / ml penicillin, 50 mg / ml streptomycin, 100 mg / ml Normocin™). The seeded cells were allowed to adhere for 18 hours in a tissue culture incubator at 37°C in a 5% CO atmosphere.
[0538] Plasmid-based transfection NmeCas9 sgRNA truncation variants with identical 23-nt complementarity to the SEAP cassette but different sgRNA scaffold cleavage were designed and cloned into HEK-Blue™ cells using the standard Gibson assembly method. The final plasmid reaction was plated onto Luria Broth (LB) plates (Teknova, L8000) supplemented with ampicillin (Teknova, L5104) and incubated at 37°C in a tissue culture incubator. Plasmid colonies were inoculated onto 4ml Luria Broth plates (Teknova, L8000) supplemented with 100µg / mL ampicillin (Teknova, A2135) and incubated overnight at 37°C. Plasmids were purified using the Zyppy Plasmid Purification Kit (Zymo Research, D4036) according to the manufacturer's instructions.
[0539] After incubation, the plasmid concentration was measured using a Qubit HS assay (Invitrogen, catalog no. Q32851) and diluted to 50 ng / μL. Plasmid DNA for each sgRNA and the pcDNA3.1 transfection plasmid encoding Nme1Cas9 (SEQ ID NO: 645) were diluted in Opti-MEM (Thermo Fisher, L3000015) and lipoplexed using Lipofectamine 3000 (Thermo Fisher, catalog no. 51985091) according to the manufacturer's instructions. Briefly, the Lipofectamine-DNA mixture was incubated at room temperature for 15 minutes. After incubation, 10 μl of the mixture was added to HEK-Blue™ cells and incubated for 72 hours at 37°C in a 5% CO2 atmosphere in a tissue culture incubator. After transfection, the cells were harvested. Genomic DNA isolation and NGS analysis were performed as described in Example 1.
[0540] Editing efficiency was determined for unmodified sgRNA designs with identical 23-nt complementarity to the SEAP locus but different truncations of the sgRNA scaffold. Assays were performed in three replicate screening rounds to identify truncations that, alone or in combination, altered editing efficiency. Cells were prepared and analyzed using the same protocol and a control plasmid (RNAWT-145). Each assay included triplicate samples. The average editing results and standard deviations (SD) are shown in Table 5 and Figure 1. The relatively low levels of editing efficiency observed are likely due to the SEAP sgRNA editing both the endogenous human SEAP gene and the exogenous SEAP expression cassette integrated into HEK-Blue™ cells. NGS primers were designed to quantify only editing events at the exogenous SEAP locus. However, editing at the endogenous locus is not expected to alter the relative editing levels measured at the exogenous SEAP locus using the truncated SEAP sgRNA. [Table 7]
[0541] Example 2.2. Evaluation of gRNA chemical modifications in HEK-293 cells We further evaluated the guide modification patterns of the selected cleavage sgRNAs tested in the above study to assess the impact of modifications on guided editing efficiency. A stable cell line expressing Nme2-Cas9 from a lentiviral expression construct (herein referred to as HEK-Nme2) was engineered for constitutive Nme2-Cas9 expression.
[0542] Preparation of HEK cells HEK-293 (ATCC, CRL-1573) cells were thawed in maintenance medium (DMEM (Corning, #10-013-CV), 10% FBS (Gibco, #A31605-02)). Cells were then seeded at a density of 200,000 cells per well in a 6-well plate (Corning, #353046) in Dulbecco's Modified Eagle Medium (Corning #10-013-CV) containing 10% FBS (Gibco, #A31605-02). Cells were transduced using Cellecta #SVCRU617-L lentiviral vector encoding Nme2 Cas9 (SEQ ID NO: 640) in the presence of polybrene (Millipore Sigma, TR-1003) according to the manufacturer's protocol.
[0543] Cells were incubated in a tissue culture incubator at 37°C under a 5% CO atmosphere for 10 days. Afterwards, cells were washed, sorted using a cell sorter (Sony Biotechnologies, SH800Z), and analyzed using the FlowJo software package for GFP emission. A polyclonal mixture of selected HEK-Nme2 cells was prepared at an MOI of 2 and used for subsequent studies.
[0544] The transduced HEK-Nme2 cells were thawed and resuspended in serum-free Dulbecco's Modified Eagle Medium (Corning #10-013-CV) containing 10% FBS (Gibco #A31605-02) and 1% penicillin-streptomycin (Gibco #15070063). The cells were counted and seeded at a density of 20,000 cells per well in Dulbecco's Modified Eagle Medium (Corning #10-013-CV) containing 10% FBS (Gibco #A31605-02) on a 96-well tissue culture plate (Falcon, #353072). The seeded cells were allowed to adhere for 18 hours in a tissue culture incubator at 37°C in a 5% CO atmosphere.
[0545] Cell transfection using MessengerMAX Guide modification patterns consisting of 2'-O-methyl (2'-OMe) and phosphorothioate (PS) modifications were tested in the context of sgRNAs to assess the impact of the modifications on guided editing efficiency.
[0546] Truncated dual guide RNAs (dgRNAs) were generated by annealing modified truncated tracrRNAs targeting one of two sites on VEGFA (T25 or T47, target sites previously published in WO2019094791) to modified crRNAs in a mixture of 1 μL 100 μM crRNA, 1 μL 100 μM tracrRNA, and 8 μL Duplex Buffer (Integrated DNA Technologies, #11-05-01-12). The Nme2-Cas9 tracrRNA and crRNA solution was annealed at 95°C for 3 minutes, then ramped down to 20°C at 0.1°C / s increments. Samples were stored on ice until use. Dual-guide RNAs at an initial concentration of 10 μM were diluted in Opti-MEM (Thermo Fisher, #51985091) to a concentration of 250 nM per 10 μL and mixed with Lipofectamine MessengerMAX (Invitrogen, catalog number LMRNA001) according to the manufacturer's instructions. A 20 μL aliquot of each solution was added to each tissue culture well and incubated for 72 hours at 37°C in a 5% CO2 atmosphere in a tissue culture incubator.
[0547] After incubation, genomic DNA was isolated and NGS analysis was performed as described above.
[0548] Editing efficiency was assessed as described in Example 1 for a dgRNA containing 16 truncated tracrRNAs (TR0#####) annealed to the crRNAs (CR0#####) shown in Table 6, targeting two genomic sites (T25, T47) of the VEGFA gene at a dgRNA concentration of 50 nM. Duplicate samples were included in the assay. Average editing results and standard deviations (SD) are shown in Table 6 and Figure 2. [Table 8]
[0549] Example 3. In vitro editing with chemically modified Nme2Cas9 sgRNA Example 3.1 Evaluation of modified sgRNAs in HEK-Nme2 cells Guide modification patterns consisting of 2'-O-methyl (2'-OMe) and phosphorothioate (PS) modifications were tested in the context of sgRNAs to assess the impact of the modifications on guided editing efficiency.
[0550] Preparation of HEK cells HEK-Nme2 cells were prepared as described in Example 2. Cells were counted and seeded at a density of 30,000 cells / well (Falcon, #353072). Cells were transfected as described in Example 2.2. 72 hours after transfection, cells were prepared for NGS analysis as described in Example 1.
[0551] The editing efficiency of 43 chemically modified sgRNAs targeting the T47 site of the VEGFA gene was evaluated as described in Example 2.2. Two separate experiments were performed, with samples tested in triplicate in each assay. Because the results obtained in both experiments were comparable, the average editing results and standard deviations (SD) from the single experiments are shown in Table 7 and Figure 3. "ND" in the table represents values that could not be determined due to experimental failure. [Table 9]
[0552] Example 3.2 Evaluation of alternative sgRNA modification patterns in HEK-293 cells Additional Nme2 sgRNAs with alternative modification patterns were tested in HEK-293 cells (ATCC, CRL-1573) to assess the impact of additional chemical modifications on guided editing efficiency. Cells were prepared and transfected as described in Example 1 to deliver 100 ng of Nme2 mRNA and sgRNA at a final concentration of 50 nM. Cells were seeded at a density of 15,000 cells / well. 72 hours after transfection, genomic DNA was isolated and analyzed via NGS as described in Example 1.
[0553] Editing efficiency was evaluated for 54 chemically modified sgRNAs targeting the VEGFA gene at the T47 site as described above. Triplicate samples were tested for each assay. The mean editing results and standard deviations (SD) are shown in Table 8 and Figure 4. [Table 10]
[0554] Example 4. In vitro editing with selected guides in primary mouse hepatocytes (PMH) A modified sgRNA screen was conducted to evaluate the editing efficiency of 95 different sgRNAs targeting various sites within the mouse TTR gene. Based on this study, two sgRNAs (G021320 and G021256) were selected for evaluation in a dose-response assay. These two test guides were compared with a mouse TTR SpyCas9 guide (G000502) with a 20-nucleotide guide sequence. The tested NmeCas9 sgRNA targeting the mouse TTR gene contains a 24-nucleotide guide sequence (represented by N) and the following guide scaffold: mN*mNNNNNNNNmNNNmNNNNNNNNNNNNNNmGUUGmUmAmGmCUCCCmUmGmAmAmAmCmCGUUmGmCUAmCAAU*AAGmGmCCmGmUmCmGmAmAmAmGmAmUGUGCmCGCmAmAmCmGCUCUmGmCCmUmUmCmUGmGCmAmUC*mG*mU*mU (SEQ ID NO: 4). Here, unless otherwise noted, A, C, G, U, and N are adenine, cytosine, guanine, uracil, and any ribonucleotide, respectively. m indicates a 2'O-methyl modification, and * indicates a phosphorothioate linkage between nucleotides. Unmodified and modified versions of the guide are listed in Tables 1-2.
[0555] Guide and Cas9 mRNA were lipofected into primary mouse hepatocytes (PMH) as described below. PMH (In Vitro ADMET Laboratories MCM114) were prepared as described in Example 1. Lipofection was performed as described in Example 1 using a dose response of sgRNA and mRNA. Briefly, cells were incubated at 37°C and 5% CO2 for 24 hours before treatment with lipoplexes. Lipoplexes were incubated at 37°C for 10 minutes in maintenance medium containing 10% fetal bovine serum (FBS). After incubation, lipoplexes were added to mouse hepatocytes, and an 8-point, 3-fold dose-response assay was performed, starting with a maximum dose of 300 ng Cas9 mRNA and 50 nM sgRNA. Table 9 lists only the gRNA dose; however, the messenger RNA dose varied depending on the gRNA dose in each condition. Cells were lysed 72 hours after treatment, and NGS analysis was performed as described in Example 1.
[0556] A dose response of editing efficiency versus guide concentration was performed on triplicate samples. Table 9 shows the mean editing rate and standard deviation (SD) at each guide concentration, as well as the calculated EC 50 The mean and standard deviation (SD) are shown in Figure 5. [Table 11]
[0557] Example 5. In vitro editing of primary mouse hepatocytes (PMH) using a dilution curve Example 5.1. Modified sgRNA evaluation using a dilution series Modified sgRNAs with various scaffold structures targeting all previously published sites in the mouse pcsk9 gene (see WO2019094791) were designed as shown in Tables 1-2 and tested for editing efficiency using primary mouse hepatocytes (PMH). Cells were prepared using PMH cells (In Vitro ADMET Laboratories) as described in Example 1 and seeded at a density of 20,000 cells / well. Cells were transfected with 1 ng / μl Nme2 Cas9 mRNA (mRNA U) and sgRNA at the concentrations shown in Table 10 using MessengerMax (Invitrogen) according to the manufacturer's protocol. Duplicate samples were included in the assay. Cells were harvested 72 hours post-transfection and analyzed by next-generation sequencing as described in Example 1. The average editing rates and standard deviations are shown in Table 10 and Figure 6. [Table 12]
[0558] Example 5.2. Evaluation of mRNA polyA tail modification and cargo ratio sgRNAs targeting the mouse pcsk9 gene were selected from Table 10, and the guided editing efficiency resulting from specific combinations of polyA tail modification and sgRNA:mRNA ratios was evaluated. PMH cells used were prepared, treated, and analyzed as described in Example 1 unless otherwise noted. PMH (Gibco) were seeded at a density of 15,000 cells / well.
[0559] LNPs were generally prepared as described in Example 1. LNPs were prepared with a lipid composition of 50 / 9 / 38 / 3, expressed as the molar ratio of ionizable lipid A / cholesterol / DSPC / PEG, respectively. LNPs were formulated to achieve a lipid amine to RNA phosphate (N:P) molar ratio of approximately 6. LNPs encapsulated gRNA G017566 or one of three mRNAs encoding the same Nme2Cas9 open reading frame (ORF) but with different encoded polyA tails, as shown in Table 11. Preliminary experiments, in which the amount of sgRNA applied was kept constant and the amount of mRNA applied varied, indicated that a 1:1 sgRNA:mRNA weight ratio resulted in the highest editing rate. In this example, mRNA LNPs and gRNA LNPs were gradually administered to cells in 100 μl of medium, maintaining a 1:1 sgRNA:mRNA weight ratio, as shown in Table 11. Table 11 and Figure 7 show the average editing rate and standard deviation (SD). [Table 13]
[0560] Example 5.3. sgRNA:mRNA Ratio for sgRNA or pgRNA Using LNP A study was conducted to evaluate the editing efficiency of sgRNA designs containing PEG linkers (pgRNA). This study compared two gRNAs targeting TTR with the same guide sequence. As shown in Table 12, one of them contained three PEG linkers in the constant region of the guide (pgRNA, G021846), while the other did not (G021845). The guide and mRNA were formulated in separate LNPs and mixed in the desired ratio for delivery to primary mouse hepatocytes (PMH) via lipid nanoparticles (LNPs).
[0561] PMH cells were prepared, treated, and analyzed as described in Example 1 unless otherwise noted. PMH cells (Lot No. MCM114) from In Vitro ADMET Laboratories were seeded at a density of 15,000 cells / well. Cells were treated with LNPs as follows: LNPs were generally prepared as described in Example 1. LNPs were prepared with a lipid composition of 50 / 9 / 38 / 3, expressed as molar ratios of ionizable lipid A / cholesterol / DSPC / PEG, respectively. LNPs were formulated to achieve a lipid amine to RNA phosphate (N:P) molar ratio of approximately 6. LNPs encapsulated a single RNA species, either gRNA G021845, gRNA G021846, or mRNA (mRNA M; SEQ ID NO: 631), as described in Example 1.
[0562] PMH cells were treated with varying amounts of LNP to achieve gRNA-to-mRNA ratios of 1:4, 1:2, 1:1, 2:1, 4:1, or 8:1 by weight of RNA cargo. Duplicate samples were included in each assay. The guides were tested in an 8-point, 3-fold dose-response curve starting from a total RNA concentration of 1 ng / uL, as shown in Table 12. The mean editing rate results are shown in Table 12. Figure 8A shows the mean editing rate for sgRNA G021845, and Figure 8B shows the mean editing rate for sgRNA G021846. "ND" in the table indicates undetectable values due to experimental failure. [Table 14-1] [Table 14-2]
[0563] Example 5.4 In vitro editing of modified pegylated guide (pgRNA) in PMH using LNP Modified pgRNAs with the same target site in the mouse TTR gene were assayed to assess editing efficiency in PMH cells. PMH cells were prepared, treated, and analyzed as described in Example 1 unless otherwise noted. PMH cells (Lot No. MC148) from In Vitro ADMET Laboratories were used and seeded at a density of 15,000 cells / well. LNP formulations were prepared as described in Example 1. LNPs were prepared with a lipid composition of 50 / 9 / 38 / 3, expressed as molar ratios of ionizable lipid A / cholesterol / DSPC / PEG, respectively. LNPs were formulated with a lipid amine to RNA phosphate (N:P) molar ratio of approximately 6 and with the gRNA or mRNA listed in Table I.
[0564] PMH in 100 μl medium were treated with LNP for 30 ng of total mRNA (mRNA P) by weight and LNP for the amount of gRNA shown in Table 13. Samples were run in duplicate. The average editing results for PMH are shown in Table 13 and Figure 9. [Table 15-1] [Table 15-2]
[0565] Example 6. Chemical modification screening Example 6.1. Chemical Modification Screening in HEK-293 Cells We determined the editing efficiency of chemically modified crRNAs targeting two different VEGFA target sites (TS-25 and TS-47). Each dgRNA contained a combination of chemically modified crRNA and tracrRNA. Chemical modifications included phosphorothioate (PS) or 2'-O' methyl (2'-OMe) modifications to the 5' and 3' terminal bases of both the crRNA and tracrRNA (EndMod).
[0566] HEK-Nme2 cells were prepared as described in Example 2, except that an MOI of 0.8 was used in this study. Cells were seeded at a density of 10,000 cells per well. Next, cells were transfected with dual guide RNAs at a final concentration of 25 nM dgRNA using the MessengerMax protocol described in Example 2.2. Duplicate samples were included in the assay. After 72 hours, genomic DNA (gDNA) was extracted from the cells and prepared for NGS analysis as described in Example 1. NGS analysis results were evaluated using Graphpad Prism software (version 9). The average editing rates are shown in Table 14 and Figures 10A-10B. [Table 16-1] [Table 16-2]
[0567] To evaluate editing efficiency, additional combinations of chemically modified crRNA and tracrRNA were tested. Editing efficiency was determined for a chemically modified dgRNA targeting the previously described TS47 site in the VEGFA gene. Each dgRNA contained a combination of chemically modified crRNA and tracrRNA. HEK-Nme2 cells were obtained and prepared as described in Example 2. Cells (MOI = 2) were seeded at a density of 10,000 cells per well. Next, cells were transfected with dual guide RNAs at a final concentration of 25 nM dgRNA using the MessengerMax protocol described previously in Example 2.2. Duplicate samples were included in the assay. After 72 hours, gDNA was extracted from the cells and prepared for NGS analysis. The NGS results were analyzed as described above and in Example 1. The average editing rates are shown in Table 15 and Figure 11. [Table 17]
[0568] Example 6.2 Evaluation of Guide Sequence Chemical Modifications in PMH Pegylated guide RNAs (pgRNAs), which incorporate chemical modifications to the guide sequence, were tested for their editing efficacy at two different mouse TTR regions (exon 1 and exon 3) in PMHs. PMHs (In Vitro ADMET Laboratories) were prepared as described in Example 1. Premixed lipid compositions, as described in Example 1, were used for lipofection of Nme2 Cas9 mRNA (mRNA SEQ ID NO: 633) and gRNAs targeting two different loci in mouse TTR as shown in Table 16. Cells were treated with 100 ng / 100 μl of Nme2 mRNA and gRNAs at the concentrations shown in Table 16 using lipoplexes. Cells were incubated in maintenance medium + 10% FBS (Corning #35-010-CF) at 37°C for 72 hours. After incubation, genomic DNA was isolated, and NGS analysis was performed as described in Example 1.
[0569] The editing efficiency of various guide modification patterns was determined at three gRNA concentrations (3 nM, 8 nM, or 25 nM). Duplicate samples were included in the assay. The average editing results for test guides with N79 pgRNA designs (G023066 or G023067), which lack a 2'-OMe at the specified nucleotide position within the target-binding region of the gRNA, are shown in Table 16 and Figures 12A-12B. Table 17 and Figures 12C-12D show the average editing rates for test guides using End-Mod pgRNA designs (G023070 or G023104), which add an additional 2'-OMe modification at the specified nucleotide position within the target-binding region of the gRNA. "ND" in the table indicates values that could not be detected due to experimental failure. [Table 18] [Table 19]
[0570] Example 7. Base editing by Nme2 base editor and chemically modified sgRNA in HepG2 cells Base editor constructs containing the APOBEC3A deaminase domain fused to the Nme2Cas9 D16A nickase were tested for base conversion efficiency using different guide designs in HepG2 cells.
[0571] HepG2 cells constitutively overexpressing solute carrier family 10 member 1 (SLC10A1) (HepG2-NTCP, Seeger et al. Mol Ther Nucleic Acids. 2014 Dec;3(12):e216) were thawed, resuspended in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (medium Y), and centrifuged. The supernatant was discarded, and the cells were resuspended in medium Y and seeded at a density of 25,000 cells per well in 100 μL of medium Y in a 96-well collagen-coated plate (Corning, catalog 354407).
[0572] Nme2Cas9 base editor mRNA was prepared by in vitro transcription from plasmids encoding mRNA R (2XNLS N-terminus, 1XC-terminus NLS Nme2 base editor), mRNA S (2XNLS N-terminus, NLS Nme2 base editor ORF), and mRNA T (1X C-terminus NLS Nme2 base editor ORF), essentially as described in Example 1. SpyCas9 mRNA and uracil glycosylase inhibitor (UGI) mRNA (SEQ ID NO: 625) were transcribed from plasmids using the same method.
[0573] Chemically modified NmeCas9 sgRNAs targeting NTCP with different PAM sequences (G020927, G020928) or VEGFA (G020073), and SpyCas9 sgRNA targeting NTCP (G020929) were synthesized using standard methods.
[0574] Guide RNA, editor mRNA, and UGI mRNA were mixed at a 1:1:1 weight ratio with a premixed transfection reagent containing lipid A, cholesterol, DSPC, and PEG2k-DMG at molar ratios of 50:38:9:3, respectively. The reagent was mixed to achieve a lipid amine to RNA phosphate (N:P) molar ratio of approximately 6.0. The RNA-lipid mixture was mixed with 10% FBS medium at an approximately 1:1 ratio and incubated for 10 minutes. After incubation, cells were treated with the RNA-lipid mixture in an eight-point, two-fold serial dilution, starting with 400 ng of total editor RNA per well.
[0575] At 72 hours post-treatment, cells were lysed for NGS analysis as described in Example 1.
[0576] A dose-response of editing efficiency versus guide concentration was performed in triplicate. Table 18 shows the calculated average editing rate and calculated EC50 value at each guide concentration. The VEGFA target site is prone to indel formation due to its high GC content. All editor mRNAs achieved the same maximum C-to-T editing. There were slight differences in EC50, with mRNA S being superior to mRNA R and mRNA T. [Table 20]
[0577] Example 8. Base editing with chemically modified sgRNA in PMH Base editor constructs containing the APOBEC3A deaminase domain fused to the Nme2Cas9 nickase were tested for base conversion efficiency using various guide designs in mouse primary hepatocytes (PMH). PMH (In Vitro ADMET Laboratories, Catalog No. MC148) were thawed and plated as described in Example 1. Nme2Cas9 base editor mRNA, mRNA R, mRNA S, and mRNA T, as well as uracil glycosylase inhibitor (UGI) mRNA (SEQ ID NO: 625), were prepared as described in Example 1 and paired with a series of chemically modified sgRNAs targeting mouse TTR and screened with a single dose of 128 ng of base editor mRNA. 72 hours after treatment, cells were lysed for NGS analysis as described in Example 1. The average edits (proportions of editing types) for representative guides are shown in Table 19. [Table 21]
[0578] Example 9. Nme2-mRNA studies Example 9.1 In vitro editing in primary mouse hepatocytes Messenger mRNAs encoding Nme2Cas9 ORFs with different NLS configurations were tested for editing efficiency in primary mouse hepatocytes (PMH).
[0579] PMH were prepared as described in Example 1. Lipofection was performed using Lipofectamine MessengerMAX Transfection Reagent (Invitrogen LMRNA001) according to the manufacturer's protocol, and cells were transfected with 100 nM sgRNA G020361 targeting mouse PCSK9 and mRNA at the concentrations listed in Table 20. Triplicate samples were included in the assay. After 72 hours of incubation at 37°C in maintenance medium, cells were harvested and NGS analysis was performed as described in Example 1. The mean edited results and standard deviations (SD) are shown in Table 20 and Figure 13. [Table 22-1] [Table 22-2]
[0580] Example 9.2 Dose Response of Guides Containing Nme2 ORF Mutants and Chemically Modified Mutants The editing efficiency of messenger mRNAs encoding Nme2Cas9 ORFs with different NLS configurations was examined in primary human hepatocytes (PHH) and HEK-293 cells. Assays were performed using gRNAs with the same guide sequence targeting the VEGFA locus, TS47, with varying lengths and chemical modification patterns. PHH cells were prepared as described in Example 1. HEK293 cells were thawed and seeded at a density of 30,000 cells / well in 96-well plates in DMEM (Corning, 10-013-CV) containing 10% FBS and incubated for 24 hours. Lipofection was performed using Lipofectamine MessengerMAX Transfection Reagent (Invitrogen LMRNA001) according to the manufacturer's protocol. Cells were transfected with gRNA at the concentrations listed in Tables LS3.1 and LS3.2, using a dose-response 1:3 dilution series starting with the highest dose of 100 nM gRNA and 1 ng / µL mRNA. Assays included replicate samples. After 72 hours of incubation at 37°C, cells were harvested and NGS analysis was performed as described in Example 1. The mean edited results and standard deviations (SD) are shown in Table 21A and Figures 14A-14C for HEK cells and in Table 21B and Figures 14D-14F for PHH cells. [Table 23] [Table 24]
[0581] Example 9.3 Dose Response of Nme2 NLS Mutants with LNP in PMH We tested messenger mRNAs encoding Nme2Cas9 ORFs with different NLS configurations for editing efficiency in primary mouse hepatocytes (PMH). This assay tested guides targeting the mouse TTR locus and included both sgRNA and pgRNA designs.
[0582] PMHs were prepared as in Example 1. LNPs were prepared generally as described in Example 1 with a single RNA species as cargo, as shown in Table 22. LNPs were prepared with a lipid composition of 50 / 9 / 38 / 3, expressed as molar ratios of ionizable lipid A / cholesterol / DSPC / PEG, respectively. LNPs were formulated to achieve a lipid amine to RNA phosphate (N:P) molar ratio of approximately 6.
[0583] Cells were treated with 60 ng / 100 μl LNPs containing gRNA by RNA weight and LNPs containing mRNA as shown in Table 22. Cells were incubated at 37°C for 72 hours in Williams' E medium (Gibco, A1217601) containing maintenance supplements and 10% fetal bovine serum. After 72 hours of incubation at 37°C, cells were harvested and editing was assessed by NGS as described in Example 1. The average editing rate data are shown in Table 22 and Figure 15. [Table 25-1] [Table 25-2]
[0584] Example 9.4 Dose Response of Nme2 NLS Mutants with LNP in PMH Messenger mRNAs encoding Nme2Cas9 ORFs with different NLS configurations were tested for editing efficiency in primary mouse hepatocytes (PMH).
[0585] PMH (Gibco, MC148) was prepared as described in Example 1. LNPs were generally prepared as described in Example 1 with a single RNA species as cargo. LNPs were prepared with a lipid composition of 50 / 9 / 38 / 3, expressed as molar ratios of ionizable lipid A / cholesterol / DSPC / PEG, respectively. LNPs were formulated to achieve a lipid amine to RNA phosphate (N:P) molar ratio of approximately 6.
[0586] Cells were treated with 30 ng / 100 μl LNPs containing gRNA G021844 by RNA weight, or with LNPs containing mRNA as shown in Table LS4. Cells were incubated for 24 hours in Williams' E medium (Gibco, A1217601) containing maintenance supplements and 10% fetal bovine serum. After 72 hours of incubation, cells were harvested and editing was assessed by NGS as described in Example 1. Average editing rate data are shown in Table 23 and Figure 16. [Table 26-1] [Table 26-2] [Table 26-3]
[0587] Example 10 NmeCas9 Protein Expression Example 10.1 Protein Expression in Primary Human Hepatocytes To quantify the expression of each mRNA construct, mRNA encoding either SpyCas9 or NmeCas9 was delivered by LNP into primary human hepatocytes, and then mRNA and protein expression levels were measured.
[0588] PHH cells were prepared as described in Example 1. LNPs were prepared generally as described in Example 1 with a single RNA species as cargo. LNPs contained lipid A, cholesterol, DSPC, and PEG2k-DMG in molar ratios of 50:38:9:3, respectively. LNPs were formulated to achieve a lipid amine to RNA phosphate (N:P) molar ratio of approximately 6.
[0589] Cells were administered one LNP containing mRNA (mRNA only) or two LNPs containing either mRNA or gRNA. Each LNP was applied to cells at 16.7 ng of total RNA cargo per 100 μl. Upon LNP treatment, cells were incubated at 37°C for 24 hours in Williams' E medium (Gibco, A1217601) containing maintenance supplements and 10% fetal bovine serum. After 24 hours of incubation, cells were harvested and expression was quantified using the Nano-Glo HiBiT Lytic Detection System (Promega, N3030) according to the manufacturer's instructions. Raw luminescence was normalized to a standard curve using HiBiT Control Protein (Promega, N3010). Protein expression of the various Cas9 variants, shown in Table 24 and Figure 17, was normalized to SpyCas9 expression measured in corresponding hepatocytes delivered with SpyCas9 mRNA alone. Consistent with the data shown in Table 24, protein expression from these same constructs was higher for the NmeCas9 constructs than for the SpyCas9 constructs, as measured by Western blot with anti-HiBiT antibody from PHH cell extracts or by HiBiT detection in PMH, PCH, PHH, and PRH cells. [Table 27]
[0590] Example 10.2: Protein Expression in T Cells To quantify the expression of each mRNA construct, mRNA encoding either SpyCas9 or Nme2Cas9 was delivered into T cells with LNPs, and then protein expression levels were measured.
[0591] Apheresis from healthy human donors was obtained commercially (Hemacare, catalog number). T cells from two donors (W106 and W864) were isolated by negative selection using the EasySep Human T cell Isolation Kit (Stem Cell Technology, catalog number 17951) on a MultiMACS Cell24 Separator Plus instrument according to the manufacturer's instructions. Isolated T cells were cryopreserved in CS10 cryopreservation medium (Cryostor, catalog number 07930) for future use.
[0592] Upon thawing, T cells were cultured in complete T cell growth medium consisting of CTS OpTmizer Base Media (CTS OpTmizer Media (Gibco, A1048501) supplemented with 1x GlutaMAX, 10 mM HEPES buffer, and 1% penicillin / streptomycin) supplemented with cytokines (200 IU / ml IL2, 5 ng / ml IL7, and 5 ng / ml IL15) and 2.5% human serum (Gemini, 100-512). After overnight incubation at 37°C, 10 6 T cells at a density of / mL were activated with T cell TransAct reagent (1:100 dilution, Miltenyi) and incubated for 48 h in a tissue culture incubator.
[0593] Activated T cells were treated with LNPs delivering mRNA encoding HiBiT-tagged Nme2 mRNA or Spy mRNA. LNPs were prepared generally as described in Example 1. LNPs were formulated to achieve a lipid amine to RNA phosphate (N:P) molar ratio of approximately 6. For LNPs encapsulating Nme2Cas9 mRNA, lipid A, cholesterol, DSPC, and PEG2k-DMG were used in a molar ratio of 50:38:9:3, respectively. For LNPs encapsulating SpyCas9 mRNA, lipid A, cholesterol, DSPC, and PEG2k-DMG were used in a molar ratio of 50:10:38.5:1.5, respectively. No guide RNA was provided in this experiment.
[0594] Immediately prior to LNP treatment of T cells, LNPs were preincubated at 37°C for 5 minutes at a concentration of 13.33 μg / ml total RNA containing 10 μg / mL ApoE3 (Peprotech, Cat. No. 350-02) in complete T cell medium supplemented with cytokines (200 IU / ml IL2 (Peprotech, Cat. No. 200-02), 5 ng / ml IL7 (Peprotech, Cat. No. 200-07), 5 ng / ml IL15 (Peprotech, Cat. No. 200-15), and 2.5% human serum (Gemini, Cat. No. 100-512). After incubation, LNPs were mixed 1:1 with T cells in complete T cell medium containing the cytokines used for ApoE incubation. T cells were harvested at 24, 48, and 72 hours after LNP treatment for protein expression analysis. T cells were analyzed using Nano-Glo® HiBiT Lytic Assay (Promega) and quantified Cas9 protein levels using the Nano-Glo® Nano-Glo HiBiT Extracellular Detection System (Promega, catalog N2420) according to the manufacturer's instructions. Luminescence was measured using a Biotek Neo2 plate reader. Protein counts and luminescence readings from standard controls were used to plot a linear regression on GraphPad, with the line passing through X=0, Y=0. Protein counts per lysate were calculated using the equation Y=ax+0.
[0595] Samples were normalized to the average SpyCas9 at 0.83 μg / ml LNP dose. Tables 25A-25B and Figures 18A-18F show the relative Cas9 protein expression in activated cells 24, 48, and 72 hours after LNP treatment of mRNA from donor 1 or donor 2. Cas9 was expressed in activated T cells in a dose-dependent manner. Protein expression was higher in activated T cells in Nme2Cas9 samples than in SpyCas9 samples. [Table 28] [Table 29]
[0596] Example 11. In vivo editing in mouse liver using lipid nanoparticles (LNPs) LNPs used in all in vivo studies were formulated as described in Example 1. Deviations from the protocol are noted in each example. The transport and storage solution (TSS) used in LNP preparation was administered in the experiment as a solvent-only negative control.
[0597] In vivo editing in a mouse model Selected guide designs were tested for editing efficiency in vivo. Six- to ten-week-old CD-1 female mice were used in each mouse study. Animals were weighed prior to administration. LNPs were generally formulated as described in Example 1. The LNPs contained ionizable lipid A, cholesterol, DSPC, and PEG2k-DMG in molar ratios of 50:38:9:3, respectively. The lipid-nucleic acid assemblies were formulated to achieve a lipid amine to RNA phosphate (N:P) molar ratio of approximately 6.
[0598] LNP was administered via the lateral tail vein at a volume of 0.2 mL per animal (approximately 10 mL per kilogram of body weight). Body weight was measured 24 hours after administration. Approximately 6–7 days after LNP delivery, animals were euthanized by exsanguination under isoflurane anesthesia. Blood was collected into serum separator tubes via cardiac puncture. For in vivo editing studies, liver tissue was collected from the left medial lobe of each animal, and DNA was extracted and analyzed.
[0599] For in vivo studies, genomic DNA was extracted from tissues using a bead-based extraction kit, such as the Zymo Quick-DNA96 kit (Zymo Research, Cat. No. D3010), according to the manufacturer's protocol. NGS analysis was performed as described in Example 1.
[0600] Transthyretin (TTR) ELISA assay used in animal studies Blood was collected and serum separated as described above. Total TTR serum levels were measured using a mouse prealbumin (transthyretin) ELISA kit (Aviva Systems Biology, catalog OKIA00111). Kit reagents and standards were prepared according to the manufacturer's protocol. Mouse serum was diluted with 1x assay diluent to a final dilution of 10,000. Both the standard curve dilutions (100 μL each) and diluted serum samples were added to each well of an ELISA plate precoated with capture antibody. The plate was incubated for 30 minutes at room temperature and then washed. Enzyme-antibody conjugate (100 μL per well) was added and incubated for 20 minutes. Unbound antibody conjugate was removed, and the plate was washed again before adding the colorimetric substrate solution. After incubating the plate for 10 minutes, 100 μL of stop solution (e.g., sulfuric acid (approximately 0.3 M)) was added. The plate was read at 450 nm absorbance using a Clariostar plate reader. Serum TTR levels were calculated using SoftMax Pro software version 6.4.2 or Mars software version 3.31 using a four-parameter logistic curve fit to the standard curve. Final serum values were adjusted for assay dilution. Percent protein knockdown (%KD) values were determined relative to the control group, which was typically sham-treated animals with vehicle (TSS) unless otherwise noted. Percent TSS was calculated by dividing each sample's TTR value by the mean value of the TSS group to adjust for a percentage value.
[0601] Example 11.1. In vivo editing using co-formulated LNPs The editing efficiency of the modified sgRNAs tested in Example D.2 was further evaluated in a mouse model. Guide RNA designs targeting mouse PCSK9 with identical guide sequences but varying lengths of the conserved region were tested, and LNPs were prepared as described in Example 1. LNPs were prepared using ionizable lipid A, cholesterol, DSPC, and PEG2k-DMG in molar ratios of 50:38:9:3, respectively. LNPs were formulated to achieve a lipid amine to RNA phosphate (N:P) molar ratio of approximately 6. As shown in Table 26, gRNAs targeting the PCSK9 gene and mRNA C were co-formulated in LNPs at a gRNA to mRNA ratio of 1:2 by weight. LNPs were administered to female CD-1 mice (n=5) at a dose of 1 mg / kg total RNA as described above. Mice were euthanized 7 days after administration. The editing efficiencies of LNPs containing the indicated sgRNAs are shown in Table 26 and illustrated in Figure 19. [Table 30]
[0602] Example 11.2. In vivo editing using pgRNA and mRNA LNPs The editing efficiency of the modified pgRNA was evaluated in vivo. In addition to the guide modifications specified in the previous study in Example 11.1, four nucleotides within each loop of the repeat / anti-repeat region, hairpin 1, and hairpin 2 were replaced with the spacer 18 PEG linker.
[0603] LNPs were prepared generally as described in Example 1, with a single RNA species as cargo. LNPs contained lipid A, cholesterol, DSPC, and PEG2k-DMG in molar ratios of 50:38:9:3, respectively. LNPs were formulated to achieve a lipid amine to RNA phosphate (N:P) molar ratio of approximately 6.
[0604] LNPs containing gRNAs targeting the TTR gene shown in Table 27 were administered to female CD-1 mice (n=5) at a dose of 0.1 mg / kg or 0.3 mg / kg of total RNA as described above. LNPs containing mRNA (mRNA M; SEQ ID NO: 631) and LNPs containing pgRNA (G021846 or G021844) were delivered simultaneously at a 1:2 ratio by RNA weight. Mice were euthanized 7 days after administration.
[0605] The editing efficiency, serum TTR knockdown, and percent TSS of LNPs containing the indicated pgRNAs are shown in Table 27 and illustrated in Figures 20A-20C, respectively. [Table 31]
[0606] The pgRNA (G021844) from the above study was evaluated in mice carrying various dose levels of alternative mRNAs. LNPs were generally prepared as described in Example 1 using a single RNA species as cargo. LNPs containing pgRNA (G21844) or mRNA (mRNA P or mRNA M) were formulated as described in Example 1. The LNPs used were prepared with ionizable lipid A, cholesterol, DSPC, and PEG2k-DMG in molar ratios of 50:38:9:3, respectively. LNPs were formulated to achieve a lipid amine to RNA phosphate (N:P) molar ratio of approximately 6. Both G000502 and G021844 target exon 3 of the mouse TTR gene. The pgRNA-containing LNPs and mRNA-containing LNPs were administered simultaneously at a guide:mRNA ratio of 2:1 by RNA weight, based on the total RNA weight. The additional LNPs were co-formulated with G000502 and SpyCas9 mRNA at a weight ratio of 1:2, respectively, which is the preferred SpyCas9 guide:mRNA ratio.
[0607] The LNPs shown in Table 28 were administered to female CD-1 mice (n=4) at a dose of 0.1 mg / kg or 0.03 mg / kg of total RNA. The editing efficiencies of LNPs containing the indicated gRNAs are shown in Table 28 and illustrated in Figures 20D-20E. [Table 32]
[0608] Example 11.3. In vivo editing using sgRNA and mRNA LNPs LNPs were generally prepared as described in Example 1 using a single RNA species as cargo. The LNPs used were prepared using lipid A, cholesterol, DSPC, and PEG2k-DMG in molar ratios of 50:38:9:3, respectively. LNPs were formulated to achieve a lipid amine to RNA phosphate (N:P) molar ratio of approximately 6. sgRNAs were designed to target the pcsk9 gene (G020361) or the Rosa26 gene (G020848).
[0609] LNPs containing sgRNA or mRNA were administered to female CD-1 mice (n=5) at a dose of 1 mg / kg total RNA. The tested mRNAs (mRNA C (SEQ ID NO: 622), mRNA J (SEQ ID NO: 628), mRNA Q (SEQ ID NO: 635), and mRNA N (SEQ ID NO: 632)) were designed with varying numbers and positions of NLSs. LNPs were administered simultaneously at a 1:1 ratio of gRNA:mRNA by RNA weight, based on the total weight of the RNA cargo. The average editing rates are shown in Table 29 and illustrated in Figure 21. [Table 33]
[0610] Example 12. In vivo editing with NmeCas9 and sgRNA or pgRNA The editing efficiency of modified pgRNAs tested with Nme2Cas9 was tested in a mouse model. All Nme sgRNAs tested consisted of the same 24-nt guide sequence targeting mTTR.
[0611] LNPs were generally prepared as described in Example 1 using a single RNA species as cargo. The LNPs used were prepared using lipid A, cholesterol, DSPC, and PEG2k-DMG in molar ratios of 50:38:9:3, respectively. LNPs were formulated to achieve a lipid amine to RNA phosphate (N:P) molar ratio of approximately 6. LNPs were mixed with gRNA and mRNA cargo in a weight ratio of 2:1. Dosages were calculated based on the total RNA weight of gRNA and mRNA. The transport and storage solution (TSS) used for LNP preparation was administered in the experiment as a solvent-only negative control.
[0612] For each mouse study, 6- to 10-week-old CD-1 female mice were used (n=5 per group, except for the TSS control group, n=4). The formulations were administered intravenously via tail vein injection according to the doses listed in Table 30. Animals were regularly observed for adverse reactions for at least 24 hours after administration. Six days after treatment, animals were euthanized by cardiac puncture under isoflurane anesthesia, and liver tissue was harvested for downstream analysis. Liver punches weighing 5-15 mg were collected to isolate genomic DNA and total RNA. Genomic DNA samples were analyzed by NGS sequencing as described in Example 1. The editing efficiencies of LNPs containing the indicated mRNAs and gRNAs are shown in Table 30 and illustrated in Figure 22. [Table 34]
[0613] Example 13. In vivo base editing with Nme2Cas9 gRNA The editing efficiency of gRNAs modified with different mRNAs was tested using Nme base editor constructs in a mouse model. This experiment was performed in parallel with Example 12, and the same control samples were used. LNPs were generally prepared as described in Example 1 using a single RNA species as cargo. The LNPs used were prepared using lipid A, cholesterol, DSPC, and PEG2k-DMG in molar ratios of 50:38:9:3, respectively. LNPs were formulated to achieve a lipid amine to RNA phosphate (N:P) molar ratio of approximately 6. The LNPs used were formulated as described in Example 1, except that each component, guide RNA, or mRNA, was formulated individually into the LNP, and the LNPs were mixed prior to administration as described in Table 31. For Nme2Cas9 and Nme2Cas9 base editor samples, LNPs were mixed at a weight ratio of 2:1 gRNA to editor mRNA cargo. For SpyCas9 base editor samples, LNPs were mixed at a 1:2 weight ratio of gRNA to editor mRNA cargo. Dosages were calculated based on the total RNA weight of gRNA and editor mRNA, as shown in Table 31 and Figure 14. Base editor samples were treated with an additional 0.03 mpk of UGI mRNA. The transport and storage solution (TSS) used for LNP preparation served as a solvent-only negative control in the experiment.
[0614] For each mouse study, 6- to 10-week-old CD-1 female mice were used (n=5 per group, except for the TSS control group, n=4). The formulations were administered intravenously via tail vein injection according to the doses listed in Table 31. Animals were periodically observed for adverse reactions for at least 24 hours after administration. Six days after treatment, animals were euthanized by cardiac puncture under isoflurane anesthesia, and liver tissue was harvested for downstream analysis. Liver punches weighing 5-15 mg were collected to isolate genomic DNA and total RNA. Genomic DNA was extracted using a DNA isolation kit (ZymoResearch, D3010), and samples were analyzed by NGS sequencing as described in Example 1. The editing efficiencies of LNPs containing the indicated gRNAs are shown in Table 31 and illustrated in Figure 23. [Table 35]
[0615] Example 14. Dose-response curve of NmeCas9 gRNA in PMH containing Nme2Cas9 The editing efficiency of the modified gRNAs was tested using the Nme2Cas9 construct in primary mouse hepatocytes (PMH). All tested Nme sgRNAs consisted of the same 24-nt guide sequence targeting the mouse TTR gene (mTTR).
[0616] PMH (Gibco, lot MC931) were thawed and resuspended in hepatocyte thawing medium containing William's E medium (Gibco, catalog A12176-01) with dexamethasone plus cocktail supplement (Gibco, catalog A15563, lot 2019842) and plating supplement containing FBS (Gibco, catalog A13450, lot 1970698), followed by centrifugation. The supernatant was discarded, and the pelleted cells were resuspended in hepatocyte plating medium and supplement pack (Invitrogen, catalog A1217601 and Gibco, catalog CM3000). Cells were counted and seeded at a density of 15,000 cells / well onto Bio-coat collagen I-coated 96-well plates (Thermo Fisher, catalog 877272). The seeded cells were allowed to adhere for 4–6 hours in a tissue culture incubator at 37°C with a 5% CO atmosphere. After incubation, the cells were checked for monolayer formation and washed once with Hepatocyte Maintenance Medium (Invitrogen, Cat. A1217601 and Gibco, Cat. CM4000).
[0617] LNPs were generally prepared as described in Example 1 with a 1:2 weight ratio of gRNA to mRNA cargo. The LNPs used were prepared with a molar ratio of 50% lipid A, 38% cholesterol, 9% DSPC, and 3% PEG2k-DMG. LNPs were formulated to achieve a lipid amine to RNA phosphate (N:P) molar ratio of 6. Each LNP was applied to cells using eight four-fold serial dilutions, starting with 300 ng of total RNA per 100 μl well (approximately 32.25 nM gRNA concentration per well), as shown in Table 32. Upon LNP treatment, cells were incubated at 37°C for 24 hours in Williams' E medium (Gibco, A1217601) containing maintenance supplements and 3% fetal bovine serum. Samples were run in triplicate. After 72 hours, cells were harvested and analyzed by NGS as described in Example 1.
[0618] The editing efficiencies of LNPs containing...
Claims
1. A guide RNA (gRNA) comprising a guide region and a conserved region, the conserved region comprising one or more of the following: (a) a truncated repeat / anti-repeat region, wherein said truncated repeat / anti-repeat region lacks 2 to 24 nucleotides, (i) relative to SEQ ID NO:500, one or more of nucleotides 37-48 and 53-64 are deleted, and optionally one or more of nucleotides 37-64 are substituted; and (ii) nucleotide 36 is linked to nucleotide 65 by at least two nucleotides; or (b) a truncated hairpin 1 region, wherein said truncated hairpin 1 lacks 2 to 10 nucleotides, optionally 2 to 8 nucleotides, wherein: (i) relative to SEQ ID NO:500, one or more of nucleotides 82-86 and 91-95 are deleted, and optionally one or more of positions 82-96 are substituted; and (ii) nucleotide 81 is linked to nucleotide 96 by at least four nucleotides; or (c) a truncated hairpin 2 region, wherein said truncated hairpin 2 lacks 2 to 18 nucleotides, optionally 2 to 16 nucleotides, wherein (i) relative to SEQ ID NO:500, one or more of nucleotides 113-121 and 126-134 are deleted, and optionally one or more of nucleotides 113-134 are substituted; and (ii) nucleotide 112 is linked to nucleotide 135 by at least 4 nucleotides; relative to SEQ ID NO:500, optionally with one or both of nucleotides 144-145 deleted; The gRNA, wherein at least 10 nucleotides are modified nucleotides.
2. The gRNA is a single guide RNA (sgRNA), and the gRNA (a) comprises a truncated repeat / anti-repeat region, the truncated repeat / anti-repeat region lacking 2-24 nucleotides; (i) relative to SEQ ID NO:500, one or more of nucleotides 37-48 and 53-64 are deleted, and optionally one or more of nucleotides 37-64 are substituted; and (ii) nucleotide 36 is linked to nucleotide 65 by at least two nucleotides.
3. 3. The gRNA of claim 1 or 2, wherein the guide region (i) has an insertion of 1 nucleotide or a deletion of 1 to 4 nucleotides within positions 1 to 24 relative to SEQ ID NO:500, or (ii) is 24 nucleotides in length.
4. 4. The gRNA of Claim 3, wherein the guide region is 25, 24, 23, 22, 21, or 20 nucleotides in length, optionally wherein the guide region is 25, 24, 23, or 22 nucleotides in length.
5. The gRNA of claim 4, wherein the guide region is 23 to 24 nucleotides in length.
6. The gRNA of any one of claims 1 to 5, wherein the gRNA further comprises a 3' tail.
7. 7. The gRNA of claim 6, wherein the 3' tail comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides.
8. The gRNA of claim 7, wherein the 3' tail comprises 1, 2, 3, 4, or 5 nucleotides.
9. The gRNA of any one of claims 6 to 8, wherein the 3' tail terminates with a nucleotide that contains uracil or modified uracil.
10. The gRNA of any one of claims 6 to 9, wherein the 3' tail is 1 nucleotide in length.
11. The gRNA of any one of claims 6 to 10, wherein the 3' tail consists of nucleotides containing uracil or modified uracil.
12. The gRNA of any one of claims 6 to 11, wherein the 3' tail comprises a modification to any one or more of the nucleotides present in the 3' tail.
13. 13. The gRNA of any one of claims 6 to 12, wherein the modification of the 3' tail is one or more of 2'-O-methyl (2'-OMe) modified nucleotides and phosphorothioate (PS) internucleotide linkages.
14. The gRNA of any one of claims 6 to 13, wherein the 3' tail is fully modified.
15. The gRNA of any one of claims 1 to 14, wherein the 3' nucleotide of the gRNA is a nucleotide containing uracil or modified uracil.
16. The gRNA of any one of claims 1 to 5, wherein one or more of nucleotides 144 and 145 are deleted relative to SEQ ID NO:
500.
17. The gRNA of any one of claims 1 to 5, wherein both nucleotides 144 and 145 are deleted relative to SEQ ID NO:
500.
18. The gRNA of any one of claims 1 to 5, wherein the gRNA does not comprise a 3' tail.
19. The gRNA of any one of claims 1 to 18, wherein the truncated repeat / anti-repeat region lacks 2 to 24 nucleotides.
20. 20. The gRNA of any one of claims 1 to 19, wherein the length of the truncated repeat / anti-repeat region is 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides.
21. 21. The gRNA of any one of claims 1 to 20, wherein the truncated repeat / anti-repeat region lacks 12 to 24 nucleotides, optionally 18 to 24 nucleotides, optionally 20 to 22 nucleotides.
22. 22. The gRNA of any one of claims 1 to 21, wherein the length of the truncated repeat / anti-repeat region is 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides.
23. 23. The gRNA of any one of claims 1 to 22, wherein the length of the shortened repeat / anti-repeat region is 28, 29, 30, 31, 32, 33, or 34 nucleotides, or 30, 31, or 32 nucleotides.
24. 24. The gRNA of any one of claims 1 to 23, wherein nucleotides 37 to 64 of SEQ ID NO: 500 form the upper stem, and one or more base pairs of the upper stem of the truncated repeat / anti-repeat region are deleted.
25. 25. The gRNA of any one of claims 1 to 24, wherein the upper stem of the truncated repeat / anti-repeat region comprises no more than 1, 2, 3, or 4 base pairs.
26. 26. The gRNA of any one of claims 1 to 25, wherein all of positions 39-48 and all of positions 53-62 of the upper stem of the truncated repeat / anti-repeat region have been deleted, and optionally nucleotide 38 or 63 has been substituted.
27. 27. The gRNA of any one of claims 1 to 26, wherein all of positions 38-48 and all of positions 53-63 of the upper stem of the truncated repeat / anti-repeat region have been deleted, and optionally nucleotide 37 or 64 has been substituted.
28. 28. The gRNA of any one of claims 1 to 27, wherein all of nucleotides 37-48 and 53-64 of the upper stem of the truncated repeat / anti-repeat region have been deleted, and optionally nucleotide 36 or 65 has been substituted.
29. 29. The gRNA of any one of claims 1 to 28, wherein the truncated repeat / anti-repeat region has a duplex portion 11 base pair nucleotides in length.
30. The gRNA of any one of claims 1 to 29, wherein the truncated repeat / anti-repeat region has a single duplex portion.
31. 30. The gRNA of any one of claims 1 to 29, wherein the truncated repeat / anti-repeat region has a first duplex portion and a second duplex portion.
32. 32. The gRNA of Claim 31, wherein the length of the second duplex portion is 2 to 3 base pair nucleotides.
33. 32. The gRNA of Claim 31, wherein the first duplex portion is 11 base pair nucleotides in length and the second duplex portion is 3 base pair nucleotides in length.
34. The gRNA of any one of claims 1 to 33, wherein the upper stem of the truncated repeat / anti-repeat region comprises one or more substitutions relative to SEQ ID NO:
500.
35. The gRNA of any one of claims 1 to 34, wherein one or more of nucleotides 49 to 52 are substituted with respect to SEQ ID NO:
500.
36. The gRNA of any one of claims 1 to 33, wherein the truncated repeat / anti-repeat region is not substituted.
37. 37. The gRNA of any one of claims 1 to 36, wherein the truncated repeat / anti-repeat region has 12 to 22 modified nucleotides.
38. 38. The gRNA of Claim 37, wherein the truncated repeat / anti-repeat region does not contain a modification at nucleotide 76.
39. 38. The gRNA of Claim 37, wherein the truncated repeat / anti-repeat region does not contain a phosphorothioate (PS) modification at nucleotide 76.
40. 40. The gRNA of any one of claims 1 to 39, wherein the shortened Hairpin 1 region lacks 2 to 10 nucleotides, optionally 2 to 8 or 2 to 4 nucleotides.
41. 41. The gRNA of any one of claims 1 to 40, wherein the length of the shortened hairpin 1 region is 13, 14, 15, 16, 17, 18, 19, 20, or 21 nucleotides.
42. 42. The gRNA of any one of claims 1 to 41, wherein the shortened Hairpin 1 region has a duplex portion of 4 to 8, optionally 7 to 8 base pair nucleotides in length.
43. The gRNA of any one of claims 1 to 41, wherein the shortened hairpin 1 region has a single double-stranded portion.
44. The gRNA of any one of claims 1 to 43, wherein one or two base pairs of the shortened hairpin 1 region are deleted.
45. 45. The gRNA of any one of claims 1 to 44, wherein the stem of the shortened hairpin 1 region is 7 or 8 base pair nucleotides in length.
46. 46. The gRNA of any one of claims 1 to 45, wherein one or more of positions 85-86 and one or more of nucleotides 91-92 of the truncated hairpin 1 region are deleted.
47. The gRNA of any one of claims 1 to 46, wherein nucleotides 86 and 91 or nucleotides 85 and 92 of the shortened hairpin 1 region are deleted.
48. The gRNA of any one of claims 1 to 47, wherein one or more of nucleotides 82 to 95 of the shortened hairpin 1 region are substituted relative to SEQ ID NO:
500.
49. The gRNA of any one of claims 1 to 48, wherein one or more of nucleotides 87 to 90 are substituted with respect to SEQ ID NO:
500.
50. The gRNA of any one of claims 1 to 48, wherein the shortened hairpin 1 region is not substituted.
51. 50. The gRNA of any one of claims 1 to 49, wherein the shortened hairpin 1 region has 6 to 15 modified nucleotides.
52. 51. The gRNA of any one of claims 1 to 50, wherein the shortened hairpin 2 region lacks 2 to 18, optionally 2 to 16 nucleotides.
53. 52. The gRNA of any one of claims 1-51, wherein the length of the shortened hairpin 2 region is 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides.
54. 53. The gRNA of any one of claims 1 to 52, wherein the length of the shortened hairpin 2 region is 28, 29, 30, 31, 32, 33, or 34 nucleotides.
55. 54. The gRNA of any one of claims 1 to 53, wherein one or more of nucleotides 113 to 121 and one or more of nucleotides 126 to 134 of the truncated hairpin 2 region are deleted.
56. The gRNA of any one of claims 1 to 54, wherein the shortened hairpin 2 region comprises an unpaired region.
57. 56. The gRNA of any one of claims 1 to 55, wherein the shortened hairpin 2 region has two double-stranded portions.
58. 57. The gRNA of any one of claims 1 to 56, wherein the shortened hairpin 2 region has a duplex portion 4 base pair nucleotides in length.
59. 59. The gRNA of any one of claims 57 to 58, wherein the shortened hairpin 2 region has a duplex portion 4 to 8 base pair nucleotides in length.
60. 60. The gRNA of any one of claims 57 to 59, wherein the shortened hairpin 2 region has a duplex portion 4 to 6 base pair nucleotides in length.
61. 61. The gRNA of any one of claims 1-60, wherein nucleotides 109-138 of SEQ ID NO:500 form an upper stem, and wherein the upper stem of the shortened Hairpin 2 region comprises 1, 2, 3, or 4 base pairs.
62. The gRNA of any one of claims 1 to 61, wherein at least one pair of nucleotides 113 and 134, nucleotides 114 and 133, nucleotides 115 and 132, nucleotides 116 and 131, nucleotides 117 and 130, nucleotides 118 and 129, nucleotides 119 and 128, nucleotides 120 and 127, and nucleotides 121 and 126 are deleted.
63. 63. The gRNA of any one of claims 1 to 62, wherein all of positions 113-121 and 126-134 of the truncated hairpin 2 region are deleted.
64. The gRNA of any one of claims 1 to 63, wherein one or more of nucleotides 113 to 134 of the shortened hairpin 2 region are substituted relative to SEQ ID NO:
500.
65. The gRNA of any one of claims 1 to 64, wherein one or more of nucleotides 122 to 125 are substituted relative to SEQ ID NO:
500.
66. The gRNA of any one of claims 1 to 64, wherein the shortened hairpin 2 region is not substituted.
67. 67. The gRNA of any one of claims 1 to 66, wherein the shortened hairpin 2 region has 6 to 15 modified nucleotides.
68. 68. The gRNA of any one of claims 1 to 67, wherein the guide region of the gRNA comprises at least two modified nucleotides, optionally at least four modified nucleotides.
69. 69. The gRNA of any one of claims 1-68, wherein the guide region of the gRNA comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 modified nucleotides, optionally 1, 2, or 3 modified nucleotides.
70. 70. The gRNA of any one of claims 1-69, wherein the guide region of the gRNA comprises 4, 5, 6, 7, 8, 9, 10, 11, or 12 modified nucleotides.
71. 71. The gRNA of any one of claims 1-70, wherein the guide region of the gRNA comprises 6, 7, 8, 9, 10, 11, or 12 modified nucleotides.
72. 72. The gRNA of any one of claims 1 to 71, wherein the guide region does not comprise 3' modified nucleotides in the first three nucleotides of the guide region.
73. The gRNA of any one of claims 1 to 66, wherein the guide region does not comprise modified nucleotides.
74. The gRNA of any one of claims 1 to 72, wherein the gRNA comprises a 5' end modification.
75. The gRNA of any one of claims 1 to 74, wherein the gRNA comprises a 3' end modification.
76. The gRNA of any one of claims 1 to 75, wherein the gRNA comprises a 5'-end modification and a 3'-end modification.
77. 77. The gRNA of any one of claims 1 to 76, comprising a modification in the upper stem region of the repeat / anti-repeat region.
78. 78. A gRNA according to any one of claims 1 to 77, comprising a modification in the hairpin 1 region.
79. 79. The gRNA of any one of claims 1 to 78, comprising a modification in the hairpin 2 region.
80. 80. The gRNA of Claim 79, wherein the modification in the hairpin 2 region comprises modifications at 1, 2, 3, or 4 nucleotides from nucleotides 106 to 109.
81. 81. The gRNA of claim 80, wherein the modifications in the hairpin 2 region comprise modifications at each of nucleotides 106-109.
82. 82. The gRNA of claim 80 or 81, wherein the modification comprises a 2'-O-methyl (2'-O-Me) modification.
83. 83. The gRNA of any one of claims 1 to 82, comprising a 3' end modification and comprising a modification in the upper stem region of the repeat / anti-repeat region.
84. 84. A gRNA according to any one of claims 1 to 83, comprising a 3'-end modification and a modification in the hairpin 1 region.
85. 84. A gRNA according to any one of claims 1 to 83, comprising a 3'-end modification and a modification in the hairpin 2 region.
86. 86. The gRNA of any one of claims 1 to 85, comprising a 5' end modification and comprising a modification in the upper stem region of the repeat / anti-repeat region.
87. 87. A gRNA according to any one of claims 1 to 86, comprising a 5'-end modification and a modification in the hairpin 1 region.
88. 88. A gRNA according to any one of claims 1 to 87, comprising a 5'-end modification and a modification in the hairpin 2 region.
89. 89. The gRNA of any one of claims 1 to 88, comprising a 5'-end modification, a modification in the upper stem region of the repeat / anti-repeat region, and a 3'-end modification.
90. 90. The gRNA of any one of claims 1 to 89, comprising a 5'-end modification, a modification in the hairpin 1 region, and a 3'-end modification.
91. 91. The gRNA of any one of claims 1 to 90, comprising a 5'-end modification, a modification in the hairpin 1 region, a modification in the hairpin 2 region, and a 3'-end modification.
92. 92. The gRNA of any one of claims 1 to 91, comprising a 5'-end modification, a modification in the repeat / anti-repeat region, a modification in the hairpin 1 region, a modification in the hairpin 2 region, and a 3'-end modification.
93. 93. The gRNA of any one of claims 1 to 92, wherein the modification in the repeat / anti-repeat region does not include a phosphorothioate (PS) modification at nucleotide 76.
94. 94. The gRNA of any one of claims 1 to 93, wherein the modification in the repeat / anti-repeat region does not include a modification at nucleotide 76.
95. 95. The gRNA of any one of claims 74 to 94, wherein the 5'-end modification comprises a modified nucleotide selected from a 2'-O-methyl (2'-OMe) modified nucleotide, a 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotide, a 2'-fluoro (2'-F) modified nucleotide, an internucleotide phosphorothioate (PS) linkage, or an inverted abasic modified nucleotide.
96. 96. The gRNA of any one of claims 74 to 95, wherein the 3'-end modification comprises a modified nucleotide selected from a 2'-O-methyl (2'-OMe) modified nucleotide, a 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotide, a 2'-fluoro (2'-F) modified nucleotide, an internucleotide phosphorothioate (PS) linkage, or an inverted abasic modified nucleotide.
97. The 5' end modification is i. one or more modifications of the first 1, 2, 3, or 4 nucleotides; ii. one modified nucleotide; iii. two modified nucleotides; iv. three modified nucleotides; and v. The gRNA of any one of claims 74 to 96, comprising any of four modified nucleotides.
98. The 5' end modification is i. phosphorothioate (PS) internucleotide linkages; ii. 2'-OMe modified nucleotides; iii. 2'-O-moe modified nucleotides; iv. 2'-F modified nucleotides; and v. The gRNA of any one of claims 74 to 97, comprising one or more inverted abasic modified nucleotides.
99. The 3'-end modification is i. modification of one or more of the last 4, 3, 2, or 1 nucleotides; ii. one modified nucleotide; iii. two modified nucleotides; iv. three modified nucleotides; and v. The gRNA of any one of claims 74 to 98, comprising any of four modified nucleotides.
100. The 3'-end modification is i. phosphorothioate (PS) internucleotide linkages; ii. 2'-OMe modified nucleotides; iii. 2'-O-moe modified nucleotides; iv. 2'-F modified nucleotides; and v. The gRNA of any one of claims 74 to 99, comprising one or more inverted abasic modified nucleotides.
101. The 5' end modification comprises at least one PS linkage and includes one or more of the following: i. there is one PS linkage, the linkage being between the first nucleotide and the second nucleotide; ii. there are two PS linkages between the first three nucleotides; iii. There is a PS linkage between one or more of the first four nucleotides; and iv. The gRNA of any one of claims 74 to 100, wherein there is a PS bond between one or more of the first five nucleotides.
102. The gRNA of claim 101, wherein the 5' end modification further comprises at least one 2'-OMe, 2'-O-moe, inverted abasic, or 2'-F modified nucleotide.
103. The 5' end modification is i. one or more modifications of the first 1 to 4 nucleotides, said modifications being a PS linkage, an inverted abasic nucleotide, 2'-OMe, 2'-O-moe, or 2'-F; ii. a modification to the first nucleotide with 2'-Ome, 2'-O-moe, or 2'-F and any one or two PS linkages to the next nucleotide or the first nucleotide of the 3' tail; iii. modification of the first or second nucleotide with 2'-Ome, 2'-O-moe, or 2'-F, and optionally one or more PS linkages; iv. modification to the first, second, or third nucleotide with 2'-Ome, 2'-O-moe, or 2'-F, and optionally one or more PS linkages; or v. The gRNA of any one of claims 1 to 102, comprising a modification to the first, second, third or fourth nucleotide with 2'-Ome, 2'-O-moe or 2'-F, and optionally one or more PS linkages.
104. The 3' end modification comprises at least one PS linkage and includes one or more of the following: vi. there is one PS linkage between the last nucleotide and the penultimate nucleotide; vii. there are two PS linkages between the last three nucleotides; and viii. The gRNA of any one of claims 1-103, wherein there is a PS linkage between one or more of the last four nucleotides.
105. The gRNA of claim 104, wherein the 3' end modification further comprises at least one 2'-Ome, 2'-O-moe, inverted abasic, or 2'-F modified nucleotide.
106. The 3'-end modification is ix. one or more modifications of the last 1 to 4 nucleotides, said modifications being a PS linkage, an inverted abasic nucleotide, 2'-OMe, 2'-O-moe, or 2'-F; x. a modification to the last nucleotide with 2'-OMe, 2'-O-moe, or 2'-F and any one or two PS linkages to the next nucleotide or the first nucleotide of the 3' tail; xi. modification of the last or penultimate nucleotide with 2'-OMe, 2'-O-moe, or 2'-F, and optionally one or more PS linkages; xii. modification of the last, penultimate, or penultimate nucleotide with 2'-OMe, 2'-O-moe, or 2'-F, and optionally one or more PS linkages; or xiii. The gRNA of any one of claims 1 to 105, comprising a modification to the last, the penultimate, the third penultimate, or the fourth penultimate nucleotide with 2'-OMe, 2'-O-moe, or 2'-F, and optionally one or more PS linkages.
107. 107. The gRNA of any one of claims 1 to 106, wherein the modifications in the repeat / anti-repeat region, the hairpin 1 region, or the hairpin 2 region comprise modified nucleotides selected from 2'-O-methyl (2'-OMe) modified nucleotides, 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotides, 2'-fluoro (2'-F) modified nucleotides, or phosphorothioate (PS) internucleotide linkages.
108. 107. The gRNA of any one of claims 1 to 106, wherein the modification in the repeat / anti-repeat region, the hairpin 1 region, or the hairpin 2 region comprises modified nucleotides selected from 2'-O-methyl (2'-OMe) modified nucleotides, 2'-fluoro (2'-F) modified nucleotides, or phosphorothioate (PS) internucleotide linkages.
109. 107. The gRNA of any one of claims 1 to 106, wherein the modification in the repeat / anti-repeat region, the hairpin 1 region, or the hairpin 2 region comprises modified nucleotides selected from 2'-O-methyl (2'-OMe) modified nucleotides, or phosphorothioate (PS) internucleotide linkages.
110. The gRNA of any one of claims 1 to 109, wherein the modification in the repeat / anti-repeat region does not include a phosphorothioate modification at nucleotide 76.
111. The gRNA of any one of claims 1 to 110, wherein the modification in the repeat / anti-repeat region does not include a modification at nucleotide 76.
112. 112. The gRNA of any one of claims 1-111, wherein at least 20%, 30%, 40%, or 50% of the nucleotides are modified nucleotides.
113. 113. The gRNA of claim 112, wherein the gRNA comprises modified nucleotides selected from 2'-O-methyl (2'-OMe) modified nucleotides, 2'-O-(2-methoxyethyl) (2'-O-moe) modified nucleotides, 2'-fluoro (2'-F) modified nucleotides, phosphorothioate (PS) internucleotide linkages, or combinations thereof.
114. 114. The gRNA of any one of claims 1 to 113, wherein the modification comprises modifications at 1, 2, 3, or 4 nucleotides from nucleotides 106 to 109.
115. 115. The gRNA of claim 113 or 114, wherein the modification comprises a modification at each of nucleotides 106 to 109.
116. The gRNA of any one of claims 114 to 115, wherein the modification comprises a 2'-O-methyl modification.
117. 117. The gRNA of any one of claims 112 to 116, wherein the gRNA comprises modified nucleotides selected from 2'-O-methyl (2'-Ome) modified nucleotides, 2'-fluoro (2'-F) modified nucleotides, phosphorothioate (PS) internucleotide linkages, or combinations thereof.
118. The gRNA of any one of claims 1 to 117, wherein nucleotides 1 to 3 of the guide region are modified, and nucleotides other than nucleotides 1 to 3 in the guide region are unmodified.
119. The gRNA of any one of claims 1 to 118, wherein a 3' tail of nucleotide 144 is present on the gRNA, comprising 2'-O-Me modified nucleotides at nucleotides 141 to 144, and comprising two PS linkages between nucleotides 141 to 142 and 142 to 143, respectively.
120. The gRNA of any one of claims 1 to 120, wherein one or more of positions 49-52, 87-90, or 122-125 are substituted.
121. A single guide RNA (sgRNA) comprising any one of SEQ ID NOs: 1 to 19 and 21 to 42.
122. The gRNA according to any one of claims 1 to 121, comprising a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 85%, 80%, 75%, or 70% identity to the nucleotide sequence of any one of SEQ ID NOs: 1 to 19 and 21 to 42.
123. 122. The gRNA of any one of claims 1 to 121, comprising a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 85%, 80%, 75%, or 70% identity to the nucleotide sequence of any one of SEQ ID NOs: 1 to 19 and 21 to 42, wherein the modifications in each nucleotide of said gRNA corresponding to a nucleotide of a reference sequence identifier in Table 1 are the same or equivalent to the modifications shown in the reference sequence identifier in Table 2.
124. The gRNA of any one of claims 1 to 122, comprising a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, or 90% identity to the sequence from X to the 3' end of any one of the nucleotide sequences of SEQ ID NOs: 1-5, 7, 8, 11, 12, 13, 15, 16, 18, 19, 21, 23, 24, 26, 27, 28, 30, 31, 33, 34, 35, 37, 39, 41, 101-291, 301-494, 931-946, 951, and 952, wherein X is the first nucleotide of the conserved region.
125. 125. The gRNA of any one of claims 121 to 124, further comprising a 3' tail comprising 2'-O-Me modified nucleotides.
126. The gRNA of any one of claims 1 to 125, wherein the gRNA directs a nuclease to a target sequence for binding.
127. The gRNA of any one of claims 1 to 126, wherein the gRNA guides a nuclease to a target sequence and induces a double-stranded break within the target sequence.
128. The gRNA of any one of claims 1 to 127, wherein the gRNA guides a nuclease to a target sequence to induce a single-stranded break within the target sequence.
129. The gRNA of any one of claims 126 to 129, wherein the nuclease is Nme Cas9.
130. The gRNA of any one of claims 1 to 129, wherein the gRNA comprises conservative substitutions, and optionally, the conservative substitutions maintain at least one base pair.
131. 131. A composition comprising a gRNA according to any one of claims 1 to 130 associated with a lipid nanoparticle (LNP).
132. An LNP composition comprising a gRNA described in any one of claims 1 to 130.
133. A composition comprising the gRNA of any one of claims 1 to 130 or the composition of any one of claims 131 to 132, further comprising a nuclease or an mRNA encoding said nuclease.
134. The composition of claim 133, wherein the nuclease is a Cas protein.
135. The composition of claim 134, wherein the Cas protein is Nme Cas9.
136. The composition of claim 135, wherein the Nme Cas9 is Nme1 Cas9, Nme2 Cas9, or Nme3 Cas9.
137. The composition of any one of claims 133 to 136, wherein the nuclease has double-strand cleavage activity.
138. The composition of any one of claims 133 to 137, wherein the nuclease has nickase activity.
139. The composition of any one of claims 133 to 138, wherein the nuclease has a dCas DNA binding domain.
140. The composition of any one of claims 133 to 139, wherein the nuclease is modified.
141. The composition of claim 140, wherein the modified nuclease comprises a heterologous functional domain.
142. The composition of claim 141 , wherein the heterologous functional domain is a deaminase.
143. The composition of claim 142, further comprising a UGI or an mRNA encoding a UGI.
144. The composition of any one of claims 142 to 143, wherein the heterologous functional domain is cytidine deaminase.
145. The composition of any one of claims 140 to 144, wherein the modified nuclease comprises a nuclear localization signal (NLS).
146. The composition of any one of claims 133 to 145, comprising an mRNA encoding the nuclease.
147. The composition of claim 146, wherein the mRNA comprises the sequence of any one of SEQ ID NOs: 636-638.
148. 148. A pharmaceutical formulation comprising a gRNA according to any one of claims 1 to 130 or a composition according to any one of claims 131 to 147 and a pharma- ceutically acceptable carrier.
149. A method of modifying a target DNA, comprising the steps of: i. a gRNA according to any one of claims 1 to 130; ii. the composition of any one of claims 131 to 147; and iii. The method comprising delivering one or more of the pharmaceutical formulations of claim 148 to a cell.
150. 150. The method of claim 149, wherein the method results in the insertion or deletion of a gene.
151. 151. The method of Claim 149 or 150, wherein the method results in at least one base edit.
152. 152. The method of any one of Claims 149-151, further comprising delivering a template to said cell, wherein at least a portion of said template is incorporated into target DNA at or near the site of the double stranded break induced by said Cas protein.
153. A gRNA according to any one of claims 1 to 130, a composition according to claims 131 to 147, or a pharmaceutical formulation according to claim 148, for use in the preparation of a medicament for treating a disease or disorder.
154. Use of a gRNA according to any one of claims 1 to 130, a composition according to claims 131 to 147, or a pharmaceutical formulation according to claim 148 in the manufacture of a medicament for treating a disease or disorder.
Citation Information
Patent Citations
Engineering systems, methods and optimization guide compositions for sequence manipulation
JP2016504026A
Targeted CRISPR Delivery Platform
JP2021502097A
Modified guide RNAs for gene editing
JP2021526804A
Polynucleotides, compositions, and methods for genome editing involving deamination
JP2023553935A
